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ABSTRACT 
This thesis presents data to enhance our understanding of the composition, assembly, 
and structure of the nucleosome remodeling and deacetylase (NuRD) complex, a 
transcriptional coregulator that is strongly linked to cancer. Understanding the 
structure and function of the gene regulating complexes will lead to a better 
understanding of mechanisms of gene regulation. This should ultimately both allow 
insight into disease processes that originate from gene regulatory network malfunction 
and might enable reprogramming of the gene expression for application in health, 
agriculture and industry. The Thesis is broken into four sections: the first Chapter is a 
general introduction to gene regulation, the second chapter is materials and methods. 
Chapter 3 is a manuscript that is written about the stoichiometry and composition of 
the complex in cancer cells. Chapters 4 and 5 are results chapters investigate the 
structure of the subcomplexes. Chapter 6 discuss the finding of this thesis. 
Chapter 1 represents a general introduction to gene regulation and the NuRD complex. 
The NuRD complex is a 1mDa multisubunit transcriptional coregulator protein complex, 
which is widely expressed and harbours both chromatin remodelling and histone 
deacetylase activities. Abnormalities in a number of its components are associated with 
various types of cancers and neurodegenerative diseases. Although the core 
components of the complex have been well established, the structural basis of the 
complex has poorly been studied. Chapter 2 describes the details of the materials and 
methods used in this research. Chapter 3 investigates NuRD complex stoichiometry 
and interactome using a label-free quantitative proteomics method and provides 
biochemical evidence for two new direct interactors of the complex. Chapter 4 and 5 
investigate the recombinantly produced subcomplexes using biochemical and a mass 
spectrometry-based hybrid method for structural modelling of the NuRD complex. 
Chapter 6 discuss the findings and outlines the future directions. 
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Chapter1. Introduction 
The complex molecular networks of mammalian cells are modulated in part through 
spatiotemporal regulation of gene expression. Gene regulation occurs at many 
different levels, including at the level of transcription. The NuRD complex is a 
multisubunit protein complex in higher organisms that directly regulates gene 
transcription through its dual enzyme activities: (i) nucleosome remodelling and (ii) 
protein deacetylation. Our understanding of how (and which) NuRD subunits assemble 
to form the complex and how this molecular machine functions remains limited. This 
thesis seeks to shed more light on the structure and function of the NuRD complex 
using biochemical, molecular & cellular biology and proteomics approaches. 
1.1 Gene regulation  
How does a gene, which is composed simply of a sequence of DNA, ‘know’ when it 
should expose itself to the transcription machinery and as a result be transcribed into 
mRNA? How does a gene know how to escape from that machinery? How does this 
transcribed mRNA undergo appropriate processing to produce a string of amino acids 
called a protein? How do cells in different tissues know which genes they must express 
and at what times? The answers to such questions lie in the study of mechanisms and 
factors involved in gene regulation. 
The extent to which proteins are expressed depends on rates of gene transcription, 
the stability of mRNA, translation rates and protein stability [1-3]. In prokaryotes, 
transcription of several genes occurs under a unique promoter at the same time within 
blocks of genes named “operons”. Then the single transcribed mRNA can encode 
several proteins with different functions [4-6]. However, eukaryotic genomes are 
bigger and more complex than prokaryotic ones, thereby, gene regulation mechanisms 
in eukaryotes are more intricate [7-10]. Eukaryotic gene transcription is controlled by 
mechanisms that include the following: (i) transcription factors (TFs) and co-regulating 
proteins that bind to specific regulatory DNA sequences (e.g., promoters and 
enhancers) and consequently modulate the activity of RNA polymerase [11]; (ii) 
reversible covalent modifications of histone proteins and DNA sequences (e.g., histone 
lysine acetylation and DNA cytosine methylation), which together have been referred 
Chapter 1: Introduction 
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to as epigenetic modifications and which are used as a platform to recruit various 
regulators and chromatin remodelling enzymes (the latter are herein termed 
remodellers) [12, 13] and (iii) changes in chromatin composition arising from 
replacement of canonical histones with histone variants. The coordination between 
epigenetic modifications and transcriptional regulators can guide remodellers to alter 
the structure of the chromatin and activate or repress transcription of nearby genes 
[14-16]. 
1.2 Chromatin 
In humans, each cell contains 6.4 billion base pairs (bp) of DNA sequence, which 
stretched end-to-end would exceed one meter in length [17, 18]. Not only must each 
human cell fit all this genetic information within a nucleus that is ~10 µm across, but 
the cell must also properly replicate and express that genetic information [18]. To 
achieve these goals, cells have developed a nucleoprotein structure, named 
chromatin, which greatly facilitates the storage of eukaryotic genome within cells. 
Chromatin fibers are made of a series of nucleosome modules which in turn are made 
of 147 bp of DNA wrapped around a histone octamer that comprises two copies of 
each core histone protein (i.e., H2A, H2B, H3 and H4) [18, 19]. In general, DNA is 
found in transcriptionally active (open) euchromatin or repressed (tightly packed) 
heterochromatin states. The conversion between euchromatin and heterochromatin is 
controlled by a range of mechanisms, including the remodelling of chromatin structure 
by remodellers using energy derived from ATP hydrolysis and through the effects of 
specific combinations of covalent modifications of both histones (e.g., acetylation, 
methylation, phosphorylation, and ubiquitylation) and DNA [20, 21]. 
1.3 The histone code hypothesis and chromatin remodelling 
Histone proteins are highly conserved from yeast to human, a measure of their 
invaluable structural and functional roles in regulating genome structure and gene 
expression [22, 23]. Histones are highly positively charged proteins of 15-20 kDa in 
size that feature unstructured N-terminal tails that protrude out of the nucleosome. 
The positive charge of histones facilitates their interaction with negative charged DNA. 
The histone tails contain numerous residues, including basic lysines and arginines, 
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that are subject to a variety of reversible posttranslational modifications (PTMs) by 
specific enzymes (Fig 1-1) [24]. Particular combinations of PTMs on a range of 
histones in a nucleosome appear to create a signal to the cell that the transcriptional 
status of a gene should be altered in a particular way, seemingly via the recruitment 
of enzymes and other proteins that recognize these PTMs. For example, the 
methylation of arginine and acetylation of lysine residues in the histone tails are both 
associated with gene activation. In contrast, lysine methylation and serine 
phosphorylation are associated with either activation or repression, depending on the 
location of these modifications [25]. Thus, trimethylation of Lys4 of histone H3 
(referred to as H3K4me3) promotes gene repression, whereas the H3K9me3 
modification is more prevalent at repressed genes [26]. It has also been shown that 
crosstalk between histone modifications is necessary to fine tune the transcriptional 
state of a particular locus. As one example, the methylation of H3K4 by the COMPASS 
protein complex and of H3K79 by the methyltransferase Dot1 are completely 
dependent upon the ubiquitylation of H2BK123 by scRad6/Bre1 [26].  
 
Fig 1-1. Histone codes. Schematic representation of histone modifications on 
histone tails. The posttranslational modifications are shown with different colour 
codes.  
1.4 Histone acetylation and deacetylation 
Histone lysine acetylation first was reported in 1964 by Alfrey et al [27]. Since then it 
has been shown that this PTM is highly dynamic and regulated by the opposing action 
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of histone acetyltransferases (HATs) [27, 28] and deacetylases (HDACs) [28]. These 
enzymes also act on many proteins other than histones, and so have been renamed 
lysine acetyltransferases (KATs) and lysine deacetylases (KDACs).  
In humans, there are 18 proteins annotated as KDACs, which are classified into four 
distinct classes: class I, IIa, IIb, III, IV [28-30]. There are 11 enzymes (HDAC1-11) in 
classes I, II, and IV together; these are known as classical deacetylase enzymes as 
their activities are inhibited by the small-molecule inhibitor trichostatin A (TSA) and 
activity of the enzymes is dependent on metals such as zinc. Crystallography studies 
of mammalian HDACs have shown that the amino acid sequences are conserved in 
the active sites of class I and II and that structure of catalytic domains are very similar 
[31]. In class III, there are 7 deacetylase enzymes (Sir 1-7); these are not inhibited 
by TSA and are known as sirtuins.  
On the other hand, the KATs are composed of three major protein families: GNAT, 
MYST, and p300 enzymes. Each of these families contains several members that share 
a very similar structure containing a core region [32-35].  
Histone deacetylation contributes to maintaining a transcriptionally permissive 
euchromatic state. In part, this outcome might be achieved by the reduction in positive 
charge that results from acetylation. Primarily though, acetylated lysines are thought 
to serve as a recognition signals for protein domains known as bromodomains, which 
are found in ~40 human transcription coactivators and chromatin remodelling 
complexes [36].  
For example, Ferreira et al. showed that acetylation of Lys14 of H3 (H3K14ac) can 
enhance binding affinity of a remodeller named Remodelling the Structure of 
Chromatin (RSC) to the nucleosomes, while acetylated H4 reduces the activity of Chd1 
and Isw2 remodellers by reducing catalytic activity without affecting recruitment [37]. 
In an in vitro study, Chandy et al. demonstrated that the SWI/SNF complex can 
preferentially displace acetylated histones, demonstrating the necessity of histone 
acetylation in chromatin remodelling [38]. Moreover, Bdf1 protein, a bromodomain-
containing subunit of the TFIID complex is able to recognize acetylated H4 and 
consequently regulate the transcription of target genes [39]. Most recently, it has been 
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demonstrated that the activity of CoREST complex (a chromatin silencing complex) is 
limited in the presence of the H3K4ac mark, highlighting the functional importance of 
even a single lysine modification in gene regulation [40].  
1.5 Chromatin remodelling protein complexes 
There are numerous enzymes that have the ability to directly alter nucleosome 
structure and composition, hinting at the importance of this process for the correct 
expression of the genome [20]. In many cases, these remodellers are embedded in 
multi-subunit protein complexes, giving rise to remodelling complexes. 
Chromatin remodelling complexes slide, assemble, remove and substitute histones on 
DNA using energy derived from ATP hydrolysis [15, 41]. This activity takes place at 
DNA elements such as enhancers and promoters, which control gene transcription. 
However, remodellers are indispensable regulators of almost every chromosomal 
process (e.g., DNA replication and repair), and remodeller deregulation leads to a 
variety of diseases, including cancer and neurodegenerative diseases [41].  
Phylogenetic studies have defined four families of chromatin remodellers: CHD 
(chromodomain helicase DNA binding, Mi-2) [42], SWI/SNF (switching 
defective/sucrose non-fermenting) [43], ISWI (imitation switch) [44] and INO80 
(inositol requiring 80) [45]. Interestingly, the same remodeller can promote both 
activation and repression of gene transcription under different circumstances. For 
instance, Brahma-associated factor (BAF) complex, the human homologue of 
SWI/SNF, is capable of switching between these two modes of action even at the 
same gene [46]. It is thus likely that the interaction of chromatin remodelling 
complexes with various transcription factors across tissues and cells allow them to 
take on context-dependent functions. The mechanisms responsible for these 
seemingly opposed activities are not yet well understood. 
1.6 Our structural understanding of chromatin remodellers 
Structural and biochemical studies on ATP-dependent chromatin remodellers reveal 
that they prefer different nucleosomes as substrates to carry out nucleosome 
assembly, editing, and organization, suggesting that different mechanisms of action 
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are employed by various remodellers. For instance, the INO80 remodeller is well 
known for its histone exchange function. INO80 exchanges canonical H2A and H3 with 
H2A.Z and H3.3 variants, respectively [45, 47]. It has also been shown that Chd1 and 
ISWI enzymes are involved in nucleosome assembly and spacing. They are also 
involved in the maturation of pre-nucleosomes into octameric nucleosomes [48, 49]. 
The SWI/SNF subfamily regulates the accessibility of the chromatin to transcription 
factors and other regulating molecules by sliding or ejecting histone octamers from 
chromatin [50].  
Despite the abovementioned diversity in mechanisms of action, remodellers share 
particular properties. As a common example, they show more affinity toward 
nucleosomes rather than naked DNA. All remodeller subfamilies contain a catalytic 
motor ATPase/translocase domain that encompasses two RecA-like lobes (lobe 1 and 
2). Despite their commonality in the ATPase domain they have their own specific 
partner proteins and/or domains that regulate the ATPase activity. As one example, a 
published crystal structure of Chd1 suggests that the activity of the ATPase domain is 
blocked through its double chromodomain, which blocks the binding of the enzyme to 
DNA [51]. The chromodomains also allow for discrimination between nucleosome and 
naked DNA. In addition, the basal ATPase activity of the enzyme is inhibited by an N-
terminal auxiliary domain, named dCD [51]. Similarly, the crystal structure of the ISWI 
enzyme reveals that the catalytic function of the enzyme is regulated by the AutoN 
domain. The AutoN domain binds lobe 1, leading to inactivation of the enzyme. 
Conversely, H4 histone can compete away the AutoN domain and activate the ATPase 
domain [52]. Unlike Chd1 and ISWI, the catalytic activity of Snf2 is not inhibited by 
the regulatory elements. Snf2 has evolved a distinct mechanism whereby the two 
lobes are stacked together and keep the necessary elements away from each other, 
inhibiting ATP hydrolysis [53].  
Most recently published cryo-EM structures of the INO80 complex with a nucleosome 
illustrates that it makes multivalent contacts with DNA and the histones of one gyre 
of nucleosome [54] (Fig 1-2A). The translocase domain binds to nucleosomal DNA 
at superhelical location (SHL) -6 and disrupts the H2A-DNA contacts, unwrapping 15 
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bp of DNA [54]. The structural data suggest a distinct ratchet mechanism of histone 
editing and sliding by INO80 complex.  
Cryo-EM data for the Snf2 remodeller indicate that upon interaction with nucleosome 
the two lobes are realigned and their relative orientation is rotated by 80°, leading to 
activation of the translocase domain (Fig 1-2B ) [55]. Snf2 interacts with the first 
DNA gyre through its helicase motifs in the major domain and the second gyre via a 
positively charged surface. The structure of Snf2 bound to the nucleosome shows that 
Snf2 binds the nucleosome at SHL+2 and SHL+6. In addition to interaction of the 
translocase domain with nucleosomal DNA at SHL2, the basic patch of the H4 tail and 
acidic surface the Snf2 interact with each other. A “wave-ratchet-wave” model has 
been suggested for Snf2 remodeller. 
Similar to Snf2, the Chd1 translocase domain can bind the DNA at SHL+2 and anchor 
to the H4 tail (Fig 1-2C) [56]. Chd1 is able to detach two turns of DNA from the 
histone octamer and bind between the two DNA gyres, facilitating the catalytic activity. 
The DNA binding domains (SANT and SLIDE) grab the detached DNA at SHL-7. The 
structural data suggest a translocation model in which ratcheting between lobe1 and 
lobe 2 of the ATPase underlies the remodeling process. The model indicates that in 
the presence of one ATP molecule binding of the ATPase to DNA in a partially closed 
conformation leads to complete closure of the ATPase and movement of lobe 2, which 
initiates DNA translocation by one base pair. ATP hydrolysis resets the ATPase to the 
previous stage at the new DNA position [56].  
Taken together, despite the available structures for the abovementioned remodellers, 
there is no structural data available for the NuRD complex, even at low resolution. 
Therefore, it seems crucial to investigate the structure and function of the NuRD 
complex. 
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Fig 1-2. Comparison of Cryo-EM structures of chromatin remodellers bound 
to a nucleosome. (A) Structure of Ino80 translocase bound to SHL -6. (B) Snf2 
translocase bound to SHL + 6. (C) Chd1 translocase bound to SHL + 2. Different 
colours were used to show the structure; cyan (remodellers) and pink (histones). 
<Need PDB codes> 
1.7 The NuRD complex  
The Nucleosome Remodelling and Deacetylase (NuRD) complex is perhaps the most 
enigmatic of the major remodellers present in mammals. NuRD is found throughout 
the animal kingdom and plays a critical role in gene silencing and activation during 
normal development, reprogramming of pluripotent stem cells, neuronal connectivity, 
and cancer progression [53, 57-60]. The NuRD complex was first purified two decades 
ago from both human and amphibian cells and was found to exhibit both histone 
deacetylase and ATP-dependent nucleosome remodelling activities [61, 62]. In 
addition, proteins with homology to individual NuRD components have been identified 
in organisms as diverse as nematode worms and plants, although it is currently unclear 
whether the full complex exists in plants.  
In mammalian cells, the canonical NuRD complex appears to consist of six core 
subunits (Fig 1-3) and each of these exists as two or more closely related paralogues. 
Two of the subunits have enzymatic activities: (i) CHD3, CHD4, and CHD5 which utilize 
the energy of ATP hydrolysis to move histone octamers relative to DNA; and (ii) HDAC1 
and HDAC2, which remove acetyl groups from lysine residues of histones and non-
histone proteins. The non-enzymatic subunits are MBD2/MBD3, GATAD2A/GATAD2B, 
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MTA1/MTA2/MTA3, and RBBP4/RBBP7, and DOC-1 or CDK2AP1. The HDAC and RBBP 
subunits are also found in another transcriptional regulatory complexes, including the 
SIN3 [63] and COREST complexes [64, 65], whereas MTA, MBD and GATAD2 proteins 
are largely confined to the NuRD complex.  
 
 
Fig 1-3. NuRD complex subunits. The NuRD complex is composed of MTA1-3 
(metastasis associated proteins), HDAC1/2 (histone deacetylases), RBBP4/7 
(retinoblastoma-associated proteins), MBD2/3 (methyl-CpG-binding domain proteins), 
and GATAD2A/B, and CHD3-5 (chromodomain-helicase-DNA-binding proteins). All 
components have been repeatedly identified as part of the NuRD complex. Question 
marks on the figure indicate the interaction, assembly and stoichiometry of the 
subunits have not been well understood. A homodimeric SANT-ELM2 domain make an 
interaction with the HDAC protein, leading to the formation of a 2 x MTA-HDAC 
heterodimer. Some data suggest that BAH domain is the contact surface of the MBD 
protein, but yet to be characterized. The C-terminal half of MTA interacts with RBBP4 
though a single α-helix. MBD and GATAD2 interact with each other through an 
antiparallel heterodimeric helices.  
1.8 Recruitment of the NuRD to target sites 
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The canonical subunits of the NuRD complex have no sequence specific DNA-binding 
domains but have domains and/or proteins for interaction with sequence specific 
transcription factors or chromatin chaperons and proteins. These properties enable 
selective action of the complex on nucleosomes at specific locations. Site specific 
transcription factors guide the complex to specific regions of the genome during 
development and under different physiological conditions. For example, the interaction 
of ZMYND8 and the NuRD complex can recruit the NuRD complex to sites of DNA 
damage during homologous recombination [57]. In addition, it has been shown that 
the Zinc-finger protein of the cerebellum 2 (Zic2) recruits NuRD to transcriptional 
enhancers in mouse embryonic stem cells (mESCs) and regulates the chromatin state 
and transcriptional output of genes responsible for differentiation [66, 67]. WDR5 and 
UpSET have been shown to recruit NuRD to promoter regions in ESCs [68, 69]. Various 
transcription factors involved in a range of signaling pathways such as friend of GATA 
protein 1 or FOG-1, Snail, Ikaros, and TIF1β have been shown to recruit NuRD to 
regulate a subset of genes in different signaling pathways [70-72]. Similarly, the 
association of chromatin-interacting proteins with NuRD mediates NuRD recruitment 
to regions with varying epigenetic modifications. For instance, BEND3 recruits NuRD 
to H3K9me3 enriched heterochromatin [73]. Most recently, a H2A.Z-specific chromatin 
binding protein named PWWP2A/B has been shown to make a variant NuRD complex 
by competing away the MBD2/3, GATAD2/A, and CHD3/4 proteins. The PWWP2A/B-
NuRD module is most enriched at actively transcribed genes [74]. In summary, 
molecular machines and remodellers such as NuRD need to interact with various 
proteins to exert their function spatially and temporally genome-wide. 
1.9 Molecular function of the NuRD  
Due to the presence of HDAC1/2 in the NuRD complex, several studies published in 
1998 reported that NuRD complex is a transcriptional repressor complex [61, 62, 75]. 
The notion that NuRD is primarily a co-repressor has persisted since that time. 
However, as noted above, ATP-dependent chromatin remodelling complexes have 
been demonstrated to regulate transcriptional activation, and NuRD is no exception. 
In 2004 [76] and 2007 [77], CHD4 was reported to be a transcriptional activator 
because it was shown that CHD4 occupies the regulatory region of CD4 gene and that 
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its removal leads to a significant reduction in CD4 expression. However, whether CHD4 
acted in the context of the entire NuRD complex remained unclear until 2010, when 
Miccio et al. for the first time using a combination of ChIP-Seq and knock-out studies 
showed that the NuRD components MTA2, RBBP4, and CHD4 were present at both 
active and repressed FOG-1 target genes in vivo [58]. They concluded that NuRD is 
widely used by transcription factors to fine-tune the transcription program in a given 
cellular context.  
More recently, Bornelov et al. made use of an inducible transgenic cell line system in 
which MBD3 was fused to the ligand binding domain of the murine estrogen receptor 
(ER) both at the N- and C-terminal ends. This domain localizes MBD3 into the 
cytoplasm, and thus led to disruption of NuRD in the nucleus. Addition of tamoxifen 
into the cell culture medium translocates MBD3 into the nucleus and therefore restores 
NuRD function. Consistent with previous data [78, 79], they demonstrated that both 
Chd4 and Mbd3 occupy active promoters and enhancers. Despite the presence of 
NuRD at active sites, loss of the Mbd3/NuRD resulted in only a moderate change in 
gene expression. Therefore, they concluded that NuRD fine-tunes the gene 
transcription program in embryonic stem (ES) cells by either activating or silencing 
genes [80].  
They further investigated NuRD function in chromatin structure and nucleosome 
positioning (the localization of nucleosomes with respect to the genomic DNA 
sequence) at two genes responsive to NuRD activity: Ppp2r2c and Bmp4. NuRD target 
genes showed positioned nucleosomes at enhancer regions following tamoxifen 
treatment, suggesting that changes in transcription levels of the target genes were 
due to the nucleosome remodelling activity of NuRD. They further investigated the 
binding pattern of pluripotency-associated transcription factors (e.g., Klf4 and Nanog) 
upon tamoxifen treatment and realized that NuRD does not globally decrease the 
binding of TFs but in some cases enhances their binding to target sites.  
1.10 NuRD in pluripotency  
Embryonic stem cells (ESCs) are both pluripotent (they can differentiate into any tissue 
type) and are capable of self-renewal [81, 82]. These abilities are controlled by 
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complex mechanisms that involve epigenetic regulators, a network of transcription 
factors and a range of signaling pathways [82, 83]. ESCs constantly need to silence 
or activate particular sets of genes to either maintain their pluripotency or differentiate 
towards specific lineages. The NuRD complex has been repeatedly implicated as an 
important player in ESC biology [84, 85]. For example, Hendrich and colleagues 
showed that a NuRD complex containing MBD3 but not MBD2 silences pluripotency 
genes and thus allow ESCs to differentiate in a defined medium [86]. In apparent 
contrast, however, Zhu et al., have shown that NuRD is involved in maintaining the 
pluripotent state of mouse ESCs by repressing genes responsible for trophectoderm 
differentiation [87]. In 2013, Rais et al. conducted a loss of function study for several 
epigenetic repressor factors in mouse and human ESCs and noted that MBD3 inhibition 
in the presence of the Oct4, Sox2, Klf4 and Myc transcription factors (OSKM factors 
are reprogramming factors responsible for converting terminally differentiated cells 
back into pluripotent cells) stopped somatic cell proliferation and enabled near 100% 
efficient reversion of somatic cells into pluripotent cells, a feat that had not been 
achieved before [60]. In 2018, the same group demonstrated that GATAD2A but not 
GATAD2B depletion has an even more striking effect; it can enable deterministic 
reprogramming without affecting the proliferation of somatic cells [88]. These findings 
may give a clue to answer questions such as “Why is NuRD absent in less complex 
eukaryotes (e.g., yeast) but present in eukaryotes with a complex gene regulatory 
program?”. It appears that the NuRD complex need to be present to fine tune the 
transcriptional program of higher eukaryotes throughout embryogenesis and 
development.  
1.11 NuRD in disease 
As one might expect for a transcriptional regulatory complex, dysregulation of the 
activity of NuRD complex subunits has been associated with a number of human 
pathologies, such as different types of cancers and neurodegenerative diseases [89-
91]. Regarding cancer, there are lines of evidence implicating the complex both as a 
tumor co-suppressor and as a promoter of cancer [92-94]. NuRD is unique in that it 
carries both MTA1, a tumor activator, and CDK2AP1, a tumor suppressor protein. The 
MTA family proteins are the subunits most frequently associated with cancer. They 
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are linked with poor prognosis and are widely overexpressed in tumors derived from 
different tissues including breast, pancreas, ovary, and prostate [94-97]. The MTA 
family proteins appear to modulate a range of cancer promoting processes, including 
invasion, epithelial-mesenchymal transition (EMT), DNA-damage, metastasis, and 
inflammation [97, 98]. For example, it has been shown that MTA1 and MTA2 promote 
breast cancer progression and metastasis but MTA3 has an opposing function because 
it inhibits the epithelial to mesenchymal transition (EMT) by repressing the expression 
of the Snail gene, a key transcription regulator of EMT pathway, and consequently 
restoring the expression of E-cadherin [99]. Expression of E-cadherin increases 
epithelial cell adhesion, which potentially leads to the suppression of metastasis.  
The MTA proteins regulate the expression and activity of target genes through 
recruiting NuRD to target genomic sites. In addition to transcription repression, MTAs 
can directly interact with transcription factors and deacetylate transcription factors 
involved in cancer, and thus regulate their stability or localization post-translationally 
[100]. For example, deacetylation of p53, a tumor suppressor transcription factor, by 
MTA1- and MTA2-NuRD leads to apoptosis and cell death [101]. Interaction of 
MTA1/HDAC1 with ATF4 leads to deacetylation and increased stability and activity of 
ATF4 which promotes osteosarcoma progression [100]. In addition, MTA1/HDAC1 
interacts with hypoxia inducible factor 1α transcription factor (HIF-1α), leading to an 
increase in its stability and an increase in tumor angiogenesis in a mouse model [102].  
In addition to the studies implicating MTA subunits in cancer progression, exome 
sequencing of endometrial tumors has reported high frequencies of somatic mutation 
in CHD4 (17%) [103]. Likewise, a genetic study on the expression pattern of CHD 
family members in 28 gastric cancer and 35 colorectal cancer (CC) samples revealed 
that the CHD4 protein is depleted in >50% of both types of cancer [104]. However, 
the role of CHD4 in cancer is not clear-cut, and it may be involved in either tumor 
progression or suppression under different circumstances. For example, in 2015 
Sperlazza and colleagues showed that acute myeloid leukemia (AML) cells lacking 
CHD4 failed to show tumorigenesis behavior because the AML cells were unable to 
form xenografts in mice [105].  
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The function of CHD family remodellers has been linked to transcription, which is the 
first step of the central dogma of molecular biology. It can therefore be concluded 
that dysregulation of these proteins can led to aberrations in gene expression and 
cause various diseases. For example, the Cancer Gene Census (CGC) consortium has 
catalogued CHD4 as an oncogene, meaning that CHD4 is mutated in cancerous tissues 
[106]. Several studies have investigated the role of CHD4 in genome integrity and 
DNA damage repair. For example, Burd et al. showed that the expression of CHD4 is 
increased upon irradiation with UV, and that the protein is subsequently localized to 
DNA damage sites [107]. It is likely that in this situation, it assists in DNA repair by 
making the surrounding DNA more accessible to the repair machinery, but there are 
no clear data that define its role. 
1.12 NuRD subunits 
As noted above, each NuRD subunit has several paralogues, leading potentially to the 
creation of variants of the complex in different cells and tissues or at different times. 
As shown in Fig 1-4, some of these paralogues share a very high sequence identity. 
For example, RBBP4/7 and HDAC1/2 are 89% and 85% identical. In contrast, some 
subunit paralogues share identities that are as low as 45%. 
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Fig 1-4. NuRD subunit homology. The graph represents the protein sequence 
identity between paralogues. BLAST was used to determine  identity [108]. 
 
1.12.1 MTA1-3 
The MTA family include three genes and multiple alternatively spliced variants. MTA1, 
MTA2 and MTA3 have ~60% sequence identity to each other and are 80 kDa, 75 kDa, 
and 65 kDa, respectively (Fig 1-5A). All three MTA paralogues display fundamentally 
the same domain structure [109], with the exception that MTA3 lacks one RBBP4 
binding site. The N-terminal bromo-adjacent homology domain (BAH), Egl-27 and 
MTA1 homology2 (ELM2), Swi3, Ada2, N-Cor, and TFIIIB (SANT) and zinc finger (ZnF) 
domains of these proteins are very conserved, whereas the C-terminal regions are 
more divergent [110]. Phylogenetic analysis of the MTA family proteins indicates that 
the BAH, the ELM2, the SANT, and ZnF domains are also well-conserved across 
evolutionary space [108].  
All of these domains have been implicated in chromatin recognition. The BAH domain 
is generally found in proteins that interact with nucleosomes. For example, a crystal 
structure of yeast Sir3 BAH domain bound to nucleosome is available (Fig 1-5B) 
[111]. Interestingly, most ELM2 domain-containing proteins also have a SANT domain, 
which suggests a functional and/or structural association between these two domains 
[112]. It has also been shown that the ELM2-SANT domains together interact with 
HDAC proteins [112, 113]. The structure of ELM-SANT has actually been determined 
in complex with HDAC1 (Fig 1-5C). The structure of the MTA-HDAC complex is a 
critical part aspect this thesis because we normalize the determined stoichiometry 
based on this structure (see Results) [111]. 
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Fig 1-5. Structural domains of MTA family proteins. (A) BAH, ELM2, SANT, and 
ZNF domains located at the N-terminus are highly similar, whereas the C-terminal half 
of MTA proteins is divergent. (B) High resolution crystal structure of Sir3 BAH domain 
with two views. Different colours was used to show the structure: Orange (H2A), green 
(H4), light pink (H2B), blue (H3), and yellow (H2A) ((B) was adapted from [111]. (C) 
Crystal structure of the MTA1-HDAC1 complex. Subunit colours are as in Fig 1-3. 
1.12.2 HDAC1/2 
HDAC1 and HDAC2 are highly conserved (~85% sequence identity) proteins and 
belong to the family of class I histone deacetylases (Fig 1-6). It has been shown that 
HDACs cannot act independently but function as subunits of multiprotein complexes 
[113, 114]. HDAC1/2 are highly and widely expressed across fetal and adult tissues. 
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In addition to the NuRD complex, they are found in other multisubunit protein 
complexes, including Sin3 [63], CoREST [65], and NCoR [113, 115]. HDAC1/2 use a 
zinc-containing deacetylase catalytic domain remove acetyl groups (O=C-CH3) from a 
ε-N-acetyl lysine in histones, transcription factors and other proteins. They remove 
the acetyl mark with the aid of the cofactor inositol-tetraphosphate [Ins (1, 4, 5, 6) 
P4] [112].  
There are lines of evidence indicating that HDAC1 and HDAC2 may have distinct 
functions [116]. For example, during oogenesis HDAC2 has been suggested to play a 
more important role than HDAC1, whereas HDAC1 may play a more critical role than 
HDAC2 in oocyte development at the preimplantation stage [117]. In addition, it has 
been shown that HDAC2 expression is dysregulated significantly compared to HDAC1 
in schizophrenia patients [118].  
 
Fig 1-6. A schematic of HDAC1 domain structure. HDAC1 and HDAC2 share a 
highly conserved N-terminal HDAC domain  that is essential for homo- and hetero-
dimerization. HDAC2 contains a predicted coiled-coil domain at the C terminus.  
1.12.3 CHD3-5 
In humans, the CHD family of ATP-dependent DNA translocase proteins comprises 
three subfamilies that display specific domain architectures in addition to the DNA-
translocase and pair of chromodomains: (i) CHD1/2; these remodellers contain a DNA-
binding domain at the C-terminal region that is capable of binding to AT-rich DNA 
motifs [51, 119] (ii) CHD3/4/5; these remodellers appear to lack the DNA-binding 
domain at the C-terminal part but harbour a pair of PHD-finger like domains. There is 
a discrepancy about the classification of CHD5 as it contains both the CHD fingers and 
a SANT-like domain in the C-terminus [120] (iii) CHD6-9; the signature of this family 
is a SANT-like domain in the C-terminus [120, 121].  
The plant homeodomains (PHDs) are exclusively found in CHD3/4/5, which might 
indicate a specific mode of action to these remodellers compared to other remodellers 
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[120]. Structural studies have demonstrated that PHD1 and PHD2 bind methylated 
Lys9 in peptides corresponding to the N-terminal tail of histone H3 [122, 123]. It was 
concluded that CHD4 can coordinate the binding of the NuRD complex to two separate 
H3 N-terminal tails on the same nucleosome or alternatively on a dinucleosome. 
Therefore, PHD1 and PHD2 fingers might be critical for the remodelling activity of the 
NuRD complex. Our laboratory determined the structure of an N-terminal region of 
CHD4. The N-terminal domain is a four-helix bundle, which is structurally similar to 
the mobility group box (HMG-box), a domain that is well known as a DNA-binding 
module. Unlike other regions, the C-terminal part of the CHD4 protein has not been 
well studied yet. Mutational analysis on the C-terminal domain (CTD) of CHD4 shows 
that it is important for NuRD complex function but not for remodelling activity [124]. 
Structural studies using a combination of small-angle X-ray scattering (SAXS) and 
crosslinking (XL) mass spectrometry (MS) or XL-MS/MS indicate that CHD4 PHD and 
CHD domains make an extensive contact with each other [125]. This interaction 
appears to limit the activity of the ATPase domain and also interaction of the CHD4 
with nucleosomes. Therefore, it appears that the tandem PHD-CHD region can play a 
regulatory function and that a rearrangement in the structure of CHD4 might be 
required to stimulate its enzymatic activity (Fig 1-7).  
Genome-wide expression studies show that CHD3 and CHD4 are ubiquitously 
expressed across human tissues but at different levels; CHD4 is found at higher levels 
than CHD3 [126]. In contrast, CHD5 expression is restricted to the brain and 
cerebellum. Consistent with expression data, biochemical studies demonstrate that 
CHD4 is the dominant NuRD associated translocase, whereas CHD5 is only purified 
with NuRD isolated from brain tissue [127].  
 
 
Fig 1-7. Structural domains of CHD4. CHD family proteins contain an HMG-box 
domain involved in DNA binding [128], two PHD domains, two chromo domains (CDs), 
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and a SNF2-type DNA translocase domain. C-terminal domains (CTDs) of unknown 
structure or function also exist.  
1.12.4 GATAD2A/B 
GATA Zinc Finger Domain containing 2A and 2B (GATAD2A/B) share 52% sequence 
identity and are widely expressed in various tissues [87]. GATAD2A/B share two highly 
conserved coiled-coil regions, named CC1 and CC2, as well as a GATA-type zinc finger 
(GATA ZnF) [129] (Fig 1-8A, B). It has been shown that the CC1 region in 
GATAD2A/B is responsible for direct interaction with the MBD2/3 proteins [130, 131]. 
MBD2 and MBD3 have the same CC– and GATAD2A and B both do too. 
Biochemical assays have demonstrated that the CC2 region and GATA ZnF mediate 
the binding of GATAD2 proteins to all histone tails but detailed structural analysis is 
needed to further validate these findings [130]. In addition, a single amino acid 
mutation (K149R) in GATAD2A disrupts the interaction with MBD2 and consequently 
losing its repressive function [130]. Similarly, the depletion of GATAD2 proteins 
interferes with the repression mediated by MBD2 protein. In 2011, Gnanapragasam et 
al. solved the coiled-coil structure formed between GATAD2A and MBD2 [132]. 
Interestingly, two recent studies have pointed out a paralogue specific function for 
GATAD2-NuRD. Spruijt et al. have shown that GATAD2A but not GATAD2B interacts 
with ZMYND8 via a short motif (PPPL in GATAD2A) [57], suggesting that the two 
paralogues define mutually exclusive NuRD subcomplexes. Furthermore, as noted 
above, Mor et al. have demonstrated that GATAD2A but not GATAD2B is a determining 
factor for the production of iPS cells from somatic cells [88]. 
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Fig 1-8. Structural domains of GATAD2A/B. (A) GATAD2A/B contain two distinct 
coiled-coil domains to interact with MBD2/3 and GATA domain. The structure of the 
CC1 is available and is indicated in green, but the structure of CC2 has not been solved 
yet. (B) Solution structure of the p66α (green)–MBD2 (brown) coiled-coil complex. 
Subunit colours are as in Fig 1-3. 
1.12.5 MBD2/3 
MBD2/3 belongs to the methyl-CpG binding domain (MBD) protein family, which 
contains other MBD proteins as well (e.g., MBD1-4) [133]. MBD proteins have been 
reported to bind methylated DNA (Fig 1-9). MBD3 lacks the N-terminal part of MBD2, 
which contains glycine-arginine repeats. In a very recent finding Liu et al.  showed 
that, in addition to mCG sites, MBD domain can also bind mCG, mCAT, mCAC as well 
as unmethylated CA or TG sites in dsDNA. Similar to GATAD2A and –B, the MBD2 and 
MBD3 proteins are also mutually exclusive in NuRD, defining different subpopulations 
of the complex [134]. MBD3 knock-out in mice is embryonic lethal, while in contrast 
MBD2 deficient mice are viable with only minor defects [59]. It thus appears that the 
MBD3-NuRD complex plays a more important role in embryogenesis than MBD2-NuRD. 
One of the epigenetic mechanisms that cells have developed to suppress transcription 
of genes is the addition of methylation marks on promoters and enhancer DNA [135, 
136]. The NuRD complex has been proposed to read DNA with a 5-methycytosine 
modification, through the action of the methyl CpG-binding domains (MBDs) of 
MBD2/3 proteins [136].  
 
 
Fig 1-9. Schematic overview of the MBD2/3 proteins. MBD2 and MBD3 both 
contain MBD and coiled-coil (CC) domains. MBD2 contains an additional N-terminal 
region of unknown function. 
1.12.6 RBBP4/7 
RBBP4/7 are highly similar (with ~92% identity) in amino acid sequence and belong 
to a structural class of proteins known as the WD40 repeat proteins (Fig 1-10). They 
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were characterized for the first time through their interaction with the retinoblastoma 
protein [137]. Structural studies have shown that RBBP4 make a strong contact 
through its negatively charged binding pocket with the 15 N-terminal amino acids of 
the FOG-1 transcription factor [138]. Interaction of the RBBP4 and FOG-1 is of 
importance because we make use of this interaction to purify endogenous NuRD 
complexes. In addition, the first crystal structure showing the interaction of MTA1 with 
RBBP4 was published in 2014 by Alqarni et al [139]. Negative staining electron 
microscopy (EM) structures reveal an extensive interface between the MTA1 and 
RBBP4 proteins and that the C-terminal half of MTA1 contains two RBBP4 binding sites 
(Fig 1-10). RBBPs are found in several chromatin-modifying complexes, including 
NuRD and Sin3 [63], NURF (nucleosome remodelling factor) [140] and PRC2 [141]. 
Although they are highly similar, it is possible that they might carry out at least partially 
distinct functions because they are, in some cases, found in distinct complexes. For 
example, the CAF-1 complex contains only RBBP4 but not RBBP7 [142], whereas the 
HAT1 complex contains only RBBP7 [143].  
 
Fig 1-10. RBBP4/7 domain topology and structure. (A) Domain structure of 
RBBP4. (B) Both RBBP4 and RBBP7 form seven-bladed beta-propellers. The structure 
of RBBP4 (blue) bound to the R2 region of MTA1 (magenta) is shown. Subunit colours 
are as in Fig 1-3. 
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1.12.7 CDK2AP1/DOC-1 
In 1995, Todd et al. discovered DOC-1, a small 115-residue protein in oral cancer cells 
[144]. The structure of DOC1 resolved by NMR shows a homodimeric structure that 
includes an intrinsically disordered 60-residue N-terminal region and a four-helix 
bundle dimeric structure with reduced Cys105 in the C-terminal part [145]. DOC-1 was 
characterized as a tumor suppressor protein which is downregulated or absent in 
majority of cancers. For example, DOC-1 is highly downregulated in oral and colon 
cancers. In 2006, Le Guezennec and colleagues could demonstrate that DOC-1 is a 
bona fide member of MBD3-NuRD and MBD2-NuRD complexes [134]. Recently, Mohd-
Sarip and colleagues showed that DOC-1-NuRD reverses the epithelial to 
mesenchymal transition (EMT) in human squamous cell carcinomas by initiating 
epigenetic reprogramming and transcriptional silencing [146].  
 
1.13 Aims of this thesis 
Since the discovery of NuRD in 1998, the biological function of the complex has been 
investigated extensively. Structural and biochemical data have also been reported for 
individual subunit domains or several subcomplexes. However, the overall architecture 
and the biochemical details underlying the function of the complex has not been 
addressed, which is largely due to difficulties in purification of a homogenous complex, 
as well as the fact that the complex is not found in yeast (the protein source for almost 
all structural studies of chromatin remodelling complexes). The goals of this thesis are 
to begin to address the deficits in our knowledge of NuRD complex structure and 
interactions.  
Chapter 2 describes materials and methods used in this thesis. Chapter 3 aims to 
unveil the stoichiometry of the intact complex because previous studies reported 
different stoichiometries for the complex, and therefore the stoichiometry of the 
complex is open for discussion. Another aim of chapter 3 is to unveil the stoichiometry 
of the complex across multiple cell lines. We also aim to search for cell type specific 
or new interacting partners of the NuRD complex. Chapter 4 and 5 aim to draw a 
better picture of the structure and assembly of core subcomplexes of the NuRD 
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complex by probing subunit interactions, stoichiometry and topology using chemical 
crosslinking combined with mass spectrometry (XL-MS/MS), DIA-MS, and single 
particle electron microscopy (SPEM). Chapter 6 contains a final discussion that brings 
the experimental data into context.  
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Chapter 2: Materials and Methods 
2.1 Materials 
This section covers materials used for Chapters 3, 4 and 5. All buffers and solutions 
were made up in Milli-Q water (MQW) unless otherwise stated. The below tables 
(Tables 1 and 2) contain list of chemicals, reagents and consumables used, and their 
suppliers. 
Table 2-1. Chemicals, reagents and consumables 
Reagents Suppliers 
2,2-dimethyl-2-silapentane-5-sulfonic acid (DSS)  Fluka 
Piperazineethanesulfonic acid (HEPES) Gymea 
2-mercaptoethanol  Sigma-Aldrich 
2-log DNA standard  NEB 
Phenylmethanesulfonyl fluoride (PMSF)  Sigma 
Anti-FLAG® M2 Antibody Cell Signalling 
HA-Tag (C29F4) Rabbit mAb Cell Signalling 
IGEPAL Sigma 
Agar  Amyl media 
Amylose resin  NEB 
Bovine serum albumin (BSA, monomeric)  Sigma 
Bovine serum albumin, multimeric (BSA multimeric) Sigma 
3× FLAG peptide (MDYKDHDGDYKDHDIDYKDDDDK) Sigma 
Complete® EDTA-free protease inhibitor cocktail tablet  Roche 
Deoxyribonucleotide triphosphates (dNTP for PCRs)  Bioline 
Dithiothreitol (DTT)  GOLD Biotechnology 
Deoxyribonuclease I (DNaseI)  Roche 
Glutathione resin  GE Healthcare 
RevertAid First Strand cDNA synthesis kit Thermo Fisher Scientific 
Gibco Dulbecco’s Modified Eagle Medium Sigma 
Lysozyme  Sigma 
Mark 12 Protein standard  Life Technologies 
Syringe driven filter (0.22 µM)  Millipore 
Thermosensitive shrimp alkaline phosphatase  Promega 
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Tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl)  Sigma 
Glutathione Sepharose® 4B beads Sigma 
Anti-FLAG M2 Affinity Resin Sigma 
PowerUp™ SYBR™ Green Master Mix Thermo Fisher Scientific 
SMARTpool: ON-TARGETplus MTA1 siRNA Dharmacon 
SMARTpool: ON-TARGETplus MTA2 siRNA Dharmacon 
SMARTpool: ON-TARGETplus MTA3 siRNA Dharmacon 
Glutathione Sepharose 4B GST-tagged protein purification resin GE Health Care 
 
Table 2-2. Buffers and solutions 
Buffers Constituents 
SEC mobile phase 30% acetonitrile (300 mL of 100% ACN per liter), 0.1% 
trifluoroacetic acid (1 mL of 100% TFA per liter) 
3× FLAG Peptide Elution Buffer 
150 mg/mL 3× FLAG peptide, 10 mM HEPES-KOH, 150 
mM NaCl 
5% Sucrose Buffer  50 mM HEPES-KOH, 150 mM NaCl, 5% v/v sucrose 
35% Sucrose Buffer  50 Mm HEPES-KOH, 150 mM NaCl, 35% v/v sucrose 
Binding Buffer  
50 mM HEPES-KOH, pH 7.4 150 mM NaCl, 1% Triton X-
100 
Expi293™ Expression Media  Purchased from Thermo Fisher Scientific (Scoresby, VIC) 
Bead Recovery Buffer 0.1 M glycine HCl PH 3.5 
GSH Bead Wash Buffer  
20 mM HEPES-Na, pH 7.6, 300 mM NaCl, 10% v/v 
glycerol 1 mM DTT, 0.5 mM PMSF 
High Salt Binding Buffer  
50 mM HEPES-KOH pH 8.0, 500 mM NaCl, 1% v/v Triton 
X-100, 1 mM DTT  
High Salt IP Wash Buffer  50 mM Tris pH 7.9, 500 mM NaCl 0.5% v/v IGEPAL 
IP Wash Buffer  50 mM Tris pH 7.9, 150 mM NaCl, 0.5% v/v IGEPAL 
Tris Buffer  20 mM Tris-HCl pH 7.9, 
Luria-Bertani broth (LB) Media 1% w/v peptone 0.5% w/v, yeast extract 0.5% w/v NaCl 
Lysis Buffer  
50 mM Tris-HCl pH 7.9, 150 mM NaCl, 1% v/v Triton X-
100, 1 mM PMSF, 0.2 mM DTT 
PBST  100 ml PBS 10×, 1 ml Tween 20 pH 7.4 
PBS (1×) 100 ml PBS 10× pH 7.4 
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PreScission Cleavage Buffer  
50 mM HEPES-KOH, 500 mM NaCl, 1% Triton X-100, pH 
8.0, 1 mM DTT, added right before use 
 
2.2 Methods 
2.2.1 Cloning 
2.2.1.1 Primer design 
Primers were designed using online Oligo Analyzer 3.1 tool from Integrated DNA 
Technology. Regions complementary to the template had melting temperatures of 
~60 ºC. Universal sequences encoding FLAG and HA tags were also added to the 
sequences. Forward primers for both HA and FLAG were the same and had a stop 
codon (TGATCAGAATTCTGCAGATATCCATCAC). The reverse primers for HA and FLAG 
were specific as follows: HA reverse primer: CCT ATT ATG TGT TCT AGT GGA TCC 
TCT AGA AGC GTA ATC, FLAG reverse primer: CCT ATT ATG TGT TCT AGT GGA TCC 
CTT GTC ATC GTC. Nucleotides shown in Italic are linker regions for Gibson assembly 
[147], while the underlined sequences are HA and FLAG specific sequences, 
respectively. 
2.2.1.2 RNA isolation & cDNA synthesis 
RNA was extracted from 1 million fresh or frozen cells using PureLink RNA Mini Kit 
(Thermo Fisher Scientific). All materials and reagents used for RNA extraction were 
RNAse free and sterile. In brief, cells were lysed in the lysis buffer with 1% (v/v) 2-
mercaptoethanol (Sigma Aldrich). Then binding, washing and elution were performed 
using Spin Cartridges according to the manufacturer’s protocol. Two micrograms of 
the total RNA was treated with DNase I at 37 °C for 30 min, and then inactivated by 
incubation with 1 µL 25 mM EDTA at 65 °C for 10 min. RNA was then transcribed into 
complementary DNA (cDNA) using RevertAid First Strand cDNA Synthesis Kit (Thermo 
Fisher Scientific) using Olig dT primers and incubation at 25 °C for 5 min, 42 °C for 
60 min, and 70 °C for 5 min. The cDNA was further diluted 6× with dH2O for use in 
real-time polymerase chain reactions (RT-PCR). 
2.2.1.3 Polymerase chain reaction (PCR) 
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PCR was conducted in 25 μL reactions containing 2 U Phusion DNA polymerase in 
Phusion buffer (20 mM Tris pH 8.8, 10 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4, 
0.1% (v/v) Triton X-100), 10% (v/v) DMSO, 0.4 μM each of forward and reverse 
primers (Appendix A) and ~15–50 ng plasmid template (pcDNA3.1) or 100 ng cDNA 
template. PCR programs consisting of 30 cycles of 35 s denaturation (98 °C), 30 s 
annealing (60 °C, depending on primer set) and 30 s/kb extension (72 °C) were run 
on an Eppendorf Mastercycler Nexus Thermal Cycler (Sigma Aldrich). 
2.2.1.4 Gibson assembly 
A vector backbone with overhangs matched to the PCR products was produced with 
PCR. The PCR products were DpnI digested and column purified (DpnI digests the 
methylated parental vector used as the template and increases the cloning efficiency). 
PCRs on cDNA with gene specific primers were not DpnI digested as there was no 
parental vector. For those PCR products that contained non-specific products, the 
band of the correct size was cut from an agarose gel, otherwise PCR products were 
column purified. The purified gene fragments and vector backbones were combined 
in a molar ratio of 3:1 and assembled in a one-step isothermal reaction at 50 °C for 4 
h with buffer (25% (v/v) PEG-8000, 500 mM Tris-HCl pH 7.5, 50 mM MgCl2, 50 mM 
DTT, 4 mM dNTPs, 5 mM nicotinamide adenine dinucleotide) and Gibson master mix 
containing a cocktail of three enzymes: (i) T5 exonuclease, (ii) Phusion DNA 
polymerase, and (iii) Taq DNA ligase.  
2.2.1.5 Colony PCR 
Colony PCR is a convenient high-throughput method for rapid screening for the 
presence or absence of insert DNA in the plasmid of interest, following a cloning 
procedure. Following bacterial transformation, seven colonies were randomly selected 
for PCR screening to find correct clones for further analysis. Primers complementary 
to the pcDNA3.1 vector backbone on either side of the insert location were used for 
screening because it prevents false positives arising from amplification of free insert. 
Colonies were picked up with white crystal tips and dissolved in PCR reaction buffer 
by pipetting and vortexing. The PCR program was the same as mentioned above with 
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the exception that preheating at 98 °C was done for 5 min to ensure bacterial cell wall 
disruption. 
2.2.2 Cell culture 
2.2.2.1 Expi293 cells 
Expi293 cells are HEK293 cells that have been adapted to grow to a higher density 
than normal HEK293 cells and give a higher expression yield when used for 
overexpression of a transiently transfected construct. Expi293 cells are grown in either 
autoclaved sterilized conical flasks or sterile 6-well plates, depending on the scale of 
the experiment. Maintenance cultures were grown in Expi293™ Expression Medium 
with the addition of 1:1000 (U/mL) penicillin and streptomycin. They were incubated 
at 37 °C with 5% CO2 on a shaking platform spinning at 130 RPM.  
2.2.2.2 NTERA2, PC3 and MCF7 cell culture 
NTERA2 cells were cultured in modified Eagle medium (DMEM)/F12 (Thermo Fisher 
Scientific), whereas PC3 and MCF7 cells were cultured and maintained in RPMI-1640 
medium (Thermo Fisher Scientific). All media were supplemented with 200 μM L-
glutamine, 50 U/mL penicillin, 50 μg/mL streptomycin, and supplemented with 10% 
FBS. Cells were cultured in 75-cm2 flasks under conditions of 5% CO2 and 37 °C, and 
subcultured 2 times per week at a dilution of 1:5–1:10, depending on the cell line. For 
subculture, cells were detached from the plate floor by trypsinization. All cell culture 
work was performed under sterile conditions. All transfection mixes were prepared 
using the relevant medium without antibiotics and serum. 
2.2.3 siRNA knock down experiment 
For siRNA knock down, reagents and tips and tubes were RNase free and sterile. 
NTERA-2 cells were used for MTA1/2/3 knock-down because our western blotting 
analysis on the cell lysate using MTA1/2/3 specific antibodies showed that these genes 
express at a high level. For siRNA knock down, SMARTpool ON-TARGETplus siRNA 
reagents containing a pool of four siRNA duplexes specific for each MTA gene were 
purchased (Dharmacon Inc). The number of cells seeded was calculated such that the 
cells would be ~50% confluent on the transfection day. In brief, for a 6-well plate 
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transfection 214 µL of 5 µM siRNA was mixed with 1045 µL serum-free medium in one 
tube. In another tube 50 µL of dFECT1 reagent was mixed with 1210 µL serum-free 
medium in separate tubes and incubated for 5 min at room temperature (Table 2-4). 
Then tubes 1 and 2 were mixed and incubated for 20 min at room temperature. The 
mixed solutions were added into 8.2 mL complete medium (FBS+, P/S-) and mixed 
well. About 2 mL of the siRNA solution was added into each well in a 6-well plate. One 
day after transfection, the medium was changed to reduce the toxicity of the 
transfection reagents. Cells were collected 72 h post-transfection and washed 2 × with 
cold PBS and stored at -80 °C. 
 
 
2.2.4 Quantitative real-time PCR (qRT-PCR, qPCR)  
For qPCR analysis, a 20 µL PCR reaction mixture [10 µL PowerUp™ SYBR™ Green 
Master Mix (Thermo Fisher Scientific) containing Dual-Lock™ DNA polymerase 
enzyme, dNTPs, 2 µL of 6× diluted cDNA, and 5 µM of each forward and reverse 
primers (Appendix B)] were made. The following PCR protocol was used for gene 
expression analysis: denaturation for 2 min at 95 °C, annealing for 30 s at 60 °C, and 
amplification at 72 °C for 20 s. This series was repeated for 40 cycles. For qRT–PCR 
data analysis, the ddCt method (2-(ΔΔCt)) was used and GAPDH was used as an 
internal control.  
2.2.5 Protein production and FLAG-affinity purification 
Table 2-4. Amount of siRNA and reagents used for knock down in a 6-well plate (Volumes 
are in µL) 
siRNA Tube 1 Tube 2 Mix of 
Tube 1&2 
Complete 
medium (P/S-) siRNA (5 µM) Serum-Free 
medium  
 dFECT  Serum-Free 
medium  
MTA1 214 1045 50 1210 2520 8200 
MTA2 214 1045 50 1210 2520 8200 
MTA3 214 1045 50 1210 2520 8200 
MTA1/2/3 214 of each 1045 50 1210 2945 7800 
Mock  - - 50 1210 1260 9440 
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2.2.5.1 Protein production in mammalian EXPI293 cells  
For transfection, ExpiI293 cells at a density of ~1.5–2 × 106 cells/mL was used. The 
cells were cultured at 37 °C, 130 rpm and 5% CO2. For transfection of 1 mL of culture, 
plasmid DNA (2 µg) and PBS (104 µL) were first mixed. Then PEI (4 µg, Polyscience 
Inc) was added and the mixture was vortexed for 10 s. After incubation for 20 min, 
the mixture was added to the cells. The transfected cells were incubated for 72 h at 
37 °C, 130 rpm and 5% CO2. At collection time, the cells were counted, transferred 
to falcon tubes and centrifuged at 300 g and 4 °C for 5 min. The pellet was washed 
with cold PBS twice and then flash frozen in liquid nitrogen for storage at –80 °C. For 
pull down experiments, 20 µL of anti-FLAG Sepharose 4B beads [Biotool, pre-
equilibrated with 50 mM Tris-HCl, 150 mM NaCl, 0.1% (v/ v) Triton X-100, 1× 
complete EDTA-free protease inhibitor, 0.2 mM DTT, pH 7.5] was added to cleared 
HEK cell lysate. The mixtures were incubated overnight at 4 °C with orbital rotation. 
Post-incubation, the beads were washed with 1 mL wash buffer (50 mM Tris-HCl, 150 
NaCl, 0.5% (v/v) IGEPAL CA630, 0.2 mM DTT, pH 7.5). Bound proteins were eluted 
three times for 1 h in each round at 4 °C using 20 µL elution buffer (10 mM HEPES, 
150 mM NaCl, 300 µg 3× FLAG peptide, pH 7.5). Elution fractions were pooled for 
downstream analyses.  
2.2.5.2 Protein production and purification in cell free system 
(Rabbit Reticulocyte Lysate) 
Each rabbit reticulocyte lysate (RRL) was set up by adding 1.5 µg plasmid, 2 U RNAse 
inhibitor (Bioline), and 2 µL methionine to 80 µL RRL lysate (Promega) and incubating 
the mixture for 3 h at 30 °C. Twenty microliters of anti-FLAG Sepharose 4B beads 
[Biotool, pre-equilibrated with 50 mM Tris-HCl, 150 mM NaCl, 0.1% (v/v) Triton X-
100, 1× complete EDTA-free protease inhibitor, 1 mM DTT, pH 7.5] was added to the 
RRL reactions. Then, 400 µL of mixing buffer (200 mM NaCl, 70 mM Tris-HCl, pH 7.5) 
was added to RRL+beads mixture. The mixtures were incubated overnight at 4 °C 
with end-over-end rotation at 25 rpm. Post-incubation, the beads were washed 3 times 
with 800 µL wash buffer (50 mM Tris-HCl, 150 mM NaCl, 0.5% (v/v) IGEPAL CA630, 
and 1 mM DTT, pH 7.5). Bound proteins were eluted three times by 20 µL of elution 
buffer (50 mM Tris- HCl, 150 mM NaCl, 10% (v/v) glycerol, 1 mM DTT, 300 µg/mL 3× 
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FLAG peptide, pH 7.5) for 30 min to 1 h on a shaking platform at 150 rpm in a cold 
room. Elution fractions were pooled for downstream analyses. 
2.2.5.3 Preparing sucrose gradients (tilting method) 
In two different falcon tubes, buffers (50 mM HEPES-KOH pH 8.2 and 150 mM NaCl) 
were made containing either 5% (w/v) or 35% (w/v) sucrose; both buffers were 
filtered. The 5% sucrose buffer was added to a 12 mL ultracentrifugation tube 
(Beckman Coulter) using a syringe with a Pasteur pipette attached to it. Then, using 
the same syringe, 6 mL of 35% sucrose buffer was added onto the bottom of the tube 
very gently with care not to introduce any bubbles, and the tube was sealed with 
parafilm. The tube was slowly tilted onto its side (exactly horizontal) for 4 h at room 
temperature, and then were left standing at 4 °C for at least 1 h prior to usage. The 
NuRD complex sample (200 µL) was then layered on top of the gradient and 
centrifuged (186,000 g, 4 °C, 18 h). The gradients were fractionated as 200-µL 
aliquots.  
2.2.5.4 Protein concentration and buffer exchange 
For protein concentration and buffer exchange, samples from pull down experiments 
were concentrated using Amicon Ultra Centrifugal cellulose filters (Millipore) with 
molecular weight cut-offs of 50 kDa or 100 kDa, depending on the size of the protein 
complex. Protein concentration was done according to the manufacturer’s protocol but 
at low speed to prevent precipitation (700–1000 g). For larger volumes, 4-mL falcon 
tubes were used.  
2.2.6 Native NuRD complex pull down 
2.2.6.1 Preparation of bead-bound-GST-FOG  
An aliquot of 5 × 108 bacterial cells was used to purify GST-FOG1 (1-45) protein to be 
used as a handle/bait protein. Complete protease inhibitor cocktail (1×), lysozyme 
(100 µg/mL) and DNase I (10 µg/mL) were added prior to sonication (2 min at 25% 
output). The sonicated using Ultrasonic Homogenizer, lysate was cleared by 
centrifugation (16000 g, 20 min, and 4 °C). The soluble fraction was applied to 200 
µL GSH beads (Sigma Aldrich) that had been pre-equilibrated with 5 column volumes 
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of  binding buffer (50 mM HEPES-KOH pH 7.4, 150 mM NaCl, 1% Triton X-100). The 
beads and soluble fraction were incubated together for 2 h with end-to-end rotation. 
Beads were collected at 800 g at 4 °C and washed three times with five column 
volumes of wash buffer (20 mM HEPES-Na pH 7.6, 300 mM NaCl, 10% glycerol, 1 mM 
DTT, 0.5 mM PMSF).  
 
2.2.6.2 NuRD extraction from nucleus 
About 200 × 106 NTERA-2, PC3, and MCF7 cells were resuspended in lysis buffer (10 
mM HEPES-KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl) and swelled on ice for 10 min 
before addition of 0.6% v/w IGEPAL and further swelling for 15 min with occasional 
gentle pipetting. After swelling, nuclei were pelleted by centrifugation at 3000 g for 5 
min at 4 °C, then the cytoplasmic fraction (the supernatant) was collected into a new 
Eppendorf tube. The pelleted nuclei were resuspended in a further 10 mL lysis buffer 
with 0.6% IGEPAL and once again pelleted by centrifugation and the supernatant was 
removed as before to remove cytoplasmic residuals. The nuclei were then 
resuspended in 1 mL binding buffer (50 mM HEPES-KOH pH 7.4, 150 mM NaCl, 1% 
Triton X-100) and sonicated on ice at 30% output for 1 min. The disrupted nuclei were 
incubated on ice for 1 h before centrifugation at 20,000 g for 10 min at 4 °C to remove 
insoluble components (the chromatin fraction). The resulting supernatant was the 
nuclear fraction.  
2.2.6.3 NuRD pulldown experiment 
The cleared nuclear lysate was incubated with GST-FOG1 bait protein for 2 h to 
overnight at 4 °C with rotating to trap the NuRD complexes. After incubation, the 
beads were washed with 1 mL high-salt binding buffer and once with 1 mL binding 
buffer without Triton-X. NuRD complex was eluted with GSH elution buffer (50 mM 
HEPES-KOH pH 8, 150 mM NaCl, 1 mM DTT 50 mM, glutathione (0.015 g/mL). The 
resulting elutions were analyzed by SDS-PAGE to confirm the presence of NuRD 
components. 
2.2.7 Protein analysis 
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2.2.7.1 SDS-PAGE  
SDS-PAGE analysis was used to check the purity and concentration of the purified 
proteins. Before running SDS-PAGE, all samples were mixed with 4× LDS (Life 
Technologies), heated at 90 °C for 5–10 min. The gels (Bolt® Bis-Tris Plus) and buffer 
(Bolt® MES SDS) were pre-made by Life Technologies. Generally, 10-15 percent of 
the eluted materials alongside with 50 ng BSA were loaded into the gel, and the gel 
was run at 165 V for 45 min. Gels were stained with 40 mL SYPRO Rubby overnight 
at room temperature in dark, and scanned at 550 V with 100 dpi resolution using a 
Typhoon 9400 scanner. 
2.2.7.2 Western blot 
After SDS-PAGE the protein was blotted from the gel onto a PVDF membrane 
(Millipore) via a Bolt™ Mini Blot Module (Life Technologies) according to the 
manufacturer’s instructions, using Transfer buffer (25 mM Bicine, 25 mM (Bis) Tris, 1 
mM EDTA, 10% methanol, pH 7.2). The western blot was transferred at 20 V for 1 h. 
After the transfer, the membrane was washed in PBS-T (1× PBS (8 g/L NaCl, 0.2 g/L 
KCl, 1.42 g/L Na2HPO4, 0.24 g/L KH2PO4, pH 7.4, 0.1% Tween 20) at a rocking table 
for 5 min five times and then blocked in 5% skim milk in PBS-T on a rocking table for 
1 h at room temperature. Next, the membrane was incubated at 4 °C at a rocking 
table overnight with primary antibodies (Appendix C) in 5% skim milk in PBS-T. 
Secondary antibody was added for 2 h to overnight at 4 °C. After antibody 
incubation(s) the membrane was washed in PBS-T at a rocking table for 40 min at 
room temperature. The membrane was then treated with 800 µL Western Lightning 
Chemiluminescence Reagent (Perkin Elmer) and scanned with a LI-COR C-DiGit Blot 
Scanner for chemiluminescent western blots.  
2.2.8 Proteomics studies  
2.2.8.1 Sample preparation for LC-MS/MS  
After SDS-PAGE analysis and calculation of protein concentration using Image J, 
protein samples were digested in solution for MS analysis. All proteolytic digestions in 
this thesis was performed in solution by dissolving the dried protein samples in 8 M 
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urea. The dissolved, denatured proteins were then reduced (5 mM TCEP, 37 °C, 30 
min) and alkylated (10 mM iodoacetamide, 20 min, room temperature in the dark). 
Before tryptic digestion, the samples were then diluted to 6 M urea with 200 mM 
NH4HCO3. Trypsin/LysC mix (Promega) was added to an enzyme:substrate ratio of 
1:25 (w/w). The solution was incubated at 37 °C for 4 h. Following this digestion step, 
the sample was further diluted to 0.75 M urea using 50 mM Tris-HCl pH 8 and 
additional Trypsin (Promega) was added at an enzyme:substrate ratio of 1:50 (w/w). 
The sample was then incubated at 37 °C overnight (16 h). Following overnight 
digestion, the samples were acidified by addition of formic acid to a final concentration 
of 2% (v/v) and centrifuged at 16,000 g for 10 min. Peptide clean-up was done using 
homemade stage-tips. For concentrated samples such as crosslinked peptides, the 
supernatant were desalted using 50 mg Sep-Pak C18 cartridges (Waters), eluted in 
50:50:0.1 acetonitrile:water:formic acid (v/v/v), and dried in a vacuum centrifuge. 
2.2.8.1.1 Cross-linking the protein complexes 
For each crosslinking experiment, about 40-50 µg of purified protein complex at a 
concentration of 0.15 mg/mL was used. Prior to crosslinking, the excess 3× FLAG 
peptide used during the elution step was removed using Zeba Spin desalting gel 
filtration columns (7K MWCO; Thermo Fisher Scientific), and the complex was 
exchanged into a buffer comprising 25 mM HEPES pH 7.5, and 75 mM NaCl. The 
purified samples were then prepared for XL-MS/MS essentially as described elsewhere 
[148] with some modifications. Briefly, for disuccinimidyl suberate (DSS) crosslinking, 
H12- and D12-DSS (1:1 ratio, 25 mM stock solution in anhydrous dimethylformamide; 
Creative Molecules) were added to a final concentration of 1 mM and incubated for 30 
min at 37 °C with constant mixing at 750 rpm. The excess DSS was then quenched 
with 100 mM NH4HCO3 (50 mM final concentration) and further incubated at 37 °C 
for 20 min. For adipic acid dihydrazide (ADH) crosslinking, H8/D8-ADH (1:1 ratio, 100 
mg/mL stock solution in 20 mM HEPES pH 7.4; Creative Molecules) and 4-(4,6-
dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) (144 mg/mL 
stock solution in 20 mM HEPES pH 7.4; Sigma Aldrich) were added to final 
concentrations of 8.3 mg/mL and 12 mg/mL, respectively. The sample was then 
incubated for 1.5 h at 37 °C with constant mixing. The excess DSS was then removed 
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by using the Zeba Spin desalting gel filtration columns (7K MWCO; Thermo Fisher 
Scientific) into 20 mM HEPES pH 7.5, 150 mM NaCl. For crosslinking with Bis 
sulfosuccinimidyl suberate (BS3 D0/D12; Creative Molecules), samples were incubated 
with 25 mM BS3, dissolved in water, in the cold room for 10 min and then at RT for 
1.5 h. The reaction was quenched with 50 mM NH4HCO3 for 20 min at 25 °C. Finally, 
samples were dried in a speedyVac centrifuge, and subjected to digestion and clean-
up for Mass Spectrometry (MS) analysis. 
2.2.8.1.2 Size exclusion chromatography for crosslinked peptide 
enrichment 
For size exclusion chromatography fractionation (SEC), the dried desalted peptides 
were resuspended in 150 mL of SEC mobile phase (acetonitrile:water:trifluoroacetic 
acid, 70:30:0.1 (v/v/v)) and loaded onto a Superdex Peptide HR 10/30 column 
connected to a Biologic DuoFlowTM system (Bio-Rad) with a BioFracTM fraction 
collector (Bio-Rad). A flow rate of 0.5 mL/min was used and the separation was 
monitored by UV absorption at 215, 225, 254, and 280 nm by a Biologic QuadTecTM 
UV/Vis detector (Bio-Rad). Fractions were collected as 2-min windows over 1.25 
column volumes (30 mL). Based on the UV absorption traces, fractions of interest 
(retention volumes 12–17 mL) for MS were dried in a vacuum centrifuge.  
2.2.8.1.3 Peptide labeling with iTRAQ reagents 
The iTRAQ labeling of peptide samples derived from knock down and mock samples 
was performed using the iTRAQ Reagent-4plex Multiplex Kit (Applied Biosystems) 
according to the manufacturer’s protocol. Prior to iTRAQ labeling, 100 µg total protein 
pellet was resuspended in digestion buffer (0.05% w/v sodium dodecyl sulfate (SDS)) 
to a final concentration of 1 mg/mL (total protein measured by bicinchoninic acid assay 
(Sigma Aldrich). Equal aliquots (100 μg) from each lysate were denatured with 0.02% 
denaturant solution from the kit, and were reduced with 1 mM TCEP for 1 h at 60 °C, 
and were cysteine-blocked using cysteine blocking reagent for 10 min at room 
temperature. Samples were then digested with trypsin (1:40 w/w) overnight at 37 °C 
in a sealed tube. In order to maximize the labeling efficiency, the volume of the sample 
was kept less than 50 µL. Post-digestion, peptides were labeled with respective 
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isobaric tags (114 for knock down and 117 for mock samples) for 1 h at room 
temperature, and then samples were mixed.  
2.2.8.1.4 Reversed Phase HPLC (rpHPLC) 
Labeled peptides were then fractionated using a Zorbax 300 Extend-C18 (9.4 × 250 
mm, 300Å, 5 µm) running on an HPLC system (GBC) at a flow rate of 1 mL min−1. 
Retained peptides were eluted using Buffer A (5 mM ammonium formate (pH 10.0) in 
2% (v/v) acetonitrile) and Buffer B (5 mM ammonium formate (pH 10), in 90% (v/v) 
acetonitrile. The following chromatographic gradients were applied: 0–7 min 100% 
Buffer A; 7–45 min 92% Buffer A and 8% Buffer B; 45–49 min 73% Buffer A and 27% 
Buffer B; 49–65 min 69% Buffer A and 31% Buffer B; 65–72 min 73% Buffer A and 
27% Buffer B; 72–75 min 100% Buffer A. Chromatograms were recorded at 214 nm. 
The sample was fractionated into 70 fractions and then selected non-contiguous 
fractions were combined into 6 samples; these were lyophilized.  
2.2.8.1.5 Acetylated peptide enrichment 
The PTMScan Acetyl-Lysine Motif [AC-K] kit (Cell Signaling) was used for the 
immunoaffinity enrichment of Lys-acetylated peptides, based on the manufacturer’s 
protocol. Prior to enrichment, the beads (to which are bound a set of antibodies that 
each recognize acetyllysine in a different sequence context) were washed three times 
with 1.5 mL of immunoaffinity purification (IAP) buffer (50 mM MOPS pH 7.2, 10 mM 
sodium phosphate, 50 mM NaCl). The iTRAQ labeled and dried desalted peptides were 
resuspended in 1.4 mL IAP buffer, and the pH was checked by spotting 2 µL of sample 
on pH indicator paper (pH should be close to neutral). The solution was cleared at 
10000 g for 5 min at 4 °C. The soluble peptides were incubated with 10 µL of antibody 
beads for 2 h at 4 °C with end-over-end rotation. Following enrichment, anti-Kac 
antibody beads were washed three times in 1.5 mL chilled MQW grade water. Peptides 
were eluted from antibody beads with 50 μL TFA (0.15% in MQW) and desalted using 
homemade C18 stage tips.  
2.2.8.1.6 Sample preparation for absolute protein quantification 
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After sucrose gradient fractionation, 10% of the fractions containing NuRD complex 
along with 30 ng of monomeric BSA were run onto SDS-PAGE and stained with SYPRO-
Ruby. The concentration of the complexes were calculated by Image J software. Then 
synthetic 15N labeled peptides were mixed with the samples so that we had 100 fmol 
of each synthetic peptide and about 20-50 ng of the complex, depending on the size 
of the complex in each injection. Samples were then dried down in a vacuum 
centrifuge. Dried samples were dissolved in a solution comprising 8 M urea in 50 mM 
Tris-HCl (pH 7.5). Digestion and peptide purification were done based on the above 
mentioned in solution digestion protocol. Samples were reduced with 50 mM TCEP in 
water for 30 min at 37 °C, and alkylated using 100 mM iodoacetamide at room 
temperature in the dark for 20 min. Prior to proteolytic digestion, samples were diluted 
to 6 M urea with 0.2 M NH4HCO3. Endo-LysC/trypsin mix was added to add a 1:25 
enzyme:substrate ratio and the mixture incubated for 3-4 h at 37 °C. Samples again 
were diluted to <1 M urea with 50 mM NH4HCO3 and trypsin was added at a 1:50 
ratio (wt:wt); the mixture was then incubated at 37 °C for 16 h. Digested peptides 
were first cleaned up using stage tips and 0.1% (v/v) formic acid, and were then 
eluted with 50% ACN/0.1% FA. Finally, eluted peptides were dried in a vacuum 
centrifuge. 
2.2.9 LC-MS/MS  
LC-MS/MS analysis was carried out on an Easy nLC-1000 UHPLC (Thermo Fisher 
Scientific) system connected to Q Exactive Classic or Q Exactive Plus mass 
spectrometer equipped with a standard nanoelectrospray source (Thermo Fisher 
Scientific). Digested peptides (~1 µg) were resuspended in loading buffer (3% (v/v) 
acetonitrile and 1% (v/v) formic acid (FA) in dH2O) and and injected onto an in-house 
packed column1 over 2 min with a flow rate of 250 nL/min; the column was 40-50 cm 
× 75 μm inner diameter and contained 1.9 µm C18AQ particles (Dr Maisch GmbH). . 
Peptides were separated at a flow rate of 200 nL/min using a linear gradient of 5-30% 
buffer B over 120 min. Solvent A consisted of 0.1% (v/v) formic acid, and solvent B 
consisted of 80% acetonitrile, 0.1% formic acid, 20% dH2O. The end-to-end run time 
was 150 min, including sample loading and column equilibration times.  
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2.2.9.1 Shotgun proteomics method 
For data-dependent acquisition run, full scan MS1 was operated as follows: mass 
range was between 300 and 1750 m/z at a resolution of 70000 at 200 m/z and 100 
ms injection time was used with 3 × 106 automatic gain control (AGC). The top 20 
most intense precursor ions were subjected to Orbitrap mass analysis for further 
fragmentation via high energy collision dissociation (HCD) activation (R = 35,000 at 
200 m/z; 1 × 106 AGC; 120 ms injection time; 30 normalized collision energy; 2 m/z 
isolation window; 8.3 × 105 intensity threshold; minimum charge state of +2; dynamic 
exclusion of 60 s). Singly charged precursor ions and precursors of unknown charge 
states were excluded from fragmentation. A collision energy of 28 was set for iTRAQ 
MS/MS.  
2.2.9.2 SWATH mass spectrometry method 
For data-independent acquisition (DIA) or Sequential Window Acquisition of all 
Theoretical Mass Spectra (SWATH-MS) runs, after each full-scan MS1 (R = 140,000 at 
200–1600 m/z; 3 × 106 AGC; 120 ms injection time), 16 × 25 m/z windows in the 
425–825 m/z range were sequentially isolated and subjected to MS/MS (R = 17,500 
at 200 m/z, 3 × 106 AGC; 60 ms injection time; 30% normalized collision energy). 
After the first eight 25 m/z isolations and MS/MS run and before the last eight 25 m/z 
isolations, a full-scan MS1 was performed. 25 m/z isolation window placements were 
optimized in Skyline [149] to result in an inclusion list starting at 437.9490 m/z with 
increments of 25.0114 m/z. 
2.2.10 Data Analysis 
2.2.10.1 Converting RAW files to Mascot Generic Format Files 
(MGF files) 
RAW formatted fileswere converted into MGF file format using MS converter tool [150] 
for MS/MS searches in Mascot software. Filter option was set to peak Picking and MS 
levels were set to 1 to 2, while the remaining parameters were left at the default 
values. 
2.2.10.2 XL-MS/MS data analysis using pLink software 
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In order to identify cross-linked peptides, MS data were analyzed by the pLink2 
software version 2.3.1 [151]. The ini file used for the data search was configured as 
below. Carbamidomethyl cysteine was set as a fixed modification and both oxidation 
of methionine and N-terminal acetylation of protein were set as variable modifications, 
the FDR was set to 0.05, and precursor and peptide tolerance were set to ± 15 ppm. 
For database configuration, a search database containing sequences of all subunits of 
the NuRD complex and frequently eluted contaminations was created. Visualization of 
identified protein-protein cross-links was done using xiNET [152] and Xlink Analyzer 
[153]. 
2.2.10.3 Annotating tandem mass spectra of the crosslinked 
peptides 
The pLabel accessory tool of pFind Studio was used to annotate spectra/peak labeling 
of cross-linked peptides for visual inspection and publication [154]. Alpha peptide and 
beta peptide y- and b-ions were labelled. 
2.2.10.4 Quantitative proteomics data analysis  
2.2.10.4.1 MaxQuant 
The MaxQuant software package works coupled to the search engine Andromeda 
[155], which is provided together with MaxQuant [156]. Prior to data analysis with 
MaxQuant, the human proteome fasta file was downloaded from UNIPROT (proteome 
ID: UP000005640) and was configured as protein database. For iBAQ data analysis, 
standard parameters were set with the additional options including match between 
runs, label free quantification (LFQ), and iBAQ. Cysteine carbamidomethyl was 
specified as a fixed modification and oxidation of methionine was set as variable 
modification. The tolerances of precursor and fragment ions were set at ±20 ppm and 
±0.02 Da, respectively. For digestion, trypsin was set as the protease with two missed 
cleavage permitted. The false discovery rate for peptide, protein, and site identification 
was set to 1%. From the MaxQuant output, a txt file named ProteinGroups was used 
for further processing and a Peptide txt file was used for quality check of the data.  
2.2.10.4.2 SWATH-MS data using Skyline software tool 
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All DIA data were processed using Skyline v3.5.0.9319. Skyline is an open-source 
proteomics software tool which is for targeted proteomics method creation and 
quantitative data analysis and is widely used for building Selected Reaction Monitoring 
(SRM) / Multiple Reaction Monitoring (MRM) and Full-Scan (MS1 and MS/MS) 
quantitative methods and analyzing the resulting data [149]. Skyline also supports a 
variety of full-scan chromatography-based quantitative proteomics approaches, such 
as MS1 filtering, targeted MS/MS, and data-independent acquisition (DIA). Reference 
spectral libraries were built in Skyline as magellan storage file format (msf) files using 
the BiblioSpec algorithm [157]. Precursor and product ion extracted ion 
chromatograms were generated using extraction windows that were two-fold the full-
width at half maximum for both MS1 and MS2 filtering. Ion match tolerance was set 
to 0.055 m/z. For MS1 filtering, the first three isotopic peaks with charges +2, +3, 
and +4 were included while for MS2, b- and y-type fragment ions with charges +1, 
+2, and +3 were considered. To ensure correct peak identification and assignment, 
the following criteria had to be met: (i) co-elution of light and heavy peptides; (ii) dot 
product values of >0.95 between peptide precursor ion isotope distribution intensities 
and theoretical intensities for both the heavy and light peptides; (iii) dot product values 
of >0.85 between library spectrum intensities and current observed intensities; (iv) 
relative dot product values of >0.95 between the observed heavy and light ion 
intensities; (v) matching peak shape for precursor and product ions of both the heavy 
and light peptides. Finally, peptides were quantified using area under the curve of the 
M, M+1 and M+2 peaks for MS1 and a manually curated set of y-ions for MS2. Curation 
was based on: (i) linearity as determined from the standard curve, and (ii) 
reproducibility and consistent observation between technical and biological replicates.  
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3.1 Abstract 
The nucleosome remodeling and deacetylase complex (NuRD) is a widely conserved 
regulator of gene expression. Determination of the subunit composition of the complex 
and identification of its binding partners are important steps towards understanding 
its architecture and function. The question of how these properties of the complex 
vary across different cell types has not been addressed in detail to date. Here, we set 
up a two-step purification protocol coupled to LC-MS/MS to assess NuRD composition 
and interaction partners in three different cancer cell lines, using label-free intensity-
based absolute quantification (iBAQ). Our data indicate that the stoichiometry of the 
NuRD complex is preserved across our three different cancer cell lines. In addition, 
our interactome data suggest ZNF219 and SLC25A5 as possible interaction partners 
of the complex. To corroborate this latter finding, in vitro and cell-based pulldown 
experiments were carried out. These experiments indicated that ZNF219 can interact 
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with RBBP4, GATAD2A/B, and CHD4, whereas SLC25A5 might interact with MTA2 and 
GATAD2A. 
Key words; NuRD complex, chromatin remodeling, stoichiometry, protein-protein 
interactions, co-immunoprecipitations, iBAQ, ZNF219, SLC25A5,  
3.2 Introduction 
In complex organisms, there are four major classes of chromatin remodeling 
complexes that have ATP-dependent chromatin remodeling activity: (i) SWI/SNF, (ii) 
INO80, (iii) ISWI and (iv) CHD families [20, 158-160]. Several members of the CHD 
family (CHD3, 4 and 5 in mammals) are found associated with the nucleosome 
remodeling and deacetylase (NuRD) complex. In mammals, the NuRD complex is ~1 
MDa in size and comprises at least six to seven proteins, which generally exist as two 
or more paralogues: CHD4 (and its paralogues CHD3 and CHD5), MTA1 (plus MTA2 
and MTA3), HDAC1 (and HDAC2), GATAD2A (and GATAD2B), MBD3 (and MBD2), 
RBBP4 (and RBBP7) and CDK2AP1 [82, 100, 128, 161-163]. NuRD has been implicated 
in gene transcription and DNA repair and harbours both histone deacetylase and 
chromatin remodeling activities (for reviews see [164]). Overall, NuRD has been most 
commonly assigned as a repressor of gene expression [165], although it has also been 
linked to gene activation in some cases [58, 71]. However, the biochemical 
mechanisms underlying these activities are not well understood. One recent study 
showed that the conditional knock out of CHD4-NuRD in granule neurons of mice led 
to a significant decrease in H2A.Z occupancy at the promoters of a subset of genes 
and the concomitant up-regulation of these genes [166]. These data hint that 
repression of gene transcription by NuRD might in part involve histone variant 
exchange. Moreover, at specific developmental stages or in disease states, it is 
possible that NuRD can recruit other enzymes such as the lysine demethylase LSD1 to 
exert its function [90, 167].  
Our biochemical understanding of the NuRD complex has been limited by difficulties 
with producing the intact complex recombinantly. Even parameters such as the 
subunit stoichiometry of the complex have remained unclear, despite several studies 
that have addressed this question [168, 169]. The mechanism(s) by which NuRD is 
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recruited to sites of activity are also only beginning to be appreciated. To broaden our 
understanding of NuRD complex structure and function, we have used mass 
spectrometry (MS) to assess the subunit stoichiometry of the complex in three cancer 
cell lines representing three different tissues: the  embryonic stem-cell-like NTERA-2 
(hereafter referred to as NT2) cell line, the PC3 prostate cancer cell line, and the MCF7 
breast cancer cell line [67, 170]. 
and have also used these data to identify proteins that associate with the complex. 
Our data indicate that the stoichiometry of the NuRD complex is preserved across our 
three different cancer cell lines and largely in agreement with data available in the 
literature. Interaction mapping experiments demonstrate that ZNF219 and SLC25A5 
can interact with the complex. 
3.3 Results 
3.3.1 NuRD subunit expression across several cell lines 
Compositional variation can arise from differences in the expression level of the 
subunits of a complex. We therefore first examined the expression profile of NuRD 
subunits using RNA-Seq data from the Human Protein Atlas (HPA) consortium [57, 
113, 166, 171-173]. RNA-Seq data are represented as Transcripts Per Million (TPM), 
a metric that attempts to normalize transcript abundance for gene length and 
sequencing depth. Expression profiling revealed that, although the canonical 
paralogues of NuRD are all expressed in NT2, PC3, and MCF7 cells (Fig 3-1), the level 
of expression for several paralogues can vary widely across cell types. For example, 
MTA3 is expressed at a ~5- or ~10-fold higher level in NT2 cells than in MCF7 and 
PC3 cells, respectively. Likewise, RBBP4 expression is five times higher in NT2 cells 
than in MCF7 cells, whereas RBBP7 expression varies by less than 20% over the three 
cell lines (Fig 3-1).  
The profile also shows significant differences between paralogues in a given cell type. 
For example, MTA1, MTA2, and MTA3 expression are within two-fold of each other in 
NT2 cells, whereas there is a three-fold and four-fold difference between MTA2 and 
MTA1, and MTA2 and MTA3, respectively, in MCF7 cells (Fig 3-1).  
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In all three cell lines, CHD4 is the dominant CHD-family protein (Fig 3-1); transcript 
levels are 2 to 18 times higher than that for CHD3, depending on the cell type; CHD5 
was not detected above the threshold of 1 TPM. Similarly, GATAD2B and MBD2 are 
expressed at significantly lower levels than GATAD2A and MBD3, respectively. It 
should be noted that, because the RBBP4/7 and HDAC1/2 subunits are also found in 
other complexes (e.g., the SIN3A, CoREST and PRC2 complexes [174] [65, 175, 176]), 
the transcript abundance data reflects the sum of the contributions from all complexes 
in which these proteins are found. Other proteins, such as MTA1/2/3 and GATAD2A/B 
are predominantly associated with NuRD. 
 
Fig 3-1. mRNA expression pattern of NuRD subunits in MCF7, NT2, PC3, 
HeLa, U2OS and HEK293 cells. Transcript abundance was extracted from RNA-Seq 
data analyzed by the Human Protein Atlas consortium [177]. The stacked bar graph 
compares the level of expression of paralogues in a given cell line as well as the level 
of expression of paralogues across cell types. Based on transcript levels, RBBP7, MTA2, 
GATAD2A, MBD3, and CHD4 seem to be the dominant paralogues in most cell types, 
whereas HDAC1 and HDAC2 quantities are quite similar.  
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3.3.2 Affinity purification followed by sucrose gradient 
centrifugation allows isolation of specific species  
To investigate differences in NuRD composition between different cell types, we used 
a two-step purification protocol to allow isolation of the complex from cultured 
mammalian cells [82, 100, 128, 161-163]. A two-step approach reduces issues such 
as the presence of an excess of the subunit that is used as the purification ‘handle’ 
(RBBP4/7 in our case, through its interaction with FOG1 [138, 178, 179]. We first 
carried out a FOG-affinity purification step and then used sucrose gradient 
ultracentrifugation to improve the purity of isolated NuRD complex. Figure 3-2A 
shows SDS-PAGE analysis of purified NuRD from three cancer cell lines (NT2, PC3, 
and MCF7) following the first-step FOG1-affinity purification. Both similarities and 
differences (including significant differences in the amount of CHD4 observed) are 
apparent. Figure 3-2B shows the second-step sucrose gradient-based purification of 
NuRD derived from each cell line. Earlier fractions (fractions 4–19) show excess GST-
FOG1 ‘bait’ protein and excess RBBP4/7 ‘handle’; these appear to be eliminated in the 
later fractions, as intended. 
Following sucrose gradient ultracentrifugation, two fractions from each cell line 
(fractions 24 and 28) were selected for LC-MS/MS analysis as being representative of 
NuRD-type species.  
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Fig 3-2. SDS-PAGE showing the NuRD complex purified from NT2, PC3 and 
MCF7 cells. (A) SYPRO-Ruby stained SDS-PAGE showing affinity purification of NuRD 
from each cell type, based on the interaction of resin-bound GST-FOG1 with RBBP4/7. 
(B) SYPRO-Ruby stained SDS-PAGE gels show fractionation of affinity-purified NuRD 
species on a 5–35% sucrose gradient. Earlier fractions (4–19) contain excess GST-
FOG1 protein. Fractions 24 and 28, indicated with black arrows, were selected for 
stoichiometry and interactome analysis. The identification of the proteins was done 
mass spectrometry. 
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3.3.3 NuRD complex stoichiometry is conserved across NT2, PC3, 
and MCF7 cells  
Following LC-MS/MS and data quality analysis (described in Materials and Methods), 
we used the intensity-based absolute quantification (iBAQ) method to determine the 
stoichiometry of the complex [1]. In iBAQ, the sum of intensities of all tryptic peptides 
observed in the mass spectrometer for each protein is divided by the number of 
theoretically recognizable peptides. In general, because paralogues of the NuRD 
complex subunits have high sequence similarity (e.g., RBBP4 and RBBP7 are 92% 
identical), it was difficult to reliably distinguish the levels of each paralogue using iBAQ 
quantification. Thus, to estimate the stoichiometry of the NuRD components, we first 
treated each set of paralogues as a single group. We then used the MTA subunit as 
our reference point, setting its stoichiometry to be two units per NuRD assembly based 
on the X-ray crystal structure of the 2:2 MTA1-HDAC1 complex [112]. Fig 3-3 and 
Supplementary Data 1 shows the results of this analysis. For each replicate, we have 
opted to show the stoichiometry values averaged from fractions 24 and 28; fractions 
24 and 28 agree closely for most NuRD subunits, with the exceptions of CHD and 
CDK2AP. More of these two proteins were found in the heavier-sedimenting fraction 
28, as expected (refer to Supplementary Data 1 for this breakdown). In most cases, 
there was close agreement between the cell lines. For example, the MTA:HDAC ratio 
is between 2:2.1 and 2:2.3 in all cases. This suggests that the published crystal 
structure recapitulates the HDAC and MTA architecture in the NuRD complex in 
solution in diverse cell types. For the MBD subunit, the corresponding values are 1.5, 
1.4 and 1.2, and for GATAD2 0.9, 1 and 1.2 are observed (in MCF7, NT2 and PC3 
cells, respectively). Taken together, these data point towards a 
MTA:HDAC:MBD:GATAD2 stoichiometry of 2:2:1:1. 
RBBP was detected at much higher levels, with RBBP:MTA ratios of 7.7:2, 6.6:2 and 
9.3:2 observed for MCF7, NT2 and PC3 cells, respectively. More striking, however, was 
the large range of values; for example, RBBP quantities of ~5–11 were measured in 
MCF7 cells (Fig 3-3A, Supplementary Data 1). A similarly broad distribution of values 
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for RBBP has been observed in several previous iBAQ measurements of NuRD 
stoichiometry [100, 168, 180, 181].  
In contrast, both CHD and CDK2AP subunits gave values indicating less than a single 
subunit per NuRD assembly (0.07, 0.2 and 0.2 for CHD and 0, 0.4 and 0.3 for 
CDK2AP). We also noted that the quantities of CHD and CDK2AP appear to be highly 
correlated (r2 = 0.83; Fig 3-3B); higher quantities of CHD are associated with higher 
quantities of CDK2AP. 
 
 
Fig 3-3 Stoichiometry of subunits of the NuRD complex in each cell line. 
Stoichiometry of subunits of the NuRD complex in each cell line. In all panels, 
stoichiometry of subunits is shown relative to MTA, which is set to two copies per 
NuDe/NuRD assembly. (A) Calculated stoichiometry for the NuDe complex from 
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fraction 24. (B) Calculated stoichiometry for the NuRD complex from fraction 28. Each 
point is one experimental replicate. The bar graph shows the median stoichiometry 
value derived from the three experimental replicates. (C) Change in number of 
subunits per complex between NuDe and NuRD fractions. Each point is one 
experimental replicate pair (fractions 24 and 28) from the same sucrose gradient. (D) 
Graphs showing the correlation of subunit number for selected pairs of subunits. Each 
data point is an independent measurement; data from all sucrose-gradient fractions 
are included.   
3.3.4 ZNF219 and SLC25A5 can interact with NuRD subunits 
Several interaction partners have been reported for the NuRD complex, including a 
subclass of the family of ZnF transcription factors that contains FOG1 [178], ZBTB7A 
[168] and Sall1 [182]. These proteins share a common N-terminal RBBP-binding motif 
[138]. Other regulators such as Zic2 [66, 183], PHF6 [184] ZMYND8 [57], and the 
lysine demethylase LSD1 [90, 167] have also been shown to associate with NuRD. In 
some cases, these proteins most likely represent bridges between NuRD and specific 
genomic sites, whereas in other cases might expand the functional diversity of distinct 
NuRD complexes in different biological contexts. However, despite the fact that the 
NuRD complex is strongly linked to cancer onset and progression, its interaction 
partners have not been studied in cancer cells. From our LC-MS/MS data, we identified 
82 possible NuRD-interacting proteins [(Fig 3-4), also see Appendix D].  
To choose among the candidate proteins for further biochemical analysis, we further 
refined the enriched proteins by considering a combination of the following 
parameters: (i) the number of unique peptides observed (≥ 3, except for COASY); (ii) 
the score for a candidate protein in the Contaminant Repository for Affinity Purification 
(CRAPome) database (proteins with scores >50 were rejected) [185]; and (iii) 
available interactome information in the BioGRID database (candidate proteins were 
searched for interaction partners — especially NuRD subunits or other known 
interactors of NuRD, [186]). We selected eight candidate NuRD-interacting proteins, 
namely ZNF219, SLC25A5, LANCL1, PAICS, DDB1, COASY, DCAF11 and KPNA4, for 
further analysis.  
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To corroborate our LC-MS/MS data, we carried out pulldown experiments. Full-length 
candidate genes (FLAG tagged) were co-expressed with HA-tagged NuRD components 
(MTA2, GATAD2A, CHD4, MBD3 (as MBD3cc; see Methods), and RBBP, along with 
tagless HDAC1) in HEK293 cells, and anti-FLAG beads were used to capture the 
candidate proteins from the cell lysate. For six of the candidate proteins (LANCL1, 
PAICS, DDB1, COASY, DCAF11 and KPNA4), no interactions were observed with any 
NuRD subunit (data not shown). On the other hand, ZNF219 robustly pulled down 
HDAC1, MTA2, CHD4 and RBBP4, and much weaker bands were detected for MBD3cc 
and GATAD2A (Fig 3-5A). Similarly, SLC25A5 showed strong interactions with MTA2, 
HDAC1 and CHD4, and weaker bands were observed for GATAD2A, MBD3cc and 
RBBP4 (Fig 3-5B). 
Because multiple interactions were observed for both ZNF219 and SLC25A5, we 
reasoned that a subset of these apparent interactions might, actually reflect indirect 
‘bridging’ interactions that are facilitated by endogenous NuRD components. We have 
observed this bridging effect previously in NuRD pulldowns carried out from 
mammalian cell lysates [187]. Indeed, the presence of HDAC1 in all of the pulldowns 
that used ZNF219 as the bait (despite it not being transfected in most cases) and the 
fact that all tested NuRD subunits show some level of positive interaction might 
indicate that endogenous NuRD complex is being pulled down in these experiments 
and that indirect interactions could be at play. 
To address this possibility, we repeated our pulldown experiments by co-expressing 
each pair of proteins in an in-vitro transcription-translation system made from rabbit 
reticulocyte lysate (RRL); we have shown previously that this lysate contains negligible 
amounts of NuRD subunits, which should reduce the possibility of false positive 
interactions [187]. Using the RRL system, clear interactions were observed between 
ZNF219 and both GATAD2A and RBBP4 (Fig 3-5C), whereas no interaction was 
observed with MTA2, HDAC1, MBD3 or CHD4. Similarly, SLC25A5 only showed 
interactions with MTA2 and GATAD2A (Fig 3-5D). 
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Fig 3-4. Complete list of possible interacting partners of the NuRD complex. 
Heatmap showing the filtered list of possible NuRD interactors detected in by LC-
MS/MS . The proteins shown are ones that are present at least in two biological 
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replicates of a particular cell type. Cell type and experimental replicate number are 
indicated above each column. Averaged iBAQ-adjusted intensity values were divided 
by the summed intensities for MTA subunits and log₂-transformed. Core NuRD 
subunits are presented at the top, followed by the potential interactors that were 
further tested, and other proteins are listed in alphabetical order.  
 
3.3.5 ZNF219 contacts NuRD via its four N-terminal zinc fingers 
As ZNF219 has previously been shown to act as a gene co-regulator [188, 189], we 
chose to define in more detail its interaction with NuRD subunits. We used deletion 
mapping to narrow down the regions of each protein that were responsible for making 
these interactions. ZNF219 was divided into three fragments: (i) ZNF219N, which 
contained ZnFs 1–4; (ii) ZNF219M, which contained ZnFs 5–8; and (iii) ZNF219C, 
which contained ZnF9 (Fig 3-6A). At the same time, we expressed GATAD2B as two 
fragments. We also tested three fragments of CHD4, to address the possibility that 
the large size of this protein (210 kDa) prevented its correct folding in the RRL 
experiment shown in Fig 3-5C. RBBP4 was expressed as a full-length protein, given 
its known single-domain structure [139, 190]. Each of the ZNF219 fragments was then 
tested for its ability to interact with the NuRD subunit fragments.  
In the case of CHD4, the interaction mapping carried out with ZNF219 fragments as 
baits pointed most consistently to an interaction between the N-terminal end of 
ZNF219 and the C-terminal fragment of the CHD4 (Fig 3-6B). Similar results were 
obtained in reciprocal experiments with CHD4 fragments used as baits (Supplementary 
Fig 3-2). A weak interaction was also observed between ZNF219N and CHD4M in one 
replicate (Supplementary Fig 3-2), perhaps suggesting that this region might play a 
minor role in the ZNF219-CHD4 interaction. The interaction between ZNF219 and 
GATAD2B also appeared to localize to ZNF219N, which was pulled down by the C-
terminal half of GATAD2B (and much more weakly by the N-terminal half of GATAD2B) 
(Fig 3-6C). Similarly, ZNF219N was also responsible for mediating the interaction 
with full-length RBBP4 (Fig 3-6C).  
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Fig 3-5. Pulldowns show that ZNF219 and SLC25A5 can interact with NuRD 
subunits. (A) Western blots probing the interaction of ZNF219 with NuRD 
components, following co-expression of the indicated proteins in HEK293 cells and 
FLAG immunoprecipitation (IP). ZNF219 showed clear interactions with MTA2, HDAC1, 
CHD4 and RBBP4, and weaker bands were observed for MBD3cc and GATAD2A. The 
use of MBD3cc is described in Methods. Note that HDAC1 appears in all pulldowns, 
indicating that endogenous NuRD components are being pulled down along with the 
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transfected subunits. (B) The same pulldown experiment as (A) but probing the 
interactions of SLC25A5 with NuRD components instead. SLC25A5 showed clear 
interactions with MTA2, HDAC1 and CHD4, and weaker bands were observed for 
GATAD2A, MBD3cc and RBBP4. (C) The same pulldown experiment as (A) but carried 
out using co-transcription and co-translation in rabbit reticulocyte lysates (RRL). In 
this case, only GATAD2A and RBBP4 showed a robust interaction with ZNF219. (D) 
The same experiment as (B) but in the RRL system; only MTA2 and GATAD2A display 
an interaction with SLC25A5. In all panels, dashed boxes indicate the expected 
position of prey proteins for a positive interaction.  
 
 
Fig 3-6. Deletion constructs show ZNF219 contacts NuRD via its four N-
terminal zinc fingers. (A) Domain structures of ZNF219, GATAD2B and CHD4. 
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Boxed regions indicate domains for which 3D structures are known or are predicted 
to be ordered; and lines indicate regions predicted to be disordered. Deletion 
constructs used for interaction mapping are indicated below each protein. HMG = 
HMG-box domain. PHD and CD refer to PHD domains and chromodomains, 
respectively. CC = coiled coil. ZnF = GATA-type zinc finger. C2H2 = classical zinc 
finger. (B) Western blots showing the results of pulldowns with the indicated proteins. 
Fragments of FLAG-ZNF219 were co-transcribed and translated with fragments of HA-
CHD4 in the RRL system and were pulled down using FLAG beads. The gel was probed 
using both HA and FLAG antibodies. (C) Western blots showing the results of 
pulldowns with the indicated proteins. Fragments of HA- or FLAG-ZNF219 were co-
transcribed and co-translated with either full length HA-RBBP4 or fragments of FLAG-
GATAD2B. The gel was probed only with HA antibody to avoid overlap with the FLAG-
tagged bait proteins. In all panels, dashed boxes indicate the expected position of 
prey proteins for a positive interaction. 
3.6. Discussion 
Published data suggest that the composition of most protein complexes is constant 
across many cell types [57, 60, 112, 113, 166, 171-173, 191-194]. We suggest that 
the NuRD complex has a composition that can vary in a context dependent manner – 
not necessarily in architecture, however, but rather in paralogue distribution. Although 
we see that the canonical subunit composition of the complex (RBBP-MTA-HDAC-MBD-
GATAD2-CHD) is generally conserved across three different cell types – and that most 
paralogues were found in each case, we did observe some differences. Most 
prominently, MBD2 was not observed in NuRD from NT2 cells, despite the fact that 
MBD2 transcript levels are higher in NT2 cells than in MCF7 or PC3 cells. This suggests 
that MBD3-NuRD is the predominant NuRD complex in NT2 cells.  
MBD2- or MBD3-exclusive NuRD complexes have been previously described and 
shown to have distinct roles [134, 136, 195]. For example, it has been shown that 
Mbd3 knock-out mice die during early embryogenesis, whereas Mbd2 knock-out mice 
are viable and fertile, indicating that these two proteins are not functionally redundant 
[134]. Knockdown of MBD3 but not MBD2 dramatically increases the efficiency of the 
reprogramming of somatic cells to pluripotent stem cells [60]. A similar observation 
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has been made for the GATAD2 subunit: depletion of GATAD2A but not GATAD2B 
leads to highly efficient induced pluripotent stem cell formation [40, 88, 196-200]. In 
addition, GATAD2A-NuRD is also selectively recruited by ZMYND8 to DNA double-
stranded breaks [57]. CHD3-, CHD4- and CHD5-specific NuRD complexes have also 
been implicated in mouse cortical development [201]. Paralogue interchanges of these 
types will most likely be revealed to be a widespread aspect of NuRD activity. 
3.4 Materials and methods 
3.4.1 Constructs 
All genes used in this study were human, unless otherwise stated, cloned from a cDNA 
pool into FLAG-pcDNA3.1, HA-pcDNA3.1 or tagless-pcDNA3.1 expression vectors. Full-
length genes for mouse MTA2 (UniProt ID: Q9R190), HDAC1 (UniProt ID: Q13547), 
mouse GATAD2A (UniProt ID: Q8CHY6), CHD4 (UniProt ID: Q14839), and RBBP4 
(UniProt ID: Q09028), SLC25A5 (UniProt ID: P05141). ZNF219 (UniProt ID: Q9P2Y4), 
LANCL1 (UniProt ID: O43813), KPNA4 (UniProt ID: O00629), PAICS (UniProt ID: 
P22234), COASY (UniProt ID: Q13057), DCAF11 (UniProt ID: Q8TEB1), DDB1 (UniProt 
ID: Q16531), and MBD3cc [which consists of murine MBD3 (UniProt ID: Q9Z2D8) 
fused to residues 133–174 of mouse GATA2DA. This region of GATA2DA has been 
previously shown to form a coiled-coil interaction with MBD3 [132]; this fusion 
construct aims to stabilize MBD3]. We also generated a series of shorter constructs in 
the same vector: GATAD2BN (1–277), GATAD2BC (339-633), CHD4N (1–355), CHD4M 
(355– 1230), CHD4C (1230–1912), ZNF219N (1-273), ZNF219M (256-618), ZNF219C 
(600-722). 
3.4.2 Cell culture 
The human NTERA2 clone D1 EC stem cells (NT2) were cultured in DMEM/F-12 
medium, whereas PC3 and MCF7 cell lines were grown in RPMI 1640. All media were 
supplemented with 10% (v/v) fetal bovine serum and 100 units/mL penicillin and 100 
μg/mL streptomycin. PC3 and MCF7 Cells were passaged every 5–6 days but NT2 cells 
were passaged every 3–4 days. 
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3.4.3 Nuclear extract isolation and NuRD complex affinity 
purification 
Nuclear extract preparation and FOG1-affinity pulldowns were performed essentially 
as described previously [82, 100, 128, 161-163]. First, affinity purification was 
performed in two steps. Step 1: Escherichia coli BL21 (DE3) cells (500 µL) 
expressing GST-FOG1 (1–45) were lysed via sonication in GST binding buffer (50 mM 
Tris, 150 mM NaCl, 0.1% (v/v) mercaptoethanol, 0.5 mM PMSF, 0.1 mg/ml lysozyme, 
10 µg/ml DNase I, pH 7.5) and clarified via centrifugation (16,000 g, 20 min, 4 °C). 
The cleared supernatant and 300 µL of glutathione-Sepharose 4B beads (GE 
Healthcare) were incubated for 2 h at 4 °C. The beads carrying GST-FOG1 were then 
washed three times in GST wash buffer (50 mM Tris, 500 mM NaCl, 1% (v/v) Triton 
X-100, 1 mM DTT, pH 7.5) and then NuRD binding buffer (50 mM HEPES-KOH, 150mM 
NaCl, 1% (v/v) Triton X-100, 1 mM DTT, 1× complete protease inhibitor (Roche), pH 
7.4). Step 2: Nuclear extracts were prepared by incubating 2 × 108 cells with 500 µL 
of hypotonic lysis buffer (10 mM HEPES-KOH, 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT, 
complete protease inhibitor, pH 7.9) for 20 min at 4 °C. IGEPAL CA-630 was then 
added [final concentration, 0.6% (v/v)], and the cells were then further incubated for 
10 min. The mixture was then vortexed for 10 s and then centrifuged (3,300 g, 5 min). 
The cytoplasmic supernatant was discarded, and the nuclear pellet was gently washed 
once with lysis buffer (supplemented with 0.6% (v/v) IGEPAL CA-630). The washed 
nuclear pellet was re-suspended in NuRD binding buffer, then lysed by sonication, and 
incubated on ice for 30 min to allow the chromatin to precipitate. The nuclear extract 
was then clarified via centrifugation (16,000 g, 20 min, 4 °C), and the cleared 
supernatant was incubated with the above FOG1 affinity resin overnight at 4 °C. Post 
incubation, the resin was washed three times with wash buffer 1 (50 mM HEPES-KOH, 
500 mM NaCl, 1% (v/v) Triton X-100, 1 mM DTT, pH 7.4) and then 3 times with NuRD 
wash buffer 2 (50 mM HEPES-KOH, 150 mM NaCl, 0.1% (v/v) Triton X-100, 1 mM 
DTT, pH 7.4). Finally, the complex was eluted with elution buffer (50 mM HEPES-KOH, 
150 mM NaCl, 1 mM DTT, and 50 mM glutathione, pH 8).  
3.4.4 Sucrose density gradient ultracentrifugation 
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Sucrose density gradients were prepared essentially as described in [202]. To prepare 
5–35% (w/v) sucrose density gradients (in 50 mM HEPES-KOH pH 8.2, 150 mM NaCl), 
6 mL of filtered 5% sucrose buffer was transferred into a 12-mL ultracentrifugation 
tube (Beckman Coulter) using a syringe attached to a Pasteur pipette. Then, using the 
same syringe, 6 mL of 35% sucrose buffer was added onto the bottom of the tube 
very gently, so as not to introduce any bubbles, and the tube was sealed with Parafilm-
M. The tube was slowly tilted (>60s) onto its side (completely horizontal) and left 
untouched for 4 h at room temperature. The tubes are then slowly tilted back to the 
vertical position and then left standing at 4 °C for at least 1 h before use. The NuRD 
complex sample (200 µL) was then layered on top of the gradient and centrifuged 
(186,000 g, 4 °C, 18 h). The gradients were fractionated as 200-µL aliquots.  
3.4.5 Sample preparation and nano-flow liquid chromatography-
tandem mass spectrometry 
Two different sucrose gradient fractions from each biological replicate were selected 
for enzymatic digestion (fractions 24 and 28). The selected fractions were dried down 
in a vacuum centrifuge, then dissolved in 100 µL of 8 M urea (in 50 mM NH4HCO3) to 
a final concentration of 0.2–1 mg/mL. Next, samples were reduced using 5 µL of 50 
mM TCEP at 37 °C for 30 min, then alkylated for 20 min in the dark at RT with 5 µL of 
50 mM of iodoacetamide. Endo-LysC/Trypsin mix was then added at a 1:25 
enzyme:substrate (wt:wt) ratio and the mixture was incubated at 37 oC for 4 h. 
Samples were diluted with 50 mM NH4HCO3 to 0.75–1 M urea; trypsin was then added 
at a 1:50 ratio (wt:wt) and the mixture incubated at 37 °C for 16 h. Digested peptides 
were acidified and desalted using in-house packed C18 stagetips. LC-MS/MS analysis 
was carried out on Easy nLC-1000 UHPLC (Proxeon) system connected to a Q-Exactive 
Plus mass spectrometer equipped with a standard nanoelectrospray source (Thermo 
Fisher Scientific). Peptides (~1.5 µg) were dissolved in loading buffer (3% (v/v) 
acetonitrile and 1% (v/v) formic acid (FA) in double-distilled water), picked up by the 
autosampler and injected onto a 40 cm × 75 μm inner diameter column packed in-
house with 1.9-µm C18AQ particles. Peptides were separated at a flow rate of 200 
nL/min using a linear gradient of 5–30% buffer B over 120 min. Solvent A consisted 
of 0.1% (v/v) formic acid, and solvent B consisted of 80% (v/v) acetonitrile, 0.1% 
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(v/v) formic acid. The end-to-end run time was 150 min, including sample loading and 
column equilibration times.  
The Q-Exactive Plus mass spectrometer was set to a data-dependent acquisition mode 
(DDA). In the DDA run, each full scan MS1 was operated as follows: mass range was 
between m/z 300 and 1750 at resolution of 70,000 at 200 m/z and 100-ms injection 
time. The top 20 most intense precursor ions were selected to be fragmented in the 
Orbitrap via high energy collision dissociation activation (R = 35,000 at 200 m/z; 1 × 
106 AGC; 120 ms injection time; 30 normalized collision energy; 2 m/z isolation 
window; 8.3 × 105 intensity threshold; minimum charge state of +2; dynamic 
exclusion of 60 s). 
3.4.6 Analysis of MS/MS data 
Raw data were analyzed by MaxQuant (version 1.5.6.5) [156] using standard settings 
with the additional ‘match between runs’ option, LFQ and iBAQ selected. Methionine 
oxidation (M) and carbamidomethyl cysteine (C) were selected as variable and fixed 
modifications, respectively. The quality of the tryptic peptides was first analysed using 
the peptide text file created in MaxQuant. The majority of the observed peptides 
(~97%) were 7–30 amino acids in length, suggesting complete digestion of the 
samples (Supplementary Fig 3-1). Maxquant analysis identified 281 proteins at a 1% 
false discovery rate (Supplementary Data 1). Of these 281 proteins, 46 were filtered 
out; these comprised 9 protein duplicates, 34 contaminant proteins (e.g., keratin) and 
3 false positive hits (i.e., decoy hits) (Supplementary Data 1). At this stage, fraction 
28 of PC3 replicate 1 and fraction 24 of MCF7 replicate 2 were also excluded from 
further analysis, as some canonical subunits of NuRD was not detected 
(Supplementary Data 1). 
To determine the possible interactors, the list of 235 proteins was further filtered: 
proteins that were present, based on averaged iBAQ-adjusted intensity values (of the 
two fractions tested per replicate), and in at least 2 biological replicates in any set of 
3 replicates (per cell type) were shortlisted. This filter yielded a total of 36 proteins. 
Of these 36 proteins, 12 were NuRD complex paralogues and 24 were possible new 
interactors (Supplementary Data 1). For NuRD stoichiometry determination, the iBAQ-
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adjusted intensity values for MTA1, -2, and -3 were summed together (Supplementary 
Data 1) and intensity values for known NuRD complex subunits (including all paralogs 
and CDK2AP1) were divided by this summed MTA value. The final values were then 
multiplied by 2 because there are likely to be 2 MTA molecules per NuRD complex 
based on published crystal structures [112, 171]. All raw mass spectrometry data and 
search results have been deposited to the ProteomeXchange Consortium via the 
PRIDE partner repository [203]. 
3.4.7 Co-immunoprecipitation analysis in HEK293 cells and 
rabbit reticulocyte lysate 
Suspension HEK Expi293FTM cells (Thermo Fisher Scientific) were used for interaction 
analysis as detailed elsewhere [163, 187]. In brief, 4 µg plasmid DNA and 8 µg PEI 
were mixed and incubated in 200 µL sterile PBS at room temperature for 30 min, and 
then was added to 2 mL of cells (2 × 106 per mL). The transfected cells were collected 
after 65 h, and then lysed by sonication in 0.5 mL of lysis buffer (50 mM Tris pH 7.9, 
150 mM NaCl, 1 mM PMSF, 1× complete protease inhibitor (Roche), 0.2 mM DTT, 1% 
(v/v) Triton X-100). Cell lysates were cleared by centrifugation at 20,000 g at 4 °C for 
20 min and 5% of cleared lysate was used as input to check expression. Cleared 
lysates were mixed with 20 µL anti-FLAG Sepharose 4B beads (Biotool, Houston, TX, 
USA; pre-equilibrated with 50 mM Tris-HCl, 150 mM NaCl, 0.1% (v/v) Triton X-100) 
and rotated end-over-end for 2 h at 4 °C. Next, the beads were washed five times with 
1 mL of washing buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% (v/v) Igepal CA-630, 
and the bound proteins were eluted in three lots of 20 µL of elution buffer (10 mM 
HEPES pH 7.5, 150 mM NaCl, and 150 µg/mL 3× FLAG peptide).  
For cell free expression, the TNT Quick Coupled Transcription/Translation System 
(Promega, Fitchburg, WI, USA) was used. Two plasmids were co-transcribed and co-
translated in the same reaction mixture according to the manufacturer’s protocol. 
Immunopurification was performed as described above for HEK293 cells. 5% of input 
was used for expression check. 
For Western blot analysis, the gel-separated proteins were blotted onto PVDF 
membranes and probed with antibodies from Cell Signalling Technology (Danvers, MA, 
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USA): anti-FLAG-HRP (2044S, 1:20,000), anti-HA-HRP (2999S, 1:20,000), anti-HDAC1 
(5356S, 1:20,000).  
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Chapter 4. Understanding the assembly and stoichiometry of 
MMH and MMHG complexes  
4.1 Introduction 
The NuRD complex uniquely connects chromatin remodeling to DNA methylation and 
histone modifications. It brings together a methylcytosine-binding domain protein 
(MBD2/3), histone deacetylases (HDAC1/2), and a large nucleosome remodeler 
(CHD3/4) [61, 132]. It has previously been shown that HDAC1/2 and RBBP4/7 are 
recruited by MTA1-3 to form a subcomplex that we named the MHR (MTA-HDAC-
RBBP) complex [163, 204] (Fig 4-1). The remaining subunits such as MBD, GATAD2 
and CHD (which we collectively term mGC for simplicity (Fig 4-2), although we note 
that is not currently clear whether it can form a truly independent complex) can be 
sequentially added to the core MHR complex and build up the whole NuRD complex, 
which is then capable of binding and remodeling DNA.  
However, the details of these inter-subunit interactions and the stoichiometry of the 
complex are not well known. We therefore asked the question “How does the mGC 
module interact with the MHR module?” To address this question we recombinantly 
expressed two subcomplexes: one composed of MBD3, N-terminal half of the MTA2 
protein (referred to as MTA2N hereafter) and HDAC1 (hereinafter referred to as MMH 
complex), and another containing full length MTA2, MBD3, HDAC1 and GATAD2A 
(hereinafter referred to as MMHG complex) in suspension Expi293F™ cells. Then we 
investigated the stoichiometry of the subunits and topology of the complexes using 
mass spectrometry (MS) based proteomics techniques. Absolute protein 
quantification, using heavy labeled isotopes followed by data independent acquisition 
mass spectrometry (DIA-MS or SWATH-MS that can be used interchangeably), was 
performed to determine the stoichiometry. Crosslinking mass spectrometry (XL-
MS/MS) was used to assist the modeling of SPEM data. 
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Fig 4-1. Schematic representation of the MHR and MMH, and mGC 
subcomplexes. The NuRD complex is composed of six different proteins, each of 
which have several paralogs. The MTA-HDAC-RBBP complex (MHR) forms the core 
NuRD complex and the other subunits (MBD, GATAD2 and CHD) are recruited to this 
core. It has been shown by us and others that MTA and HDAC make a dimer of dimers, 
and RBBP4 is recruited by C-terminal part of MTA [163]. However, we do not exactly 
know how many RBBP4 molecules can interact with the MTA C-terminal half, which 
will be addressed in Chapter 5. Question marks indicate that we still do not clearly 
know if the MBD-MTA-HDAC or MMH complex can be formed or even the mGC module 
exists or not. The ELM2-SANT domains in the MTA protein dimerize through the ELM2 
domain and then wrap around the HDAC protein. The BAH domais is positioned to 
present nucleosomal substrate to the NuRD complex. 
4.1.1 What are DIA-MS and SWATH-MS?  
In proteomics studies, the MS can be set up to scan and analyse the peptides in 
different ways, depending on the goal of the study. There are two main modes of data 
acquisition: data dependent acquisition (DDA) [205] and data independent acquisition 
(DIA) [206]. In the DDA method, peptides are ionized into precursor ions and are 
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guided into the MS. Upon entering the mass spectrometer, these precursor ions are 
scanned in the mass analyzer. In the next step, the collected ions (known as precursor 
ions) are subjected to the collision chamber to generate fragment ions or product ions 
for analysis in a second mass analyzer. The selection of precursor peptides is 
performed based on predefined criteria in the method and is usually based on ion 
abundance (the 15 to 20 most abundant ions are usually selected). The selection of 
the most abundant ions is random, thus this method suffers from a lack of 
reproducibility. This issue is exacerbated in the case of low abundant peptides in 
complex mixtures.  
To overcome this problem, the concept of independent data acquisition was proposed 
by John Yates’ group in 2004 [207]. They proposed a modified method, named data 
independent, for tandem mass spectrometers that sequentially isolates and fragments 
10 m/z windows [208]. In contrast to DDA, every detectable ion is fragmented, not 
just the more abundant species. Sequential Window Acquisition of All Theoretical 
Peptides of All Spectra (SWATH-MS) is a recently developed implementation of data-
independent acquisition (DIA) and targeted analysis [206].  
The SWATH-MS method was first developed by Ruedi Abersold’s group and has 
become popular as it combines the advantages of DDA and single reaction monitoring 
(SRM). SRM is the gold standard approach for targeted quantitative proteomics which 
is performed in triple-quadrupole MS in which a precursor ion of a particular mass is 
selected in the first MS run and then an ion product of the precursor ion is selected in 
the second mass spectrometer stage for detection. The SWATH-MS approach 
circumvents the low reproducibility of the DDA method because all peptides within a 
defined mass-to-charge (m/z) window are subjected to fragmentation, and the mass 
spectrometer scans the full m/z range [209].  
4.1.2 Why do we need to perform absolute protein 
quantification?  
In many quantitative proteomics studies, the quantities of the detected peptides are 
not determined in absolute terms (as for example the number of femtomoles of a 
peptide present in a particular sample). This is because relative quantification reports 
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a dimensionless protein ratio that describes change in abundance of the protein 
between two or more of samples. However, relative quantification has some 
limitations, including the fact that the peak intensity of a peptide can vary across 
samples due to both the gradual deterioration of the nano-spray ESI needle and the 
reduced binding capacity of the LC column [210]. Absolute protein abundances are 
typically expressed in units such as copy number per cell, picomoles of protein per 
volume of body fluid, and protein weight per tissue or cell extract weight [211]. To 
determine the stoichiometry or copy number of subunits of the NuRD complex, we 
required an absolute quantification method. The use of a known amount of isotopically 
labeled heavy peptides is the most accurate way to quantify protein abundance [212, 
213]. In this method, heavy labelled isotope peptide standards are spiked in with the 
biological samples prior to proteolytic digestion. These internal standards have 
different masses to the peptides derived from the samples and this difference can be 
recognized in a high-resolution mass spectrometer. The abundance of the peptides 
from each sample is calculated/quantified and compared to the isotopically labeled 
heavy standards.  
4.1.3 What is XL-MS/MS and what can it tell us?  
XL-MS/MS is the process of chemically joining two or more protein molecules by a 
covalent bond, digesting the treated sample with a protease and then analyzing the 
resulting peptide mixture by mass spectrometry to identify the crosslinked peptides 
[214]. In the past few years, XL-MS/MS of large protein complexes has become a 
valuable method combining proteomics and structural biology and it has recently been 
successfully applied for the elucidation of the structure and architecture of large 
multiprotein complexes such as SWI/SNF and INO80 [215, 216]. Proteins that are 
close enough in space can be crosslinked by a crosslinker (XL), and therefore XLs 
connecting two subunits provide information on the physical proximity of these 
subunits. In addition, the distance restraints provided by the length of the crosslinker 
and sidechains can be used for interpreting  EM envelopes of the complexes [217].  
In the current study focused on NuRD, we used BisSulfoSuccinimidylSuberate (BS3) 
H12/D12 (isotopically-coded light (H12) and heavy (D12)) crosslinker, which is a 
homobifunctional amine-to-amine crosslinker that is non-cleavable (Fig 4-2). The 
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light and heavy molecules differ by 12 deuterium atoms in the heavy form instead of 
12 hydrogen atoms in light form. BS3 contains an amine-reactive sulfo-N-
hydroxysulfosuccinimide (sulfo-NHS) ester at each end of an 8-carbon spacer arm with 
a 11.4 Å length. The theoretical distance between the target groups is restricted by 
the length of this linker joining the adjacent reactive ends of the crosslinker, and this 
can be extrapolated to a maximum distance restraint between the two crosslinked 
residues. The NHS esters react with primary amines at pH 7-9 and forms stable amide 
bonds. For use in structure determination, the crosslinks detected in the mass 
spectrometer are translated into maximal distances between the two crosslinked 
amino acids, which helps when modeling structures of multi-subunit protein complexes 
[217].  
 
Fig 4-2. Structure of the BS3 crosslinker. The distance constraint between the Cα 
atoms of two residues is calculated by summing the length of the XL spacer arm and 
side chains of the residues. The length of a BS3 spacer arm and each lysine side chain 
are 11.4 Å, and 6 Å, respectively. A distance tolerance of 6 Å is also added to the 
theoretical maximum length because XL-MS/MS studies on proteins with known 
structure consistently report XLs that exceeds 24 Å [218]. A distance constraint of ≤30 
Å between alpha carbons of lysine residues has been reported as an appropriate 
distance for BS3 and DSS cross linkers [218]. 
Thus far, we do not clearly know whether one or two MBD molecules exist in the NuRD 
complex and whether MBD can make a stable complex with the MTA-HDAC (MH) core 
complex. Moreover, it is not clear whether the mGC complex can form a truly 
independent complex and if the mGC module can be sequentially added to the core 
MHR complex and build up the whole NuRD complex. The goal of the work in this 
Chapter is to begin to address this gap in our knowledge. 
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4.1.4 single particle electron microscopy (SPEM) 
In the early 1970s, Electron Tomography (ET) was used to three-dimensionally image 
biological specimens [219]. The basis of electron tomography is a tomogram that can 
be obtained from the collecting different views of the specimen. However, the 
radiation used in ET for imaging particles can limit the number of collected images 
because of the damage caused by radiation. Nevertheless, this principle has been 
extended to become the foundation for almost all three-dimensional electron 
microscopies and single particle analysis [220]. Advances in SPEM and computational 
methods circumvented the limitation of ET by combining thousands of images of the 
same macromolecule (e.g., protein) in random orientations. Over the past decade, 
SPEM techniques have helped scientists to solve the structure of very large protein 
complexes even of megadalton size, including many structures that have not been 
able to be determined using crystallography or other structural biology methods [221].  
4.2 Results 
4.2.1 Experimental design 
Figure 4-3 shows the experimental pipeline used for protein expression, purification 
and downstream analysis. Different parameters, such as the number of EXPI293F™ 
cells needed for transfection to get the right number of complexes for each 
experiment, had to be accounted for in order to manage time, consumables, and costs. 
Initially, a trial overexpression was conducted with 2 × 106 EXPI293F™ cells to check 
if the sub-complexes were formed recombinantly and optimize the best purification 
conditions. Next, large scale protein expression and purification experiments were 
planned considering that 40%-50% of sample was lost during each 
concentration/desalting and sucrose fractionation steps. We estimated that for XL-
MS/MS we would need about ~20-100 mg/mL of purified complex, for DIA-MS about 
~0.03-0.1 mg/mL, and for negative-stain single particle electron microscopy (SPEM) 
experiment about 0.5-1 mg/mL. 
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Fig 4-3. Schematic representation of the steps used to prepare samples for 
XL-MS/MS, DIA-MS, and SPEM experiments. (A) Protein complexes were 
overexpressed in EXPI293F™ cells and affinity purified and concentrated using Amicon 
Filters. (B) For DIA-MS (stoichiometry determination) and for the negative stained EM 
(structural analysis) samples were subjected to a second purification step. (C) For XL-
MS/MS experiments, protein materials from Step A were directly used because the 
excess FLAG peptides were eliminated during concentration. 
4.2.2 MMH and MMHG complexes were successfully expressed 
and purified from EXPI293F™ cells  
To produce the MMH complex, we used the MBD3cc construct that consists of full-
length FLAG-mbd3 fused to the first coiled-coil domain (CR1) of GATAD2A (Fig 4-4). 
The CR1 region forms a coiled coil with the C-term of MBD3 and makes MBD3 more 
soluble and stable [132]. Constructs encoding either tagless full-length HDAC1 or HA-
tagged N-terminal half of MTA2 (residues 1-429) were cloned into the mammalian 
expression vector pcDNA3 by Gibson assembly [147]. A tagless version of HDAC1 was 
used because we had previously established that the presence of a tag can affect 
HDAC1 deacetylase activity and may also perturb its interaction with other proteins 
[187].  
To produce the MMHG complex, we used full-length constructs for FLAG-MTA2, HA-
MBD3 (not MBD3cc), HDAC1 and HA-GATAD2A. In this case, an MBD3 construct 
without the GATAD2A coiled-coil fusion was used, because GATA2A protein is present 
and we expected it to interact with MBD3 through the coiled coil. 
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Fig 4-4. Constructs used to express MMH and MMHG complexes. The MTA2N 
construct is used because it lacks the C-terminal half responsible for binding to 
RBBP4/7 and avoids pulling down endogenous RBBP4/7. The MBD3cc construct 
contains two different coiled-coil (cc) domains. The second cc (GATAD2A CC1) was 
fused to this protein to make it soluble and folded as shown previously [132]. Full 
length HDAC1 and GATAD2A were used. Dark colours indicate domains for which 
structures are known; pale colours indicate domains for which reliable homology 
models can be built; white indicates regions predicted to be ordered but with unknown 
structures; and lines indicate regions predicted to be disordered (using PONDR). 
 
4.2.3 High salt washing buffer seems to be ideal to get a pure 
complex 
Trial experiments to optimize transfection and protein purification were performed 
using the MMH complex. About 2 × 106 EXPI293F™ cells were seeded in a 12-well 
plate and transfected with a mixture of pCDNA3.1 plasmids encoding FLAG-MBD3cc, 
HA-MTA2N, and tagless HDAC1. The same molar ratio of the plasmids were used by 
taking their length into account. Transfected cells were collected after 72 h and 
immunopurification was performed using 20 µl of anti-FLAG Sepharose 4B beads 
(hereafter referred as FLAG beads) to capture FLAG-MBD3cc as bait and consequently 
other subunits as preys. Elutions were run onto SDS-PAGE for examining the purity of 
the complex (Fig 4-5A). Results indicated that there were considerable amounts of 
other proteins that co-purified with the complex. To address this issue, we used 
washing buffers containing different concentrations of NaCl (e.g., 150 mM, 500 mM, 
and 1000 mM) (Fig 4-5B). Washing buffer containing 500 mM NaCl showed the best 
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result as the majority of the contaminant proteins were washed off without disrupting 
the MMH complex (Fig 4-5B). Despite the stringent washing conditions, we could still 
observe a band around 66 kDa, which corresponds to a heat shock protein (HSP71, 
confirmed by mass spectrometry), which co-purified with the complexes. The heat 
shock protein was removed from the sample by subjecting samples to a second 
purification step, meaning that the heat shock protein is most likely co-purifying with 
the complex by nonspecifically attaching to the FLAG beads. A similar protocol was 
used successfully for the production of MMHG. 
 
Fig 4-5. MMH complex expression and purity check on a Sypro-Ruby stained 
SDS-PAGE. (A) Sypro-Ruby stained SDS-PAGE showing MMH complex following 
overexpression in EXPI293F™ cells, FLAG beads were incubated with cell lysate and 
then washed with 150 mM NaCl, 0.5% IGEPAL, and 50 mM Tris-HCl pH 8. Elution was 
carried out from FLAG beads with FLAG peptide. (B) Sypro-Ruby stained SDS-PAGE 
showing MMH complex washed with different NaCl concentrations. HSP71 is a heat 
shock protein which is produced in cells in response to a rise in temperature. M refers 
to Mark2 protein ladder, E1-E3 refers to elution 1 to 3, and LW refers to last wash. 
The identification of the proteins was achieved with mass spectrometry. 
4.2.4 Large scale overexpression and purification of MMH and 
MMHG complexes 
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After optimizing the expression and purification of MMH, large scale experiments were 
set up to purify sufficient sample for SPEM, XL-MS/MS, and DIA-MS studies. For both 
MMH and MMHG subcomplexes, we transfected 2 × ~250 mL EXPI293F™ cells (2 × 
106 cells/mL) as indicated in Table 4-1. Protein expression was confirmed by western 
blotting using FLAG, HA and HDAC1 specific antibodies (Fig 4-6A). If protein 
expression was not visible in the western blot, a small-scale pulldown was performed 
using FLAG beads to enrich for the complex and confirm expression. For purification 
of the whole samples, 1.25 mL of FLAG beads per 250 mL transfected cells were used 
to capture and purify the complexes. The complexes were eluted from the FLAG beads 
using 5 mL 3×FLAG peptide and, upon elution, the purified complexes were further 
concentrated to 0.5 mL using 4 mL Amicon Centrifugal Filters in a swinging bucket 
centrifuge at a low speed (500 g at 4 °C) (Fig 4-6B). 
Table 4-1: Amount of plasmid used to transfect 100 mL EXPI293F™ cells  
Plasmid Quantity (µg) Complex 
FLAG-MBD3cc 27  
MMH  HA-MTA2N 61 
HDAC1 68 
HA-MBD3 42  
MMHG 
 
FLAG-MTA2 50 
HDAC1 48 
HA-GATAD2A 55 
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Fig 4-6. Expression and purification of MMH and MMHG complexes. (A) A 
western blotted SDS-PAGE (using HRP-conjugated anti-FLAG, anti-HA, and anti-
HDAC1 antibodies) probing the expression of overexpressed subunits in two 
experimental replicates (Rep1 and Rep2). The protein marker used in western blotting 
was WesternC standard. (B) Sypro-Ruby stained SDS-PAGE showing FLAG-affinity 
purified complexes. Endogenous CHD4 was co-purified with MMHG complex, as it was 
previously established that CHD4 interacts with GATAD2 [162]. Both MTA2 and 
GATAD2A are ~70 kDa so the corresponding bands can overlap with each other in the 
gel of the MMHG complex. Our MS data confirmed the presence of both proteins in 
the complex. 
The western blot experiment (Fig 4-6A) represents proteins with various intensities 
which is due to the difference in antibody quality and also protein expression level. 
Figure 4-6B represents the FLAG immunopurification results clearly showing the 
copurification of CHD4 with the MMHG complex. The CHD4 protein is not copurified 
with MMH complex where there is no GATAD2 protein available.  
Complex samples purified by FLAG-pulldown still contained a few contaminants and a 
second purification step was deemed necessary. The purpose of running a sucrose 
density gradient (called here a normal sucrose gradient, NSG) is to remove free 
subunits, handle protein (or bait protein is used to capture other proteins in a crude 
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cell lysate), and excess 3× FLAG peptides, which can lead to a bias toward 
stoichiometry determination or LC column blockage when running onto the LC-MS/MS. 
GraFix (Gradient Fixation) sucrose density gradient is another purification method 
commonly used to stabilize macromolecular complexes for SPEM analysis [222]. As 
explained in detail in chapter 2 glutaraldehyde is added to gradient during formation, 
resulting in a gradient of glutaraldehyde along with sucrose. In this method, 
macromolecules undergo a mild, intramolecular chemical cross-linking while being 
purified by density gradient ultracentrifugation. GraFix aims to stabilize 
macromolecular complexes for SPEM analysis. FLAG-purified MMH and MMHG 
complexes were subjected to both normal and GraFix sucrose density gradient 
purification. 
Gradients containing 2-25% and 5-35% sucrose were used to fractionate the MMH 
and MMHG complexes, respectively. During the preparation of GraFix gradients, 0.5% 
glutaraldehyde was added to the highest concentration sucrose buffer, in order to 
produce a gradient concentration of crosslinker throughout the gradient column. 
Figure 4-7 represents fractionated complexes on SDS-PAGE. Fractions highlighted 
with a dashed red dashed box (Fig 4-7A and 4-8A) were further processed for 
stoichiometry analysis. Every 2 or 3 adjacent fractions from GraFix gradients were 
pooled together to make different sets of samples for SPEM analysis. For the MMH 
complex, fractions 24, 25, 26 were pooled and labeled as MMH-1 and fractions 27, 28, 
29 were pooled as a separate set and labeled MMH-2 (Fig 4-7B). For the MMHG 
complex, fractions 34 and 35 were combined (MMHG-1) and fractions 36, 37, and 38 
were combined (MMHG-2, Fig 4-8B). 
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Fig 4-7. Fractionation of MMH complex on normal and GraFix sucrose 
density gradients (2-25%). (A) Sypro-Ruby stained SDS-PAGE showing different 
fractions of normal sucrose gradient containing the MMH complex from two 
experimental replicates. Fractions 18 and 20 were selected for stoichiometry analysis. 
(B) Sypro-Ruby stained SDS-PAGE showing different fractions of MMH-1 from the 
GraFix sucrose gradient. Highlighted fractions were combined and used for SPEM 
analysis. The later fractions (31-45) corresponded to higher molecular weight 
subcomplexes and some unknown complexes. BSA was loaded as a standard for 
quantification purposes. 
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Fig 4-8. Fractionation of the MMHG complex on normal and GraFix sucrose 
density gradients (5-35%). (A) Sypro-Ruby stained SDS-PAGE showing different 
fractions from a normal sucrose gradient separating MMHG species. Fractions 20-26 
contain the majority of recombinantly expressed species. Fractions 22 and 24 were 
selected for stoichiometry analysis. (B) Sypro-Ruby stained SDS-PAGE showing 
different fractions of a GraFix sucrose gradient; the selected fractions used for SPEM. 
BSA was loaded as a standard for quantification purposes.  
4.2.5 Proteotypic peptide selection 
In targeted proteomics, acquisition of a high-quality data is dependent upon the 
selection of a set of optimal peptides for all proteins of interest. Selecting a peptide 
that can provide the greatest signal-to-noise ratio in a particular assay matrix is 
important. The Skyline software package makes it easy to build a method that can 
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measure a broad range of peptides in search of the best peptide in a complex mixture. 
Results from this initial measurements and initial shotgun proteomics experiments can 
then be used to choose the best peptides. Determination of the best peptides for 
NuRD complex subunits for quantification of the NuRD subunits and the library setup, 
was carried out previously by Dr Jason Low in the Mackay laboratory. The selection of 
reliable and representative proteotypic peptides (PTPs) involved the following criteria: 
(i) reproducible and reliable detection of the peptide across different MS runs and 
biological replicates; (ii) absence of missed cleavages; (iii) absence of known post-
translational modifications (PTMs) (ascertained by querying protein databases such as 
PhosphoELM and UniProt and large scale proteomic datasets that had not been 
incorporated into UniProt at the time of experimental design) or potential predicted 
PTM sites; (iv) hydrophobicity scores (very hydrophobic peptides could present 
solubility issues and have aberrant chromatographic behavior); (v) avoidance where 
possible of residues that can be difficult  to incorporate into synthetic peptides (C, F, 
I, L, V, W, Y); (vi) avoidance of extremely long or short peptides (9-10 residues is 
ideal); (vii) where possible, avoidance of the following residues: methionine-
unpredictable oxidation; cysteines - unpredictable oxidation but can be mitigated by 
reduction and alkylation of the samples; prolines - unusual elution profile due to 
isomerization and predominant CID fragmentation pattern; N-terminal glutamines and 
glutamates - can undergo spontaneous modification to pyroglutamate; (viii) of less 
importance and where possible, to selection of peptides with precursor ions <1000 
m/z (this is due to the instrument used for data acquisition). Using these criteria, Dr 
Low selected 2-3 PTPs that were unique for each target protein and, where paralogues 
are very similar (e.g., HDAC1/2 and RBBP4/7), an additional 1-3 ‘pseudo PTPs’ shared 
between the paralogues were also chosen.  
4.2.6 Stoichiometry analysis 
The concentration of the purified complexes within each normal sucrose fraction was 
calculated by Image J software based on the BSA standard. Then, 10 ng and 15 ng of 
the MMH and MMHG complexes in combination with known quantities of the 13C/15N-
labelled internal standard peptides (up to three per protein) were digested and 
desalted using stage tips, and then subjected to DIA-MS analysis. The Q-Exactive 
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mass spectrometer was operated in a data-independent acquisition (DIA) mode. 
Raw data were collected and quality checked and analysed using Skyline software 
version 4.1.0.11796. Firstly, peptides with an isotope dot product (idotp) value less 
than 0.9 were set to be omitted from the dataset. The idotp value is extracted from 
the first MS stage (MS1) and compares the theoretical mass spectra of a precursor 
peptide and naturally abundant isotopes (M, M+1, M+2) to the experimental mass 
spectra calculated by Skyline. Thus, the idotp values are a measure of confidence that 
a detected peak corresponds to the peptide of interest. Secondly, the peak area for 
each light peptide was refined by removing any extra shoulder in selected peak areas. 
Finally, transitions with different retention time compared to the heavy peptides were 
not considered and were filtered out during data processing. We manually assessed 
the quality of the spectra arising from all peptides. As expected, all the transitions 
showed very high quality peaks. The elution profile of the precursor and product 
transitions between light and heavy peptides matched closely. Figure 4-9 shows an 
example of all transitions and retention times derived from light and heavy versions 
of the VWDPDNPLTDR peptide (from MTA2) at the level of MS1 and MS2.  
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Fig 4-9. Quality check of the peaks area at MS1 and MS2 levels. Graphs of ion 
counts for MS1 and MS2 spectra. The VWDPDNPLTDR peptide from MTA2 protein is 
used as an example. Both (A) and (B) indicate light and heavy precursor peptides 
peaks from light and heavy labeled peptides, respectively. Skyline calculates the peak 
area for both light and heavy peptides and gives a ratio, which is used to quantify the 
light peptide. (C) and (D) Peaks are shown for fragment ions (b ions) derived from 
the precursor of light and heavy labeled peptides.  
4.2.6.1 The MMH complex showed an unexpected 2:2:2 
stoichiometry  
Our ability to purify a stable complex comprising MTA2N, HDAC1 and MBD3cc 
demonstrates that MBD3 makes a direct interaction with the MTA-HDAC1 core 
complex, consistent with our published finding that MBD3 can interact with MTA1 
[187]. Given emerging data from our own lab on intact NuRD and with consideration 
of all data from the literature, our expectation was that one molecule of MBD3 is 
present in the intact NuRD complex – with MBD, GATAD2 and CHD being present in 
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the complex in one copy and the 2:2 HDAC:MTA complex binding four molecules of 
RBBP. 
To analyse the data, we used the MTA subunit as our reference point to normalize the 
processed data (MTA should be two units per NuRD assembly based on the X-ray 
crystal structure of the 2:2 MTA-HDAC complex [204]). Unexpectedly, we saw a 
2:2.6:2.2 ratio for MTA2-HDAC1-MBD3 for two biological replicates (each comprising 
three technical replicates), which suggested the presence of two molecules of MBD3 
in MMH complex (Fig 4-10). As it is depicted in the Figure 4-1, and XL-MS/MS data 
from our lab and other groups it is possible that the BAH domains in the MTA protein 
can provide a binding surface for the binding of the MBD proteins. We speculated that 
MBD3 is possibly occupying both binding sites on MTA dimer in the absence of other 
NuRD components and leading to a symmetric conformation.  
 
Fig 4-10. Stoichiometry of the MMH complex. (A) Each bar represents the 
number of subunits of each protein, relative to MTA2 being set to 2. Two biological 
replicates are shown (Rep1 and Rep2). Each bar represents the mean of three 
technical replicates. (B) In addition to DIA-MS data, we also used MMH pull down 
assay data to model the MMH complex. 
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4.2.6.2 Co-immunopurification followed by western blotting 
confirmed two copies of MBD in MMH complex. 
To biochemically corroborate the unexpected 2:2:2 stoichiometry, combinations of 
Tagless-HDAC1, HA-MTA2N and FLAG-MBD3cc – plus or minus Tagless-MBD3 – were 
co-expressed in EXPI293F™ cells. An anti-FLAG pulldown followed by a western blot 
(Fig 4-11) demonstrated that the Tagless-MBD3 (which runs separately to FLAG-
MBD3cc) co-purifies with FLAG-MBD3cc, tagless-HDAC1 and HA-MTA2N, consistent 
with the idea that two copies of MBD3 exist in the MMH complex.  
 
 
Fig 4-11. The MMH complex contains more than one MBD protein. Western 
blotted SDS-PAGE gels (using HRP-conjugated anti-FLAG, anti-HA, anti-MBD3, and 
anti-HDAC1 antibodies) probing the interaction of MBD3 with MMH components, 
following co-expression of the indicated proteins in EXPI293F™ cells and FLAG 
immunoprecipitation (IP). Samples are 1% of input samples or 10% of bead-retained 
proteins following FLAG IP. (A) Western blot in which an MBD3-specific antibody was 
used to detect the second MBD3. The tagless MBD3 was co-purified with the complex, 
consistent with the idea that FLAG-MBD3 can bind to one copy of MTA2 in the complex 
and Tagless-MBD3 can bind to the other. (B) Same gel as (A) but probed with anti-
FLAG, anti-HA, and anti-HDAC1 antibodies. 
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4.2.6.3 GATAD2 subunit may prevent binding of a second MBD 
subunit in the MMHG complex. 
In parallel work, our laboratory had demonstrated that the ratio of the 
MBD3:MTA:HDAC in the NuDe complex (a NuRD complex that lacks CHD4 but contains 
GATAD2) is 1:2:2, we therefore hypothesized that it is the presence of the GATAD2 
subunit that inhibits binding of a second MBD subunit in the NuDe and NuRD 
complexes. The stoichiometry of the MMHG complex was determined by co-expressing 
FLAG-MTA2, HDAC1, HA-MBD3 and HA-GATAD2A. The MMHG complex was purified 
using a full length FLAG-MTA2 protein. DIA-MS analysis of two biological replicates 
gave rise to complexes with subunit ratios of 2:2.5:1.3:0.8 for 
MTA:HDAC:MBD3:GATAD2 (Fig 4-12). 
 
Fig 4-12. Stoichiometry of the MMHG complex. (A) Each bar represents the 
number of subunits of each protein, relative to MTA2 being set to 2. Two biological 
replicates are shown (Rep1 and Rep2). Each bar represents the mean of three 
technical replicates. (B) Schematic model for MMHG based the DIA-MS data.  
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4.2.7 Crosslinking mass-spectrometry data analysis 
We performed XL-MS/MS experiment in order to investigate the interaction map of 
the MMH complex and enhance our understanding of the domains that are in close 
proximity. For XL-MS/MS analysis, the BS3 crosslinker was used to crosslink both the 
MMH and MMHG complexes (Fig 4-13). Briefly, the MMH complex were 
overexpressed and purified from EXPI293 cells, then ~ 40 µg of FLAG purified complex 
was mixed with BS3 for 30 min and then the crosslinkers were quenched (see materials 
and methods). Of note, MMH crosslinking with DSS failed (data not shown here) so 
we switched to BS3 and used only a 30-min incubation, as we did before for the MR 
complex (161). Because the 30-min incubation yielded a significant number of 
crosslinked peptides, we did not do any further optimization. Next, cross-linked 
complexes were digested with trypsin and Lys-C proteases, and the resulting mixtures 
run on size exclusion chromatography (SEC), in order to enrich for larger peptides, 
which are more likely to be the crosslinked ones that are being sought. The crosslinked 
peptides were then analysed using a Q-Exactive LC-MS/MS instrument.  
 
Fig 4-13. BS3 cross-linked complexes. (A) Sypro-Ruby stained SDS-PAGE 
showing a band over 200 kDa after crosslinking the MMH complex. (B) Sypro-Ruby 
stained SDS-PAGE showing a band over 200 kDa after crosslinking the MMHG complex. 
Five percent of the crosslinked materials was run onto the SDS-PAGE. Lane M is the 
Mark12 ladder. Red lines schematically indicate the BS3 crosslinker that crosslinks the 
subunits. 
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The pLink software package [223] was used for crosslinking mass spectrometry data 
analysis. Identification of spectra and peptide pairs were performed under conditions 
of 5% FDR control. XL-MS/MS data provide information about cross-linked, mono-
linked, loop-linked, and regular peptides. Monolink or deadend peptides are generated 
from XLs that have only one functional group because the other group is hydrolyzed 
during sample processing. However, looplink peptides form a reaction in which both 
functional groups of the cross-linker react with lysine residues that exist in the same 
peptide after enzymatic digestion. Inter XLs connect peptides from different proteins, 
providing information about subunit proximity in a complex whereas intra XLs connect 
lysine residues on two different peptides from the same protein.  
XL-MS/MS analysis showed the same data for both MMH and MMHG complexes and 
henceforth we only discuss the MMH XL-MS/MS data. Table 2 shows the XL-MS/MS 
data for MMH complex, in the format of spectra and peptides. It indicates that only 
25% of the identified peptides were BS3 cross-linked peptides (inter- and intra- XLs), 
while the majority (46%) were regular peptides. About ~20% and ~7% of the 
peptides were mono-linked and loop-linked peptides. The loop-linked and mono-linked 
cannot provide any distance information between proteins of the complex, but can 
yield important information regarding which lysines are exposed and available for 
crosslinking. One reason for dominance of normal peptides is that, even with 
enrichment strategies such as size exclusion chromatography, the XL peptides are of 
relatively low abundance. To increase the percentage of crosslinked peptides, different 
enrichment methods (e.g., cation exchange) as well as the use of acidic crosslinkers 
(e.g., ADH) are recommended. After sorting the crosslinked peptides (scores ≤ 1 × 
10-4), we ended up with 360 intra- and 79 inter-XL peptides. Redundant XLs linking 
residues from endogenous proteins (e.g., HDAC2, MBD2, and RBBP4, which were 
pulled down along with recombinant complex from EXPI293 cells) with the same 
crosslinked residues as recombinantly expressed proteins were eliminated from the 
data set. For example, QSQIQKEATAQK (90)-GKPDLNTALPVR (172) can be assigned 
between Lys90 in recombinantly expressed MBD3_Mouse and lysine (172) in 
P66A_Human or lysine90 in endogenously expressed MBD2_Human and lysine (172) 
in P66A_Human. After these filtering steps, a dataset of unique XLs comprising 22 
inter- XLs and 90 intra XLs was obtained (Appendix E and F). 
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Table 2. Percentage of XL types 
Types Cross-linked Spectra Loop-linked Spectra Mono-linked Spectra Regular Spectra 
Percent 12.9% 4.8% 13.9% 68.4% 
Types Cross-linked peptides Loop-linked peptides Mono-linked Peptides Regular peptides  
Percent 25.9% 7.3% 20.2% 46.5% 
Next, to check the overall distribution of the XLs in the complex, the set of inter- and 
intra-XLs were visualized using the xiNET tool (Fig 4-14). As can be seen in Figure 
4-14 the pattern of XLs indicates that the MBD domain of MBD3 lies adjacent to the 
MTA BAH, ELM and SANT domains and that GATAD2 shares XLs only with MBD3. The 
data also indicate that the N-terminal portion of HDAC1 contacts the N-terminal 
portion of MTA2. The number of detected inta-XLs was significantly higher in MBD3 
than the other subunits.  
 
 
Fig 4-14. Node-link diagram showing inter and intra XLs. Inter XLs obtained 
for the MMH complex are shown with black lines. MBD3cc is a stabilized form of 
MBD3(1-291), which is fused with the interacting coiled-coil region of GATAD2A 
(residues 133–174). 
The mass spectra corresponding to each XL were individually validated using the 
pLabel tool [223] to ensure that peptide sequences of the XLs match the 
corresponding spectra. Crosslinks with at least four fragment ions on both the alpha 
(α) and beta (β) chain were retained for modelling (in XL-MS/MS studies, the longer 
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chain in crosslinked peptide is annotated as α chain and the shorter one is named β 
chain) [224]. It is notable that the number of XLs observed for each subunit is very 
different, which might be due to the secondary structure surrounding potential XL 
sites [173] or the number of crosslinkable residues. Figure 4-15 shows a 
fragmentation spectrum for a representative XL identified in this study. 
 
 
Fig 4-15. Fragmentation spectrum of a representative crosslinked peptide 
identified in this study. Alpha peptide y- and b-ions are labelled in green and pink, 
respectively, while the beta peptide y- and b-ions are labelled in red and blue, 
respectively. The X axis is mass to charge ratio (m/z) and Y axis represents relative 
intensity. 
4.2.8 Modeling the MMH complex with PyMOL 
Chemical cross-linking is a complementary technique that enable structural modeling 
of large protein complexes by providing evidence to establish structural topologies of 
large protein complexes. We used XL-MS/MS for determination of MMH components 
interaction interfaces. To this aim, unique inter and intra XLs were selected were 
mapped onto the available crystal structures using the PyMOL software package (The 
PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.). The reference 
structures were obtained from the Protein Data Bank (PDB) and used for MMH 
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modeling. Several crystal structures are available for some fragments of the NuRD 
subunits. The structures are as following: the crystal structure of the MTA1ELM-SANT -
HDAC1 dimer (PDB:4BKX), MTA1-RBBP4 (PDB:5FXY), MTA1-RBBP4 (PDB:4PBY), MBD 
domain of MBD3 (PDB:2MB7), MBD-GATAD2 coiled coil (PDB:2L2L),. Crosslink 
distances were assessed on the basis of adhering to the to BS3 ≤ 30 Å. Nine out of 22 
inter XLs lie within sequences for which there are available structures, therefore, these 
were used in the modeling (Table 4).  
Table 4. Inter XLs used to model structures in the MMH complex. 
No Type Protein 1 Protein2 Residue 1 Residue 2 Status Linker Distance ID 
1 Inter MBD3 GATAD2A 68 149 Satisfied BS3 11 B1 
2 Inter MBD3 GATAD2A 46 146 Satisfied BS3 16 B2 
3 Inter GATAD2A MBD3 149 46 Satisfied BS3 22 B3 
4 Inter MTA2 MBD 32 46 Satisfied BS3 24 B4 
5 Inter HDAC1 MBD3 74 46 Satisfied BS3 28 B5 
6 Inter MBD3 GATAD2A 46 172 Satisfied BS3 29 B6 
7 Inter MTA2 MBD3 41 46 Satisfied BS3 11 B7 
8 Inter HDAC1 MBD3 89 46 Satisfied BS3 25 B8 
9 Inter HDAC1 MTA2 89 32 Satisfied BS3 23 B9 
 
Using the measurement function in PyMOL we were able to assess the XLs that satisfy 
or violate the distance restraints for both inter and intra XLs. Of 9 usable XLs all could 
satisfy the expected distance threshold (Fig 4-16). One XL is shown that can be 
mapped onto the GATAD2-HDAC (B1), three XLs onto the MBD-GATAD2 (B2, B3, and 
B6), two XLs onto the MTA-MBD (B4 and B7), two onto the MBD-HDAC (B5 and B8), 
one onto MTA-HDAC (B9). 
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Fig 4-16. Model of the MMH complex using our crosslinking data and 
available structures of the of NuRD subcomplexes. Observed XLs that can be 
mapped with existing structural data. The structures used in our modeling were 
MTA1ELM-SANT-HDAC1 (PDB:4BKX), MBD domain of MBD3 (PDB:2MB7), MBD-GATAD2 
coiled-coil (PDB:2L2L), and MTA1 BAH domain (was based on the structure of the Sir3 
BAH domain (PDB:2FVU). One XL is shown that can be mapped onto the GATAD2-
HDAC (B1), three XLs onto the MBD-GATAD2 (B2, B3, and B6), two XLs onto the MTA-
MBD (B4 and B7), two onto the MBD-HDAC (B5 and B8), one onto MTA-HDAC (B9). 
4.2.9 Modeling of the MMH complex using SPEM and XL-MS/MS 
data 
We next used SPEM and XL-MS/MS data to extend our understanding of how the MMH 
subunits are spatially arranged in the complex. The MMH complex model was 
generated by fitting the available crystallographic structures into our EM envelope 
(generated by Dr. Ana Silva in the Mackay laboratory) using the “fit in map” function 
of the Chimera software [225]. Crystal structures of MTA-HDAC complex together with 
two copies each of the MBD of MBD3 and the MBD3-GATAD2B coiled-coil (which is 
part of the MBD3cc construct) were fitted into the EM map. Figure 4-17 shows the 
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model that best fitted the XL-MS/MS and EM data. The two copies of MBD3cc are 
arranged symmetrically – each one positioned adjacent to each of the two MTA BAH 
domains. XLs analysis in Chimera was performed using the Xlink Analyzer, a plugin 
package in Chimera [153, 225]. XL distances threshold was also set to 30 Å. Of the 
nine inter XLs only one XL [HDAC (K74)-MBD3 (K46)] could not be satisfied in the 
model and was considered as violating XLs and is shown in red. The rest were satisfied 
(Fig 4-17).  
 
 
Fig 4-17. Structural analysis of the MMH complex using SPEM and XLs data. 
Model of the MMH complex showing all inter and intra XLs satisfying or violating in the 
model. Unsatisfied XLs are shown in red; satisfied XLs are shown in blue. Final 3D 
envelope for MMH refined to 29 Å resolution. Subunit colours are as in Figure 4-1. 
The structures used in our modeling were MTA1ELM-SANT-HDAC1 (PDB:4BKX), MBD 
domain of MBD3 (PDB:2MB7), MBD-GATAD2 coiled-coil (PDB:2L2L), and MTA1 BAH 
domain (was based on the structure of the Sir3 BAH domain (PDB:2FVU). SPEM data 
were analysed by Dr. Ana Silva.  
4.3 Discussion 
In Chapter 3, we demonstrated that only one MBD3 exists in the NuRD complex. In 
addition, DIA-MS based absolute quantification of the NuRD complex, carried out 
concurrently in the Mackay lab, also demonstrated the presence of one copy of MBD3 
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in the NuRD complex (unpublished data). These findings are consistent with previous 
work, which reported one MBD3 per NuRD complex [181]. In contrast, three iBAQ 
studies conducted by others determined different ratios for MBD3. One determined 
1:3 for MBD:MTA [169], and the other two determined a 2:2 ratio [57, 168]. These 
latter studies used MBD3 as a handle for NuRD purification and therefore it is likely 
that it leads to overestimation of the stoichiometry of MBD3. Taken together, the 
stoichiometry of the MBD3 has been relatively unclear and in this Chapter I try to 
address this ambiguity.   
Where is the binding surface of MBD3 in the NuRD complex? Our crosslinking mass 
spectrometry and previous studies suggested that MBD3 make an interaction with the 
NuRD complex via the N-terminal part of the MTA1 protein which contains the BAH 
domain in the MTA1. Since there are two BAH domains in the MTA-HDAC dimer-of-
dimers, it is likely that in the MMH complex, where other subunits are absent, MBD3 
can have access to the second BAH domain, and leading to two copies of MBD3 in the 
MMH complex. This raises the possibility that introduction of other subunits blocks the 
second binding site. 
I tested this hypothesis by adding the GATAD2A subunit into the MMH complex, 
creating MMHG. Gnanapragasam and colleagues have shown that MBD2 and 
GATAD2A make a heterodimeric coiled-coil [132]. Results indicate that introduction of 
GATAD2A into the MMH complex not only leads to the formation of a stable complex 
but also brings endogenous CHD4 (present in Expi293F™ cells) into the complex. We 
demonstrated that addition of GATAD2A and CHD4 to the complex directly competes 
away the binding of a second copy of MBD from the MTA-HDAC core, changing the 
stoichiometry to one copy and consequently introducing asymmetry into the complex. 
The data also suggest that contacts between the MTA BAH domain and the MBD3 
MBD domain are a key part of the way in which the histone deacetylase and DNA 
translocase modules of the NuRD complex come together.  
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Chapter 5. The MTA1 subunit can recruit 2 copies of RBBP4 
5.1 Introduction  
MTA1-3 and RBBP4/7 are constitutive subunits of the NuRD complex and most likely 
play key roles in the interaction between NuRD and the nucleosome (Fig 5-1) [138, 
139, 171]. RBBP4/7 forms a 7-bladed β-propeller structure (Fig 5-2A,D) [226]. The 
MTA family of proteins contain several distinct domains. The N-terminal region 
contains four domains (all residues in parentheses refer to human MTA1): (i) BAH(1-
164); (ii) ELM2 (165-283); (iii) SANT(284-335); and (iv) ZnF(387-417) (Fig 5-2B). 
Previous work, and as described in the preceding Chapters, has shown that the ELM2 
and SANT domains work together to interact with HDAC1/2 proteins to form the core 
of the NuRD complex [112]. However, elements of the C-terminal half of the MTA 
protein appears to be disordered and secondary structure predictions suggest several 
helical segments but no identifiable domains. Homology model predictions suggest 
that these disordered regions can undergo a significant conformational change upon 
binding RBBP4/7 [163]. Further, the Mackay lab has shown that MTA1(656-686) can 
interact with RBBP4 through a short motif (678-KRAARR-683 also known as R2) and 
this interaction is essential for the integration of RBBP4 into the NuRD complex (Fig 
5-2B) [139].  
However, as shown in Chapter 3, the stoichiometry of the NuRD complex suggests 
that per NuRD complex, there are two MTA subunits and at least 4 RBBPs subunits; 
suggesting that there must be additional RBBP binding sites within the NuRD complex. 
This Chapter explores this hypothesis. Using a range of biochemical and biophysical 
techniques, we demonstrated that MTA1 (and by extension, MTA2 as well) has a 2nd 
RBBP binding site, and we determined the stoichiometry of MTA:RBBP subunits using 
DIA-MS. We also carried out SPEM analysis on recombinantly produced MR complexes 
and used XL-MS/MS to model the MTA-RBBP (MR) complex. Data presented in this 
Chapter can build on our understanding of NuRD complex structure and help us 
understand the biochemical basis for the activity of this complex.  
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Fig 5-1. Schematic representation of the MR subcomplex within the NuRD 
complex. The MR complex is shown with bright colours, while the other subunits are 
faded out. The question mark indicates that we still do not know exactly how many 
molecules of RBBP4 exist in the NuRD complex. Work in previous Chapters and in the 
literature have estimated the stoichiometry of RBBP to be ~2–4 per MTA. 
 
 
Fig 5-2. Schematics and three-dimensional structures of RBBP4 and MTA1. 
Labelled boxes indicate domains for which structures are known and lines indicate 
regions predicted to be disordered. (A) RBBP4 contains seven WD40 repeats, which 
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fold into a seven-bladed β-propeller fold. (B) Schematic of MTA1; the N-terminal part 
that was not used in this study is faded out, whereas the C-terminal part of the MTA1 
used in this study contains the R1 and R2 regions, which are shown as colored boxes. 
(C) The MTA1Cmut protein, in which the R2 motif is mutated to AAAAAA. (D) Three-
dimensional structure of MTA1R2-RBBP4 (675-686; PDB 4PBY). 
5.2 Results  
5.2.1 Multiple alignment of a portion of MTA1 protein across 
eukaryotes shows two possible binding sites. 
To identify additional RBBP binding sites within MTA1, we performed both sequence 
alignment and secondary structure  prediction analysis using the CLC sequence viewer 
(CLC Bio, a QIAGEN Company, Aarhus, Denmark) alignment and PORTER [227] 
software tools, respectively. Figure 5-3 shows the sequence alignment between 
several diverse species (e.g., human, mouse, camel, bees, and fly). These 
bioinformatics data predict a region stretching ~60 amino acids (residues 483–538) 
may form four α-helices (labelled 1 to 4). Among these, α-helix 2 resembles a 
sequence that has been previously shown to mediate an interaction with RBBPs (α-
helix 5) [139]. Given that the α-helix 2 contains the highly conserved AAR motif, which 
is followed by a PYxPI loop (highlighted with a yellow box), it seems likely that this 
helix could potentially bind a second molecule of RBBP4/7. 
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Fig 5-3. Multiple sequence alignment of MTA1 (483-715) from a range of 
eukaryotes. Rectangles indicate R1 and R2 regions in sequence of MTA1 orthologues 
from Homo sapiens (Q13330), Mus musculus (Q8K4B0), Struthio camelus australis 
(A0A093HEK0), Habropoda laboriosa (A0A0L7R1K5), and Drosophila melanogaster 
(Q9VNF6). The yellow highlighted motif seems to be conserved right after α-helices 2 
and 5. Black rectangle indicates predicted α-helices (α- helices 1-4), and the red 
rectangle indicates an α-helix (α-helix 5) for which we have crystal structure.  
5.2.2 Biochemical analysis to confirm sequence alignment 
results 
To explore the possibility of this second RBBP binding site, first trial co-overexpressions 
and purification of FLAG-tagged human MTA1C (residues 449–715), human HA-tagged 
full-length RBBP4 and a mutant version of MTA1C (MTA1Cmut; residues 678-KRAARR-
683 mutated to AAAAAA; were performed. All the co-expressions of MTA1C with 
RBBP4 (MR), and MTA1Cmut and RBBP (MmutR) were performed in EXPI293F™ cells 
(see Methods for details).  
After setting up the expression and purification using pulldown assays Dr. Mario 
Torrado in the Mackay lab investigated whether the C-terminal half of MTA1 can 
indeed bind to more than one RBBP as suggested by the sequence alignment results. 
Combinations of FLAG-RBBP4, HA-RBBP4, and tagless-MTA1C and tagless-MTA1Cmut 
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were co-expressed in EXPI293F™ cells. Pulldowns were performed using anti-FLAG 
Sepharose beads to capture RBBP4 as the handle/bait protein. Western blot analysis 
(Fig 5-4A lane 4, and B) showed that HA-RBBP4 was consistently pulled down when 
tagless-MTA1C was coexpressed, indicating that this portion of MTA1 is able to bind 
two RBBP4 molecules simultaneously. However, pull downs using MTA1Cmut instead 
of MTA1C, abolished the ability of MTA1 to bind the second RBBP4 (Fig 5-4A lane 5, 
and C). These pulldowns strongly support the hypothesis that there is a second RBBP 
binding site in the MTA1 sequence. 
 
 
Fig 5-4. The C-terminal half of MTA1 can bind two molecules of RBBP4. (A) 
Pulldown analysis showing that MTA1C is able to bind two molecules of RBBP4. Cleared 
cell lysates (Input) of EXPI293F™ cells expressing the proteins indicated on top, as 
well as anti-FLAG immunoprecipitates (anti-FLAG pulldown), were analysed by 
Western Blot using anti-FLAG, anti-HA or anti-MTA1 antibodies to detect the proteins 
indicated on the left. (B) and (C) Schematic representation of the pulldowns and 
western blot results for MTA1C-RBBP4 and MTA1Cmut-RBBP4 complexes, respectively. 
This experiment was performed by Dr. Mario Torrado in the Mackay lab. 
5.2.3 Large scale expression and purification of MTA:RBBP 
subcomplexes  
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Knowing that MTA1C is able to bind to two molecules of RBBP4, I sought to perform 
stoichiometry and structural studies. Prior to a large scale pulldown experiment that 
needs a lot of beads we ran an expression check experiment at small scale to ensure 
the expression of the subunits. About 5 × 105 transfected cells were lysed and 
examined by immunoblotting using HA and FLAG specific antibodies (Fig 5-5 A). 
Following a FLAG pulldown, a fairly pure complex with little endogenous NuRD 
components could be obtained (Fig 5-5 B). For DIA-MS and XL-MS/MS experiments, 
~2.5 × 108 cells were transfected with either FLAG-MTA1C and HA-RBBP4 or FLAG-
MTA1Cmut and HA-RBBP4. For negative-stain SPEM analysis, recombinant complexes 
were produced using 1 x 109 transfected cells; in both cases, cells were collected after 
72 h. All experiments, at a minimum, were done in duplicate.  
 
Fig 5-5. Expression and purification of MR and MmutR complexes. (A) 
Immunoblotting of EXPI293F™ cell lysates from cells co-transfected with FLAG-MTA1C 
and HA-RBBP4 or FLAG-MTA1Cmut and HA-RBBP4. (B) SYPRO Ruby stained gel 
showing MR and MmutR complexes purified from transfected cells. FLAG-MTA1C or 
FLAG-MTA1Cmut immobilized on beads were used to pull down HA-RBBP4. HSP71 
copurifies with the RBBP and MTA proteins. A heat shock protein (~ 70 kDa), which 
was identified by LC-MS/MS, is commonly seen in other NuRD subcomplex 
purifications. 
As mentioned in previous Chapters, to eliminate excess ‘handle’ protein and improve 
protein crosslinking efficiency, and thereby allow for more accurate stoichiometry 
determination, sucrose density gradient ultracentrifugation was utilized as a second 
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purification step. For SPEM analysis, the GraFix (Gradient Fixation) sucrose density 
gradient ultracentrifuge protocol was used. GraFix aims to stabilize macromolecular 
complexes for SPEM analysis [222] by introducing low concentrations of a covalent 
crosslinker such as glutaraldehyde to the sucrose gradient. For each sucrose density 
gradient, ~400 µg of purified complex was used. Figures 5-6 and 5-7 show the 
resulting sucrose gradient fractionations. For the normal sucrose gradients, broad 
elution profiles were observed. Comparing the MR and MmutR subcomplexes, the MR 
subcomplex appears to elute slightly later than the MmutR subcomplex; the majority of 
the MR complex elutes at fractions 14-16 (Fig 5-6A), whereas the majority of the 
MmutR complex elutes at fractions 12-14 (Fig 5-6B). In contrast to the normal sucrose 
gradients, in GraFix sucrose gradients, the elution peak was very narrow and the MR 
subcomplex eluted as a single peak at ~120 kDa. After fraction 18 in normal gradients 
and after 16 in Grafix some bands are detected above 70 kDa (Fig 5-7), especially in 
MmutR as it seems more concentrated; these are likely to be endogenous NuRD 
subunits copurifying with the recombinantly expressed complexes. Note that we did 
not run MmutR Grafix because we sought to do SPEM only on the MR complex. 
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Fig 5-6. SDS-PAGE analysis of sucrose density gradient (2-25%), showing 
different fractions of MR and MmutR complexes purified from two different 
experimental replicates. (A) After FLAG purification, complexes were subjected to 
sucrose density ultracentrifugation and fractionated into 200 µL fractions. Then 10% 
of each fraction was run onto SDS-PAGE and stained with SYPRO-Ruby stain.  
Fractions boxed in red with dotted lines were taken for DIA-MS experiments. (B) SDS-
PAGE showing exactly the same fractions for MmutR complex. BSA with known 
concentration was used for quantification of the complex using Image J software. 
Fractions boxed in red with dotted lines were taken for DIA-MS experiments. 
 
Fig 5-7. Grafix fractions of MR complex on SDS-PAGE. SYPRO-Ruby stained 
SDS-PAGE showing selected fractions of a 2-25% sucrose plus 1% glutaraldehyde 
GraFix gradient. In comparison to non-GraFix samples, the elution peak was narrow 
and only one predominant species is detected at around 120 kDa. 
5.2.4 Stoichiometry analysis 
With purified complexes in hand, we used absolute protein quantification mass 
spectrometry (DIA-MS) to corroborate our conclusion that the C-terminal half of MTA1 
contains two RBBP binding sites. For both the MR and MmutR complexes, we chose two 
fractions, 10 and 14, from the normal sucrose gradients. 5–10 ng of each experimental 
replicate was mixed with 100 fmol of 13C,15N-labeled peptide standards, digested 
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together using trypsin enzyme and cleaned up using C18 tips. Then we ran the 
peptides onto Q-Exactive LC-MS/MS (see Methods for details). 
The resulting data were processed in the Skyline (version 4.1.0.18169) software 
package as discussed in the previous Chapter. Light-to-heavy peptide ratios for at 
least 2 peptides from each protein were calculated. For data normalization we used 
the MTA1 subunit as our reference point, setting its stoichiometry to be two units per 
NuRD assembly based on the X-ray crystal structure of the 2:2 MTA1-HDAC1 complex.  
Our stoichiometry data analyses revealed a 1:1 ratio for both fraction 10 and fraction 
14 of the MmutR complex (Fig 5-8A,B). In contrast, for the MR complex different 
stoichiometries were determined depending on the fraction being analysed. For 
example, for fraction 10 we obtained an unexpected 1:1 molar ratio of MTA1-RBBP4 
(Fig 5-8A,C), whereas a 1:2 ratio was obtained for the MR complex collected from 
fraction 14, suggesting that fraction 14 is the best representative of the complex as it 
contains more of the recombinantly expressed complex compared to fraction 10 (Fig 
5-9A,B). Of note, as the sucrose gradient separates protein complexes based on their 
sizes, thus it is reasonable to propose that the presence of the MR complex in later 
fractions (fraction 14), is suggesting the presence of 2 molecules of RBBP4 and one 
molecule MTA1. 
Overall, these data suggest that MTA1 contains two RBBP binding sites in its C-
terminal region. The observation of two different stoichiometries in different factions 
of the wild-type complex suggests that the binding of RBBP4-MTA1 interaction is 
relatively labile. Consistent with this idea, previous work described RBBP4 and RBBP7 
as the most dynamic subunits of the NuRD complex [168]. 
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Fig 5-8. Stoichiometry of the MmutR and MR complexes. (A) The bar graph 
represents the mean of ratios for each experimental replicate (n=2). There are three 
dots on the bars representing technical replicates (n=3). (A) MmutR complex collected 
from both fractions 10 and 14 shows 1:1 stoichiometry. Similarly, MR complex 
collected from fraction 14 shows 1:1 stoichiometry. Whereas, MR complex collected 
from fraction 14 shows 1:2 stoichiometry. Both technical and experimental replicates 
showed very low variation. (B) Schematic representation of the MmutR complex. (C) 
Schematic representation of the MR complex. 
 
5.2.5 Crosslinking mass-spectrometry data analysis 
As described in the previous Chapter, XL-MS/MS data are useful data for modeling 
low-resolution of the SPEM data collected from recombinantly expressed complexes in 
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this study. in combination with crystal structures. To this end, XL-MS/MS was 
performed on the MR complex to provide restraints to aid in interpreting SPEM data 
recorded for the same complex. Two crosslinkers were used in this study; 
disuccinimidyl suberate (DSS) and adipic acid dihydrazide (ADH). DSS is a water-
soluble analog of BS3 and specifically crosslinks primary amines (i.e., lysine residues 
and the protein N-termini), which has found widespread use in XL-MS/MS/MS studies 
[148]. However, as some protein regions are refractory to amine-specific crosslinkers, 
the use of an orthogonal crosslinker such as ADH can enhance the number of 
crosslinked residues. ADH crosslinks carboxylic acids (i.e., glutamate and aspartate 
residues and the protein C-terminus) in the presence of a coupling reagent named 4-
(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) [148]. 
Due to the use of DMTMM in ADH crosslinking, a separate side-reaction arising from 
DMTMM can also lead to “zero-length” crosslinks to form between carboxylic acids and 
primary amines; a direct condensation reaction between the primary amine and 
carboxylic acid. These crosslinks will be referred to as “ZLXL” crosslinks.  
We treated the MR subcomplex with either ADH or/and DSS and examined the reaction 
mixture on SDS-PAGE (Fig 5-9). The predominant crosslinked band is ~120 kDa. This 
apparent mass is consistent with the MTA-RBBP stoichiometry of 1:2; indicating that 
the crosslinking reactions were largely successful and did not result in large 
aggregates. The mixture was treated with trypsin and then, to maximize our chances 
in identifying crosslinked peptides by MS, size exclusion chromatography (SEC) of the 
digested peptide mixture was performed to enrich for crosslinked peptides [148]. 
Several SEC fractions were analyzed on the mass spectrometer and crosslinked 
peptides were identified using the pLink software [223]. 
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Fig 5-9. Sypro-stained SDS-PAGE showing crosslinked RBBP4-MTA1C after 
treatment with DSS and ADH. The major band observed for the crosslinked 
complex runs at a molecular weight consistent with the formation of a 1:1 
(RBBP4:MTA1) complex. The lower bands are most likely degraded materials or un-
crosslinked proteins. 
Data analysis for the DSS-crosslinked sample showed that only 17% (192) of identified 
peptides were crosslinked peptides (inter- and intra- XLs), while the majority of 
peptides (60%) were regular peptides. In addition, 16% and 7% of the peptides were 
mono-linked or loop-linked peptides, respectively (Table 5-1). On the other hand only 
~3% of the analyzed peptides were crosslinked in the ADH dataset, indicating perhaps 
a lower efficiency for this crosslinker compared with DSS. 
Table 5-1. pLink DSS XL-MS/MS Data analysis report  
Types Cross-linked Spectra Loop-linked Spectra Mono-linked Spectra Regular Spectra 
Percent 7.2% 3.3% 12% 77.4% 
Types Cross-linked 
peptides 
Loop-linked peptides Mono-linked Peptides Regular peptides  
Percent 17.2% 7.4% 16.1% 59.5% 
Crosslinked peptides with scores ≤ 1 × 10-4 were considered as candidates for analysis. 
These peptides were further filtered by removing duplicate or redundant XLs. Taking 
data from both crosslinkers into account, 94 unique XLs were sorted for further 
investigation. As shown in the Table 5-2, of the 94 XLs, 59 were intra- and 35 were 
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inter-XLs. Of the 35 inter-XLs, 29 were from the DSS dataset, while 2 and 4 inter-XLs 
were from the ADH and ZLXL datasets, respectively. Of the 59 intra-XLs, 48 were from 
the DSS dataset, whereas 7 and 4 were from the ADH and ZLXL datasets, respectively. 
These data suggest that the DSS crosslinker is more efficient for crosslinking of the 
MR complex in comparison with the ADH.  
Table 5-2. All unique XLs detected using two different crosslinking reagents 
Type Inter Intra Total 
DSS 29 48 77 
ADH 2 7 9 
ZLXL 4 4 8 
Total 35 59 94 
 
Next, to check the overall distribution of the XLs in the complex, the refined inter- and 
intra-XLs were visualized using the xiNET tool (Fig 5-10) [228]. The majority of XLs 
are located between C-terminus of the MTA1 and the whole sequence of RBBP4. In 
the case of RBBP4, the majority of XLs are located in either the N-terminal or C-
terminal thirds of RBBP4, with few in the middle section. A significant number of intra 
XLs were mapped into the MTA1 protein, while only a few intra XLs were detected for 
RBBP4, consistent with previous findings reporting a relative lack of XLs for proteins 
that are rich in β-sheet [173] 
 
 
Fig 5-10. Node-link diagram showing inter XLs. Inter XLs are shown with black 
lines. XL-MS/MS data support our biochemical for the interaction of C-terminal half of 
MTA1 with RBBP4. Data were visualized using xiNET software. 
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Finally, we checked the spectra of XLs to ensure that peptide sequences match the 
corresponding spectra (see Fig 5-11 for an example). The spectra were manually 
visualized and verified using the pLabel tool part of Plink2 software package. Crosslinks 
with at least four fragment ions on both the alpha (α) and beta (β) chain each were 
retained for modelling (in XL-MS/MS studies, the longer chain in the crosslinked 
peptide is annotated as the α chain and the shorter one is named the β chain) [224].  
 
Fig 5-11. Fragmentation spectrum of a representative crosslinked peptides 
identified in this study. Alpha peptide y- and b-ions are labelled in yellow and 
green, respectively, while the beta peptide y- and b-ions are labelled in russet and 
cyan, respectively The X axis is mass to charge ratio (m/z) and Y axis represents 
relative intensity. 
5.2.6 Structural evaluation of the crosslinks in Pymol 
To analyse the crosslink data further, they were visualized on the available crystal 
structures – one of RBBP4 bound to a fragment of MTA1 encompassing the R1 region 
(PDB: 4PBY [139]) and one of RBBP4 bound to an R2 peptide (PDB: 5FXY [171]). In 
addition, using the measurement function in Pymol we were able to analyse the 
distance restraints for both inter- and intra XLs and assess whether or not the XLs 
were consistent with the crystal structures. Crosslink distances were assessed on the 
basis of adhering to the following approximate distance restraints: ADH ≤ 26 Å, DSS 
≤ 30 Å, and ZLXL ≤ 14 Å. Of the 35 inter-XLs and 59 intra-XLs, only 9 and 17 of the 
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XLs, respectively, can be mapped to the known structure; the remaining XLs fall 
outside the regions with known structure. These 9 inter-XLs (7 DSS, 1 ADH, and 1 
ZLXL) and 17 intra-XLs (8 DSS, 7 ADH, and 2 ZLXL) were listed as usable XLs (Table 
5-3). 
In Pymol, of the 26 usable XLs only 3 (D1, D2, D3) did not satisfy the expected 
distance threshold (Fig 5-12A,B). The violated D2 and D3 XLs were further 
investigated in our SPEM model of the MTA1:RBBP4 1:2 complex because these XLs 
may occur between MTA and the other RBBP4 molecule in the complex (the second 
molecule is not available in one single PDB file) (Fig 5-12A).  
Table 5-3. Usable Inter- and Intra XLs (9 inter XLs and 17 intra XLs) related to the MR complex. 
No Type Protein 1 Protein2 Residue 1 Residue 2 Status Linker Distance ID 
1 Intra MTA1 MTA1 488 511 Satisfied ADH 6 A1 
2 Intra MTA1 MTA1 488 518 Satisfied ADH 6 A2 
3 Intra MTA1 MTA1 518 511 Satisfied ADH 13 A3 
4 Inter MTA1 RBBP4 518 104 Satisfied ADH 22 A4 
5 Intra RBBP4 RBBP4 104 60 Satisfied ADH 14 A5 
6 Intra RBBP4 RBBP4 160 215 Satisfied ADH 18 A6 
7 Intra RBBP4 RBBP4 166 124 Satisfied ADH 11 A7 
8 Intra RBBP4 RBBP4 5 20 Satisfied ADH 19 A8 
9 Intra MTA1 MTA1 509 532 Violated DSS 33 D1 
10 Inter MTA1 RBBP4 532 264 Violated DSS 35 D2 
11 Inter MTA1 RBBP4 532 22 Violated DSS 40 D3 
12 Intra MTA1 MTA1 509 477 Satisfied DSS 26 D4 
13 Inter MTA1 RBBP4 509 102 Satisfied DSS 24 D5 
14 Intra MTA1 MTA1 477 532 Satisfied DSS 16 D6 
15 Inter MTA1 RBBP4 509 26 Satisfied DSS 7 D7 
16 Intra RBBP4 RBBP4 162 153 Satisfied DSS 16 D8 
17 Intra RBBP4 RBBP4 212 156 Satisfied DSS 10 D9 
18 Intra RBBP4 RBBP4 156 215 Satisfied DSS 13 D10 
19 Intra RBBP4 RBBP4 264 215 satisfied DSS 28 D11 
20 Intra RBBP4 RBBP4 160 120 Satisfied DSS 10 D12 
21 Inter MTA1 RBBP4 686 317 Satisfied DSS 9 D13 
22 Inter MTA1 RBBP4 686 22 Satisfied DSS 21 D14 
23 Inter MTA1 RBBP4 686 4 Satisfied DSS 13 D15 
24 Inter MTA1 RBBP4 509 104 Satisfied ZLXL 12 Z1 
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25 Intra RBBP4 RBBP4 148 215 Satisfied ZLXL 8 Z2 
26 Intra MTA1 MTA1 511 686 Satisfied ZLXL 14 - 
A, D, and Z refers to the ADH, DSS, and ZLXL crosslinks, respectively. 
- This crosslink is not applicable in Pymol but in chimera and was satisfied in the model 
 The maximum expected distance for DSS, ADH, and ZLXL are 30 Å, 24 Å, and 14 Å, respectively. 
 Violated in the EM model as well 
 
 
Fig 5-12. Topology of MR complex using our crosslinking data and available 
crystal structures of the RBBP4 and MTA1. (A) X-ray crystal structure of MTA1-
RBBP (PDB: 5FXY). Violated XLs are shown with light orange lines. (B) X-ray crystal 
structure of MTA1-RBBP (PDB: 4PBY). Inter subunits XLs are shown with yellow lines 
and intra XLs are shown with white lines. DSS, ADH, and ZLXL crosslinks are indicated 
as D, A, and Z, respectively. 
 
5.2.7 Modeling of the MR complex using SPEM data 
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A model for the MR complex was generated by fitting the available crystallographic 
structures (4PBY and 4FXY) into our EM envelope using the “fit in map” function of 
the Chimera software. For visualizing the XLs in the EM envelope containing the crystal 
structures and analyzing how the model agree with the XLs we used the Xlink Analyzer 
software package, a plugin package in Chimera [153, 225]. As expected, the 23 XLs 
that satisfied the individual crystal structures of MTA-RBBP (4PBY and 4FXY) were also 
satisfied here. More importantly, we were able to fulfil two additional XLs, D1 and D2, 
but not D3 in the current model. In this model D2 connects MTA1-R2 with the RBBP 
subunit that binds R1. The only XL that was not satisfied in our model is D3. It is 
possible that dynamics within the complex might allow this XL to be satisfied in another 
conformation (Fig 5-13). 
 
Fig 5-13. Structural analysis of the RBBP4:MTA1C complex using SPEM and 
XL-MS/MS data. Conformation of the MR complex subunits showing all inter and 
intra XLs satisfying or violating in the model. Unsatisfied XLs are shown in red; satisfied 
XLs are shown in blue. The red XL is formed between MTA1 (532K)-RBBP4 (22K). 
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5.3 Discussion  
Here we reveal the stoichiometry of the MTA1-RBBP4 complex using biochemical and 
proteomics approaches. We report that for the MR complex the stoichiometry can 
fluctuate, depending on the fraction we analyze from the sucrose gradient. Why does 
this happen? The reason could be due to the fact that binding of RBBP4 is relatively 
weak, so that 1:1 and 1:2 complexes exist in equilibrium. Therefore, generation of 
different species of recombinant MR, containing either one RBBP4 or two RBBP4, is 
possible.  
In contrast, only a single (1:1) complex was observed in the MmutR complex 
experiment, confirming the importance of the R1/R2 sites for RBP binding. It is notable 
that any MTA1Cmut (with no RBBP4) would be removed in earlier fractions of the 
sucrose gradient, and therefore not observed, because of its low molecular weight in 
comparison with the larger size complexes. 
Based on our findings the presence of four RBBP4 subunits in the NuRD complex is 
likely; two MTA subunits per NuRD based on the two MTA1 subunits predicted by the 
2:2 crystal structure of HDAC1 bound to the N-terminal fragment of MTA1 [112].  
Although RBBP4 and RBBP7 are found in several other protein complexes involved in 
gene regulation, including SIN3 [176], NURF [140], PRC2 [141], and CAF1 [229], 
MTA1 is not found in these complexes, meaning that MR is a unique feature of NuRD 
complex. Furthermore, in the complexes that have been characterized structurally, 
only a single RBBP subunit is present. What the implications of this observation: why 
does NuRD enlist four RBBP subunits but the other complexes only one? Given that 
RBBPs are known to bind to histone H3 and H4, it is possible that NuRD uses this 
strategy to increase its affinity toward nucleosomes. This could arise from two RBBPs 
binding to the two copies of histone H3, for example, in a single nucleosome. 
Alternatively, it is possible that the physiologically relevant remodelling substrate of 
NuRD is a dinucleosome, and therefore that each of the two 1:2 MR units might 
contact a separate nucleosome [163]. This hypothesis remains to be tested. In 
addition to the abovementioned scenarios, binding of NuRD to other histone variants 
(e.g., H2AZ) might be functionally relevant, as high throughput ChIP-Seq for NuRD 
subunits (e.g., MBD3 and CHD4) show localization of NuRD complex at genomic 
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regions that are enriched with the H2AZ histone variant. These data suggest the 
possibility of MR interacting with the N-terminal tail of H2AZ via an as yet unknown 
mechanism [166]. Another question that is raised by this work is that of whether 
RBBP7 is functionally distinct from RBBP4 in any way. The MTA1 binding surface in 
RBBP4 that mediates the interaction with MTA1 is identical to that of RBBP7, 
suggesting that this interaction is not a means by which different NuRD isoforms are 
selected. In this context, it is worth noting that the R1 and R2 sequences in MTA2 and 
MTA3 are not identical to MTA1, and it is therefore possible that RBBP4/RBBP7 
selectivity in NuRD might be mediated by MTA1 vs MTA2 vs MTA3 NuRD complexes. 
Even if this were true, however, the histone H3 binding surfaces of RBBP4 and RBBP7 
are essentially identical, and so and functional distinction between RBBP4- and RBBP7-
NuRD complexes must arise through other mechanisms that are yet to be understood.  
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Chapter 6. Discussion  
The NuRD complex is perhaps the least understood of the major remodellers present 
in mammals. Although over the past two decades there have been numerous studies 
investigating the function of the NuRD during development and in disease states using 
knock out models and deep sequencing, our knowledge about the structure, assembly 
and molecular function of the complex has remained sparse.  
The first step towards gaining more insight into the structure and function of the 
complex is to investigate the stoichiometry and assembly of the complex. Dissecting 
the complex into smaller and stable subcomplexes is required to achieve this. 
A next step would be the investigation of combinatorial assembly of NuRD paralogues 
into distinct complexes. The co-regulation of paralogous proteins might be a common 
characteristic of large multi-subunit complexes to regulate their function in different 
cell types and at different times. For instance, it has been demonstrated that 
GATAD2A-NuRD but not GATAD2B-NuRD can enable deterministic reprogramming 
without affecting the proliferation of somatic cells. Combinatorial assembly of the 
mSWI/SNF or BAF complex subunit paralogues is known togive rise to several distinct 
complexes, namely npBAF, nBAF, and PBAF. The npBAF is functional in neural stem 
cells and nBAF in post-mitotic neurons [230, 231].  
Another important step to further delineate the function and specificity of the complex 
is to determine the interacting partners of the NuRD complex. The translocase subunit 
of the ATP-dependent chromatin remodelling complexes is the shared property of all 
remodellers. However, each remodeller has its own specific protein partners (e.g., 
transcription factors and chromatin binding proteins) that give them unique properties 
and specificity.  
Before this work, we had little understanding of the stoichiometry and interacting 
partners of the NuRD. It was not known that the histone deacetylase and chromatin 
remodeling subcomplexes are brought together to form a full NuRD, nor how these 
sub-complexes cooperate to modify chromatin and gene expression. We also did not 
know whether the canonical subunits and paralogues of the complex are preserved 
across cell types. In this chapter I will discuss our findings in this area. 
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6.1 High level expression of a subunit does not guarantee its integration 
into the NuRD complex. 
In Chapter 3 it was shown that one distinct NuRD complex (e.g., MBD2-NuRD) can be 
more dominant in MCF7 and PC3 cell types compared to the NT2 cell line. This 
compositional variation can arise from differences in the expression level of the 
subunits at mRNA and/or protein level [1, 172]. We therefore first examined the 
expression profile of the NuRD subunits in NT2 cells using RNA-Seq data from the 
Human Protein Atlas (HPA) consortium (Fig 6-1).  
 
Fig 6-1. mRNA expression pattern of NuRD subunits in NT2 cells. RNA-Seq 
data are represented as Transcripts Per Million. Except for GATAD2B, CHD3, and 
MBD2, which show low expression, the rest show moderate or high expression. 
In addition, we used absolute mRNA and protein abundance data from mouse 
embryonic stem cells (mESCs), which resemble NT2 cells (Fig 6-2A,B) [1]. NT2 cells 
closely resemble pluripotent stem cells, and it is therefore reasonable to speculate that 
in the NT2 cells the expression pattern of NuRD subunits is similar to that of ESCs. 
The comparison of absolute mRNA and protein data (Fig 6-2C) indicate that there is 
a relatively direct correlation between NuRD subunits mRNA and protein abundance. 
However, this rule is not true for all subunits; for example, at the level of mRNA HDAC1 
is 2.5× times less abundant than HDAC2 but at the level of protein HDAC1 is 10× 
more abundant compared to HDAC2. This type of pattern can arise because of 
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differences in the mRNA half-lives, translation rate or turnover of a particular protein. 
The comparison of the subunit copy numbers (6-2B) with their enrichment pattern in 
the NuRD complex (Fig 6-3) suggests that there is not a strong correlation between 
the protein copy number and its enrichment. For example, as has been depicted in 
Fig 6-2B, MTA2 is present 15× more than MTA1 in mouse ES cells but our data 
indicate that the distribution of MTA1 and MTA2 in the NT2 NuRD complex is very 
similar (Fig 6-3). Likewise, RBBP7 (40000 molecules/cell) is ~3× more abundant than 
RBBP4 (14000 molecules/cell) but it is propensity to involve into the NuRD complex 
appears relatively weak. In other words, it appears that RBBP4-NuRD is more 
abundant than RBBP7-NuRD in NT2 cells. This could be due to either a high propensity 
for RBBP7 to be involved in other complexes such as HAT1 or a higher propensity for 
RBBP4 to be part of the NuRD complex, effectively competing RBBP7 away from the 
complex.  
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Fig 6-2. NuRD subunit transcripts and protein copy numbers per cell in 
mESCs. (A) mRNA copy numbers of the NuRD subunits. (B) Protein copy numbers 
of the NuRD subunits per cell. Proteins copy numbers are divided by 100. (C) 
Correlation of mRNA and protein product concentrations of the NuRD subunits. The Y 
axis is log10 transformed. R-squared is a statistical measure of how close the data are 
to the fitted regression line. 
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Fig 6-3. Heatmap representing the log2 intensity of the iBAQ values for 
NuRD subunits in MCF7, NT2 and PC3 cells. The coloring is based on relative 
iBAQ intensities for each protein. CHD3 and CDK2AP2 are present in noticeably lower 
amounts in MCF7 than in PC3 and NT2. RBBP4 is the most enriched protein. 
6.2 Composition and stoichiometry of the NuRD complex 
All mammalian NuRD stoichiometry analyses done to date have been performed in 
HeLa-derived cell lines [57, 168, 169], together with a single study in mouse ES cells 
[161]. We assessed NuRD stoichiometry across several cell types to begin to 
understand whether the stoichiometry of the complex is conserved between cell types. 
Our iBAQ data indicate that the stoichiometry of the NuRD complex preserved overall 
across our three chosen cancer cell lines that reflect three different human tissues. In 
all three cell types, the consensus stoichiometry observed from multiple 
measurements suggests that: (i) MTA and HDAC subunits are in a 1:1 ratio; and (ii) 
that GATAD2 and MBD are also in a 1:1 ratio – and that there is half as much of each 
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of these two subunits as MTA and HDAC. Our observations are consistent with the X-
ray crystal structure of a 2:2 HDAC1-MTA1 complex [112] and the NMR structure of a 
1:1 GATAD2A-MBD2 complex [132]. We propose that the overall stoichiometry of the 
MTA-HDAC-MBD-GATAD2 part of the NuRD complex is 2:2:1:1. 
Several other iBAQ studies of the NuRD complex (Fig 6-4) have been published [57, 
168, 169, 181]. One [181] also uses multi-angle laser light-scattering (MALLS) data to 
directly measure the solution molecular weight of the complex. This latter study draws 
the same conclusion as we do regarding the stoichiometry of these subunits. In 
contrast, the other iBAQ studies report a range of stoichiometries for these four 
subunits. It is possible that variations in purification protocol – including the question 
of which subunit is used as the purification ‘handle’ – contribute to different observed 
estimates of the stoichiometry. This interpretation is further supported by the values 
we measure for RBBP stoichiometry. Values for the current study are presented as the 
mean across all replicates (n = 9) of all three cell types (refer to Chapter 3 Fig 3-3A). 
The amount of the RBBP subunit observed varies significantly from sample to sample 
in our measurements – ranging from ~5.5–11 RBBPs per NuRD complex. In contrast, 
the variation observed for the other subunits is much smaller. Other studies report 3–
4 RBBP subunits per complex (after normalizing the data to reflect two MTA subunits 
per complex). A value of four RBBPs is in best agreement with published structural 
and biochemical data, which indicate that two RBBP binding sites exist on each MTA 
molecule [163, 171, 190]. It is possible that the excess in RBBP that we observe is a 
consequence of using this protein as the purification handle in our first purification 
step and that the sucrose gradient does not completely remove additional, weakly 
associated RBBP. One way to address this uncertainty would be for us to use our DIA-
MS method to measure the stoichiometry of a NuRD complex purified using another 
subunit as the handle. This would require the construction of a cell line in which one 
or NuRD subunits have an affinity tag introduced into the endogenous locus by 
CRISPR/Cas9 engineering. 
Our data also show a sub-stoichiometric amount of the CHD subunit, which is most 
likely due to the peripheral nature of this protein in the complex [162], which might 
make it prone to dissociation during purification. Zhang et al (2016), who also 
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employed multi-step purification protocols, also reported sub-stoichiometric quantities 
of CHD. In contrast, the three other studies [57, 168, 169] used single-step affinity 
purifications, and consistently reported one CHD subunit per NuRD. A single copy of 
CHD is most likely, although it is worth noting that it is still unclear whether the NuDe 
complex has a cellular function. If it did, this might account for our observations. 
 
 
Fig 6-4. Comparison of NuRD complex subunit stoichiometry from different 
studies. Summary of stoichiometries deduced from all published iBAQ studies of 
NuRD, together with the current data. Previous studies used MBD3 as the purification 
handle whereas RBBP was used in the current study.  
CDK2AP1 also has very low abundance in our samples and in the purified Drosophila 
NuRD complex, whereas it is present at 1–2 copies per NuRD complex in the HeLa-
purified complexes. We note that, across all studies (including between our three cell 
lines), CDK2AP1 abundance tracks closely with CHD abundance (Fig 6-5) suggesting 
that these two proteins might directly interact. Thus, our low stoichiometry for CHD4 
would explain why we observe little CDK2AP1 in our complexes. Taking all of these 
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data into account, we suggest an overall stoichiometry for the NuRD complex of 
4:2:2:1:1:1:1 (RBBP:MTA:HDAC:MBD:GATAD2:CHD:CDK2AP1). 
 
 
Fig 6-5. Scatter plot showing the correlation of CDK2AP and CHD. Quantity 
of CDK2AP plotted against the quantity of CHD. Each data point is an independent 
measurement; data from all sucrose-gradient fractions are included. The values are 
strongly correlated (r2 = 0.88). 
6.3 NuRD complexes with different paralogue compositions are 
likely to have distinct functions 
Published data suggest that the composition of most protein complexes is constant 
across many cell types [172, 192, 194]. We suggest that the NuRD complex has a 
composition that can vary in a context dependent manner. However, the changes are 
not in overall architecture but rather in paralogue distribution. Although we did 
observe that most paralogues were found in each of our three cell types, several 
differences were observed. Most prominently, MBD2 was not observed in NuRD from 
NT2 cells, despite the fact that MBD2 transcript levels are higher in NT2 cells than in 
MCF7 or PC3 cells (Fig 6-3). This suggests that MBD3-NuRD is the predominant NuRD 
complex in NT2 cells and it is quite possible that this selectivity has functional 
consequences.  
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MBD2- or MBD3-exclusive NuRD complexes have been previously described and 
shown to have distinct roles in other cell types [134, 136, 195]. For example, it has 
been shown that Mbd3 knock-out mice die during early embryogenesis, whereas Mbd2 
knock-out mice are viable and fertile, a strong indication that these two proteins are 
not functionally redundant [134]. Furthermore, knockdown of MBD3 but not MBD2 
dramatically increases the efficiency of the reprogramming of somatic cells to 
pluripotent stem cells [60], although it should be noted that these findings are 
currently disputed [60]. A similar observation has been made for the GATAD2 subunit: 
depletion of GATAD2A but not GATAD2B leads to highly efficient induced pluripotent 
stem cell formation [200]. In addition, GATAD2A-NuRD is also selectively recruited 
(over GATAD2B NuRD) by ZMYND8 to DNA double-stranded breaks [57]. CHD3-, 
CHD4- and CHD5-specific NuRD complexes have also been implicated in mouse 
cortical development [201]. Paralogue interchanges of these types will most likely be 
revealed to be a widespread aspect of NuRD activity. 
6.4 NuRD may contact its substrate through multiple interfaces 
An important step in delineating the mechanisms of action of the NuRD complex is to 
identify the means through which the complex search for a substrate (e.g., 
nucleosomes). It has been demonstrated that remodellers such as SWI/SNF [55, 209], 
Chd1 [56], and INO80 [54] make multiple simultaneous interactions with histones 
and/or DNA during the remodelling reaction that they catalyze. Thus it is reasonable 
to suggest that the NuRD complex might contact the nucleosome substrate through 
multiple interfaces. The BAH domain of the MTA subunit is present in several 
transcriptional co-regulators, and has been shown to act as a histone recognition 
domain (Kuo et al., 2012 Du et al., 2012). In addition, the two PHD domains in the 
CHD4 subunit are also important for connection of NuRD with the nucleosome through 
H3K4 and methylated or acetylated H3K9 [123, 232]. In addition to histone binding 
domains, several domains in NuRD harbour demonstrated DNA-binding properties. It 
has been demonstrated that the N-terminal part of the CHD4 and its chromodomains 
are essential for connection of the NuRD to DNA [128]. It is unlikely that many or all 
of these direct interactions with DNA will be specific, especially given that the complex 
most likely acts on diverse DNA sequences across the genome. Therefore, specificity 
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will most likely be introduced through the interaction with site-specific transcriptional 
coregulatory proteins such as FOG-1, and several other zinc-finger containing 
transcription factors (discussed in Chapter 1) that target NuRD to particular loci. In 
line with these ideas, our data show that NuRD can recruit site-specific proteins (e.g., 
ZNF219 and PWWP2A) to bind distinct genomic regions.  
6.5 Interacting partners of the complex 
It has been proposed that interactions of chromatin remodelling complexes with a 
range of transcription factors and chromatin regulating proteins can assist the NuRD 
complex in binding to nucleosome or to differentially detect histone modifications and 
histone variants. In addition, it has been reported that the NuRD complex can interact 
with a range of proteins and deacetylate them and consequently regulate their stability 
and/or function [100, 101]. Thus understanding the interactome of the complex will 
help us understand its specificity and targets.  
In Chapter 3, we investigated the interactome of the NuRD complex using affinity 
purification coupled to MS. We identified 83 proteins that were present at least in two 
of three biological replicates. Among the interacting proteins there are a number of 
transcription factors and chromatin binding proteins. Of these proteins, some, for 
example HIF1A [233] and PWWP2A [74, 198], have already been reported as 
interacting partners of the NuRD complex. Most recently, it has been demonstrated 
that PWWP2A – a transcriptional regulator [74, 198] – can compete directly with MBD3 
for binding to MTA, meaning that it forms a complex with a NuRD subcomplex 
comprising MTA, HDAC and RBBP subunits. 
Because MBD3 connects these proteins to GATAD2 and CHD, the PWWP2A interaction 
therefore effectively generates a new variant NuRD complex that lacks chromatin 
remodelling activity. Genome-wide analysis reveals that PWWP2A prefers to bind to 
the promoters region of highly transcribed genes containing H2A.Z-containing 
nucleosomes [198]; H2A.Z is a variant of H2A [234]. Strikingly, in addition to 
PWWP2A, we also observed the enrichment of H2A.Z in our NuRD purification. Most 
recently, two papers demonstrated that chromatin binding proteins such as PWWP2A 
competes with MBD3 for binding to MTA1, consequently defining a new variant 
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without remodelling activity. This variant targets acetylation sites on H3K27 and H2AZ 
[74, 198]. 
The listed proteins in Chapter 3 can be potentially direct or indirect interactors of the 
complex or they can be pulled down due to a non-specific interaction with beads. 
Therefore, biochemical assays are needed to further delineate the interactome data. 
As explained in Chapter 3, we found the ZNF219 and SLC25A5 are capable of direct 
interaction with the NuRD complex, at least in in vitro pulldown assays.  
6.5.1 ZNF219 may target NuRD to specific loci  
ZNF219 is a moderately expressed and poorly characterized protein containing nine 
classical zinc-finger (ZnF) domains. It has been shown to repress target genes during 
the differentiation of pluripotent stem cells [188, 189], although no mechanism has 
been proposed for this repressive activity.  
Our data suggest that ZNF219 might recruit the NuRD complex to target gene 
promoters or enhancers. ZNF219 has also been observed to be enriched following 
immunoprecipitation of the NuRD complex from neural stem cells that had been 
derived from pluripotent stem cells [235]. We found ZNF219 to be enriched in all three 
NT2 cell samples but not at all in the other two cell types.  
This observation is consistent with the fact that ZNF219 transcript levels are several 
times higher in the NT2 cells, and also that NT2 cells closely resemble pluripotent stem 
cells and can readily be differentiated into neuronal cells [236]. Furthermore, 
consistent with our data, ZNF219 has also been identified as a NuRD-interacting 
protein in several affinity-purification-mass-spectrometry studies [237-239].  
Our data showed that the N-terminal portion of ZNF219 (residues 1–273) mediates 
interactions with RBBP4, GATAD2B and the C-terminal portion of CHD4 (CHD4C). 
Although ZNF219 resembles FOG1 in that it contains nine ZnF domains, it lacks the 
conserved Lys-Lys-Arg motif used by FOG1 to bind to RBBP4/7 [138], indicating that 
it recognizes RBBP4 through a distinct mechanism. CHD4C contains two domains that 
are predicted to be ordered but for which the structures are unknown. We have 
previously shown that one of these domains can bind GATAD2B [187], perhaps 
suggesting that ZNF219 makes a concerted interaction with these two regions that 
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are already co-localized. Further biochemical and structural work will be required to 
determine the molecular basis for this interaction. 
 
6.5.2 NuRD subcomplexes can be found in the cytoplasm and/or 
cytosol 
Very recently, several labs have reported the presence of gene regulating complexes 
such as COMPASS [240], PRC2 [241], and the BAP1 [191] in the cytoplasm. In some 
cases, these cytoplasmic complexes have been shown to have functional roles. For 
example, the presence of the cytoplasmic SET1/COMPASS complex was shown to be 
essential for triple-negative breast cancer pathogenesis. Similarly, Zhang et al. 
reported that catalytically active NuRD subcomplexes can be found in the cytosol 
[181].  
Potentially, an HDAC-containing NuRD subcomplex could act to deacetylate non-
histone proteins. For example, MTA/HDAC containing complexes have been 
demonstrated to deacetylate a range of transcription factors including p53 [101], ATF4 
[100], and HIF1α [242]. SLC25A5 is known predominantly as a mitochondrial inner 
membrane protein that belongs to the solute carrier family of proteins and functions 
as a gated pore that translocates ADP from the cytoplasm into the mitochondrial 
matrix and ATP from the mitochondrial matrix into the cytoplasm [243]. 
However, SLC25A5 has also been reported to be present in both the nucleus [244] 
and the cytoplasm [243]. It is notable that SLC25A5 has 24 acetylation sites [180] and 
it is possible that cytoplasmic NuRD (or a subcomplex) modulates the acetylation level 
of SLC25A5. Finally we note that genetic studies on patients with intellectual 
disabilities have identified GATAD2 and SLC25A5 as possible co-actors in this condition 
[245]; it is possible that the direct interaction between GATAD2 and SLC25A5, as 
observed in our pulldown assays, could have a role to play in this disease through a 
yet unknown mechanism.  
6.5.3 RSRC2 as a possible NuRD partner 
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The RSRC2 gene is located in Chr. 12 and encodes an arginine/serine rich coiled-coil 
protein. RSRC2 is an uncharacterized 50-kDa protein that is well conserved across 
species from fish to human (Fig 6-6). The presence of a coiled-coil domain in its 
sequence makes it tempting to speculate that this protein may make an interaction 
with NuRD subunits such as GATAD2A/B. Further work would be needed to 
characterize the molecular basis of the interaction of RSRC2 with the NuRD complex. 
Interestingly, an AP-MS study in search for chromatin associated proteins listed the 
RSRC2 protein as significant interactors of H3 and H2B histones, consistent with a role 
for this protein in chromatin regulation [183]. 
 
Fig 6-6. Multiple sequence alignment and disordered region prediction. (A) 
Protein sequences from human, mouse, and fish RSRC2 have been aligned (Q7L4I2). 
Red residues are identical between all three species. Secondary structure and domain 
predictions predict several helical segments at the C-terminal half of the protein 
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sequence. (B) Ordered and disordered regions of the protein have been predicted 
using the PONDER online tool. The C-terminal part with helical regions is likely to be 
ordered. 
6.6 The N-terminal part of MTA may bring the DNA translocase 
moiety into the deacetylase core 
The heterodimer complex formed between MTA and HDAC (MH) creates a platform 
for other subunits to build up the full NuRD complex. In Chapter 4, we used a 
combination of absolute quantification (DIA-MS) and XL-MS/MS to further delineate 
the architecture and topology of the complex by studying several subcomplexes. Our 
XL-MS/MS data for MMH suggest that MBD3 can make an interaction with the MH 
complex via the BAH domain in MTA2. Since there are two BAH domains in the MH 
heterodimer complex, it is likely that MBD3 can interact with both BAH domains.  
Consistent with the observation that there are two BAH domains, absolute protein 
quantification using DIA-MS indicate a stoichiometry of 2:2:2 for the 
MBD3:MTA2:HDAC1 complex (Fig 6-7A). Although it is consistent with the presence 
of two BAH domains, the presence of two MBD3 subunits is surprising when 
considering that our stoichiometry data for the native NuRD complex shows one MBD3 
per complex. This observation could be potentially due to one of several reasons: (i) 
overexpression of the subunits in the MMH complex described herein, which may lead 
to non-native bias towards a 2:2:2 stoichiometry; (ii) MBD3 was used as the bait 
protein to purify MMH and this could lead to an excess amount of MBD3; or (iii) the 
presence of 2 BAH domain in the MTA protein.  
We hypothesized that GATAD2A and CHD4, which are present in the whole complex 
but not MMH, may prevent the binding of the second MBD3 molecule to the MH 
complex by somehow blocking the second BAH domain. We tested this hypothesis in 
Chapter 4 by adding GATAD2A into the MMH complex. Our results indicate that 
introduction of GATAD2A into the MMH complex not only leads to the formation of a 
stable complex (Fig 6-7B). DIA-MS analysis of the MMHG complex showed a 
stoichiometry of 2:2.5:1.3:0.8 for MTA:HDAC:MBD3:GATAD2 (relatively close to 
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2:2:1:1), consistent with the idea that GATAD2A and/or CHD4 might directly compete 
away the binding of a second copy of MBD to the MH core. 
 
Fig 6-7. Schematic representation of the stoichiometry of MBD3 in MMH and 
in NuRD. (A) Two copies of MBD3 are observed per MMH complex, consistent with 
MBD3 binding the BAH domain of each MTA1 subunit. (B) After overexpressing 
GATAD2A with MMH complex only one MBD3 was observed per complex. These data 
suggest that GATAD2A or CHD4 inhibit the binding of a second MBD3 to the complex. 
Our data also suggest that contacts between the MTA BAH domain and the MBD3 
MBD domain are a key part of the histone deacetylase and DNA translocase units. As 
it appears that BAH domain of MTA1 can provide a potential platform for interaction 
of histone deacetylase core with translocase core within the NuRD complex. Now, 
another question would be if there is any other protein in cell or during development 
in different tissues that can compete away MBD2/3 and create a new version of NuRD 
with new function?  
6.7 RBBP4/7 appears to have a dynamic interaction with the MTA 
protein 
Our stoichiometry calculation for the MR complex yielded different values in different 
sucrose gradient fractions (Section 5.2.4). However, in the case of the MmutR complex, 
the stoichiometry remained constant, regardless of the fraction. As noted above, 
variable stoichiometry has been observed in numerous studies of NuRD stoichiometry, 
and it is not currently clear whether this variability is functionally relevant or is an 
artefact of the experiments themselves. 
However, in the MmutR complex, as MTA1Cmut has just one binding site the generation 
of two species is unlikely. Nonetheless, if MTA1Cmut (with no RBBP4) is generated it 
will be removed in earlier fractions because of very small size in comparison with the 
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larger size complexes. Based on the crystal structure of the MH core complex, MTA 
forms a homodimer, meaning that it can bring a total of four RBBP4 molecules into 
the complex.  
RBBP4 but not MTA1 is found in several other protein complexes, including SIN3 [176], 
NURF [140], PRC2 [141], and CAF1 [229], meaning that the MR complex is a unique 
feature of the NuRD complex. It is tempting to ask whether the formation of the MR 
subcomplex can give the NuRD complex any specificity or, in other words, what would 
be the consequence of this interaction? Why does NuRD need 4 molecules of RBBP4? 
It is possible that NuRD uses this strategy to increase its affinity toward nucleosomes. 
It is also possible that the substrate of NuRD is a dinucleosome in which each MR unit 
might connect a separate nucleosome, allowing the remodeling module or 
deacetylating module act on a two-nucleosome unit (Fig 6-8) [163]. 
6.8 The MR complex gives specificity to NuRD to bind histone H3 
but not H4 
Previous studies reported that RBBP4 was able to interact with the C-terminal half of 
MTA1/2. Alqarni et al. solved the structure of the MTA1(670–690) region in complex 
with full RBBP4 [190]. They reported that a short -helix and a hydrophobic cluster 
binds to RBBP4 in a distinct pocket.   
In the Mackay lab, Alqarni et al. also compared the affinity of the R2 region (656–686) 
towards binding to RBBP4 and H4 using isothermal titration calorimetry (ITC). They 
observed that H4 and MTA1 bound in the same groove of RBBP4. Based on the 
similarity in affinity they suggested that there may be competition between MTA1 and 
histone H4 for binding to RBBP4. The interaction of the MR complex with H4 seems to 
be not possible because the extensive interface between MTA and RBBP4 can block 
the binding site for H4.  
In contrast, the interaction of the MR complex with H3 is likely, because in RBBP4, the 
H3-binding surface lies on the ‘top’ of the WD40 domain that is not blocked by the 
RBBP-MTA interaction. This suggests that RBBP4 most likely serves to contact histone 
H3 when NuRD contacts chromatin (Fig 6-8). Consistent with this hypothesis, Millard 
et al. demonstrated that both RBBP4 alone and the MR complex show an identical 
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binding pattern to H3 peptides [171]. In contrast, the MR complex did not bind to H4 
peptides, whereas the free RBBP4 bound to the H4 peptides.  
 
Fig 6-8. Schematic representation of the recruitment of the deacetylase 
core of NuRD complex to chromatin. Subunits are colored according to the 
schematic representation in Fig 1-3. Interaction of the RBBP4/7 proteins and the H3 
tail could recruit the complex to chromatin on the same or adjacent nucleosomes. 
Other histone tails, such as those of H2A.Z or H4, would be available for deacetylation 
by HDAC1/2.  
6.9 Concluding remarks 
Research described in this thesis has found that NuRD core components are conserved 
across a number of cancer cell types and have a stoichiometry of 4:2:2:1:1:1 
(RBBP4:MTA:HDAC:GATAD2:MBD:CHD). Seemingly, MBD2-NuRD is present in MCF7 
and PC3 cells but absent in NT2 cells, suggesting an important role for MBD2-NuRD 
in MCF7 and PC3 cell lines than NT2 cells. This thesis also provides biochemical 
evidence for interaction of NuRD with specific transcription factors in specific cell types 
and perhaps hints at a role for a NuRD subcomplex in the deacetylation of the 
mitochondrial membrane protein SLC25A5. Our data also reveal that GATAD2 
connects the MHR module of NuRD to the CHD remodeller and also modulates the 
interaction of the MBD subunit with the MTA-HDAC unit. Our proteomics, biochemical 
and structural data indicate that four molecules RBBP4 are present in a NuRD complex, 
which may enhance the avidity of the complex to bind its substrate. The data 
presented in this thesis build on our understanding of NuRD complex structure and 
Chapter 6: Discussion 
 
126 
 
moves us closer towards a better understanding of mechanisms of action of the 
complex. 
Following from the findings presented here, several avenues of investigation suggest 
themselves. An investigation of the interactome of the NuRD complex across normal 
and diseased tissues might provide insight into how changes in NuRD recruitment are 
linked to disease states. The composition and interactome of the complex or 
subcomplexes of NuRD in the cytosol would perhaps shed light on the role of such 
complexes at sites remote to chromatin. Biochemical and genome wide analysis may 
provide insights into how the HDAC can alter the substrate specificity for the complex. 
Further efforts can provide insights into the cooperation of HDAC and CHD to 
remodeling chromatin structure. 
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Appendix A: Gibson assembly primer sequences. 
Name Sequence Tm 
LANCL1_fwd_Gibson GGATCCACTAGAACACATAATAGG ATGGCTCAAAGGGCCTTCC 60 
LANCL1_rev_Gibson TGGATATCTGCAGAATTCTGATCA TCAGAGTTCAAATGCAGGGAAC 59 
KPNA4_fwd_Gibson GGATCCACTAGAACACATAATAGG ATGGCGGACAACGAGAAACTG 61 
KPNA4_rev_Gibson TGGATATCTGCAGAATTCTGATCA TAAAACTGGAACCCTTCTGTTGG 60 
PAICS_fwd_Gibson GGATCCACTAGAACACATAATAGG ACAGCTGAGGTACTGAACATTGG 60 
PAICS _rev_Gibson TGGATATCTGCAGAATTCTGATCA ACATTCTCTGATTTTCTTGTCAG 58 
DCAF11_fwd_Gibson GGATCCACTAGAACACATAATAGG ATGGGATCGCGGAACAGCAG 62 
DCAF11_rev_Gibson TGGATATCTGCAGAATTCTGATCA CTGGGGTGAGGAAAAGGGTG 60 
ZNF219_fwd_Gibson GGATCCACTAGAACACATAATAGG ATGGAGGGCTCACGTCCC 61 
ZNF219_rev_Gibson TGGATATCTGCAGAATTCTGATCA CCGTTCTTGCCCCCCCAG 62 
CALML5_fwd_Gibson GGATCCACTAGAACACATAATAGG ATGGCCGGTGAGCTGACTC 62 
CALML5_rev_Gibson TGGATATCTGCAGAATTCTGATCA CTCCTGGGCGAGCATCCTC 62 
SLC25A5_fwd_Gibson GGATCCACTAGAACACATAATAGG GATGCCGCTGTGTCCTTCG 61 
SLC25A5_rev_Gibson TGGATATCTGCAGAATTCTGATCA TGTACTTCTTGATTTCATCATAC 60 
DDB1_fwd_Gibson GGATCCACTAGAACACATAATAGG ATGTCGTACAACTACGTGGTAAC 58 
DDB1_rev_Gibson TGGATATCTGCAGAATTCTGATCA CTAATGGATCCGAGTTAGCTCC 58 
COASY_fwd_Gibson GGATCCACTAGAACACATAATAGG ATGGCCGTATTCCGGTCGG 62 
COASY_rev_Gibson TGGATATCTGCAGAATTCTGATCA GTCGAGGGCCTGATGAGTCTT 61 
HIF1A_fwd_Gibson GGATCCACTAGAACACATAATAGG AACGACAAGAAAAAGATAAGTTC 60 
HIF1A_rev_Gibson TGGATATCTGCAGAATTCTGATCA AGTTAACTTGATCCAAAGCTCTG 60 
KIF20B_fwd_Gibson GGATCCACTAGAACACATAATAGG CAAGAGGGAGTACCTCGACC 58 
KIF20B_rev_Gibson TGGATATCTGCAGAATTCTGATCA TTTGGCTGTTTTTGTTCGAAGTC 59 
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Appendix B: qPCR primer sequences.  
Table 2-5.  
Name Sequence Tm (s) 
MTA1_fwd_qPCR AGGCAGACATCACCGACTTG 60 
MTA1_rev_qPCR AGTATCCATGGCGTGGAACA 60 
MTA2_fwd_qPCR TATGTGGGTGGCTGGTAATG 59 
MTA2_rev_qPCR GCCTGGCTGATAGTAATGCC 60 
MTA3_fwd_qPCR ACTTATAATGCTCGCAGATAAGC 60 
MTA3_rev_qPCR ACTTTCCCCTGATATGTGTTG 60 
MTA3_fwd_qPCR ATGCTGGCGCTGAGTACGTC 61 
MTA3_rev_qPCR CTTGAGGCTGTTGTCATACTTC 60 
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Appendix C: Antibodies used in this study. 
Antibodies Host Conjugate Source 
MTA1 Rabbit - CST (#D40D1) 
MTA2 Rabbit - abcam (#171073) 
MTA3 Rabbit - abcam (#176346) 
HDAC1 Mouse HRP CST (#10E2) 
FLAG Mouse HRP Sigma (#A8592) 
HA Mouse HRP abcam (#ab173826) 
MBD2 Rabbit HRP abcam (#ab188474) 
MBD3 Rabbit HRP abcam (#ab157464) 
Β-Actin Mouse HRP SC (#47778) 
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Appendix D. Complete list of possible interacting partners of the NuRD.  
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Appendix E. Inter crosslinked peptides.  
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Appendix F. Intra crosslinked peptides. 
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